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Poor treatment adherence is an increasing challenge for healthcare, especially for chronic 
diseases and patient-administered treatments. This research has investigated how design 
thinking can improve adherence in self-administered treatment technology. The study has 
three main objectives. The first is to investigate the current state of adherence and its 
involvement in the design process. For this objective, literature about adherence theoretical 
frameworks, design thinking, and medical technology was reviewed. Also, in five SME case 
studies, interviews provided evidence of consideration of adherence during the design 
process. The second objective was to explore consideration of adherence at an early stage of 
a design process. Postgraduate students on an MA Design project were observed while 
applying design thinking processes to develop a medical solution. The third objective was to 
assess a framework though an eDelphi study that built consensus from panellists on 
adherence factors that influence patient adherence to a treatment technology regimen, and 
the importance of each factor. 
 
A number of gaps were identified after addressing the first objective: 1) a lack of an adherence 
framework that considers the nature of self-administered treatment technology products, 2) 
There is a lack of a practical mechanism to consider adherence factors during the design and 
development of medical treatment technology, and 3) There is a need for a resource that can 
guide and help companies to consider adherence factors during the design process. 
 
Based on the research findings, the study claims two contributions to knowledge: an 
adherence framework that identifies factors that affect patient-administered technology 
treatment adherence and their level of importance, and a design-focused adherence canvas, 
based on the adherence framework (1st claim), which is a practical resource that record how 
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Chapter 1: Introduction 
 
This chapter introduces the study and 
includes an overview of the research, its 
aims, objectives and original contribution 
to knowledge. It furthermore provides an 
overview of the key terms used in the study 
that clarifies how these terms are used and 
interpreted. The limitations of the research, 




1.2 Structure of the Thesis 
1.3 Research Aims and Objectives 
1.4 Contribution to Knowledge 
1.5 Definition of Terms 
1.6 COVID-19 Impact on Research 
1.7 Conclusion and Summary 
 
  




The very early inspiration of this research project was based on my previously published 
article, ‘Designing the 3D‐printed prosthetic hand’ (Elmansy, 2015), in Design Management 
Review. The article explored the design process of eNable the Future, a US-based charity. 
The company facilitates the open-source 3D printing of affordable prosthetic hands for 
children, especially those who have no access to traditional prosthetics medical care due to 
financial or geographical barriers. The article provided an opportunity to understand the 
importance of medical technology’s contributions to patient welfare and the healthcare 
sector in general. My personal experience with chronic pain and high blood pressure 
furnished me with first-person knowledge of the critical importance of the research topic. 
The self-administration of chronic pain treatment provides an effective opportunity to take 
control of the treatment instead of waiting on long lists to see a physician. Additionally, 
medical technology (e.g. TINs) provides me the opportunity to avoid the side effects of pain 
killers. However, patients can’t benefit from the self-administered medical technology 
without full adherence to the treatment regimen. Generally, the lack of compliance with the 
chronic disease’s treatment led to catastrophic results, including death. The significance of 
this research lies in the opportunity it can provide for the increasing number of patients 
suffering from chronic diseases, especially those that have limited access to healthcare 
resources (Aldeer et al., 2018; Barnett, 2014; Haskard-Zolnierek, & DiMatteo, 2009; Nunes 
et al., 2009; Sabaté, 2003; Viswanathan et al., 2012). 
 
The healthcare system in the UK is facing increasing challenges, especially for chronic 
diseases (Wilson et al., 2005). These challenges include, but are not limited to, insufficient 
funding, lack of resources (Appleby et al., 2014), lack of staff (Buchan et al., 2017) and 
increasing demand on hospital admissions (Smith et al., 2014). These challenges became 
apparent during the COVID-19 outbreak that hit the world, including the UK, at the 
beginning of 2020 (Willan et al., 2020). Several studies have shown the benefits of adopting 
medical technology systems especially for the treatment of chronic diseases (Cutler, 2007; 
García-Lizana & Sarría-Santamera, 2007; Mirza et al., 2008; Ganasegeran et al., 2017; 
Wickramasinghe et al.,2011). The self-administered treatment technology can be as 
effective as the clinically administered treatments (Scogin et al., 1990), additionally, medical 
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technology can reduce medication costs (Hoppe et al., 2000; Scogin et al., 2003), hospital 
and General practitioners 
(GPs) admissions, the psychological impact of the disease, instances of surgical intervention 
and the side effects of using of pharmaceutical treatment.  
 
However, various literature studies have shown that poor adherence to medication regimes 
is a persistent (van Dulmen et al., 2007) and involved problem in healthcare (Aldeer et al., 
2018). An estimated 20% to 30% of patients do not take their medications (Viswanathan et 
al., 2012). This percentage increases to between 30% and 50% for patients with chronic 
diseases (Nunes et al., 2009; Sabaté, 2003; Barnett, 2014). The failure to achieve a 
significant level of adherence can lead to serious complications, including death 
(Viswanathan et al., 2012; Aldeer et al., 2018), increased healthcare costs and a negative 
impact on healthcare workforce productivity (Bosworth et al., 2011; Conn et al., 2016). 
Another consequence of poor adherence is that it blurs the actual effectiveness of the 
treatment and its success rates (Viswanathan et al., 2012). This gap may affect the accuracy 
of clinical trial results and, subsequently, the outcome of decisions related to the treatment. 
Additionally, the literature studies that investigated adherence have approached it from the 
traditional pharmaceutical perspective ignoring the unique nature of medical technology, 
and especially issues around self-administered intervention such as the design of the 
treatment device, usability issues and human-factor issues. 
 
To this end, the research aims to investigate how design thinking can improve consideration 
of patient adherence during the development of self-administered treatment technology. 
Three main goals will contribute toward achieving this aim: 1) investigate the current design 
processes in treatment technology; 2) explore the contribution of design thinking to the 
development of the treatment; and 3) assess the impact of considering adherence factors 
during the design of treatment technology on the intervention outcome. 
 
Based on the addressed aim and objectives, the research methodology of the study has 
three main stages: Investigate, Explore and Assess. The Investigate stage aims to identify the 
role of adherence in medical treatment technology from the perspective of the literature 
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and the view of practitioners and founders of self-administered medical technology 
companies. The Investigate stage includes two steps: 
• Desk research, which reviews the literature related to design thinking characteristics, 
medical innovation, self-administered treatment devices and theoretical factors of 
adherence. 
• Case study interviews. Representatives from five SMEs were interviewed to explore 
the design process inside the company and how adherence was considered.  
 
The second phase, Explore, aims to explore how adherence could be considered while 
implementing design thinking in an early design stage. In this stage, MA of Design students 
at Northumbria University were observed during WearCare II, a practice-based design 
project. This stage aims to understand how adherence is considered in an early stage of 
product idea development and how the design process ensures an acceptable level of 
consideration of adherence during the design process timeline. 
 
The final stage, Assess, implements a Delphi methodology. This stage aims to explore the 
agreement of a multi-disciplinary panel on the factors that affect adherence and the 
importance of each factor. This stage is the triangulation stage as the data collected from 
the literature, case studies and observation is presented to the panel that includes 
representative who answer the case study interview questions. The Delphi consists of three 
rounds: 
• Round one: This round consists of interviews with the panel (15 panellists) who 
received an online link with open-ended questions to answer. This setup was 
planned to provide the panellists a flexibility to answer the questions especially 
during the Covid-19 pandemic. The panellists have expertise in medical psychology, 
medical design technology and design process and are representatives of the five 
case studies SMEs. The panel also includes representation of the healthcare system 
and medical research companies such as the Academy of Health Science Network 
North East and North Cumbria (AHSN NENC), National Health Service (NHS), Centre 
of Process Innovation (CPI), Philips, GraftWorx and ORCHA. 
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• Round two: The collected data from round one is analysed and presented to the 
panellists in the form of a questionnaire (Likert rating questions) to allow them to 
rate the importance of each adherence factor in terms of self-administered medical 
technology. 
• Round three: The same questionnaire is presented to each panellist along with the 
complete panel answers and the panellist’s own answer. This round aims to allow 
the panellists to change their answers after reviewing the full answers of all the 
panellists’ responses. 
 
To determine the significance of the data collected from round one and round two of the 
Delphi method, the Inter-rater reliability procedure and Wilcoxon test used to ensure the 
agreement between the panellists is not based on chance. The data collected from the 
Delphi study contributes to building a Design-Focused Adherence Canvas that companies 
can use to measure consideration of adherence during the design of a medical treatments. 
 
The primary limitation of this research is the timeframe constraints of the study. The 
timeframe of a PhD study does not afford the opportunity to test the results of the research 
and its impact on the participated companies. Therefore, the study stopped at the 
assessment stage, which uses the panellists’ answers to build an understanding of the 
factors that affect adherence and the level of impact or importance of each factor. Further 
research would provide the opportunity to test how the consideration of adherence factors 
during the design of the treatment technology affects the outcome of the self-administered 
treatment technology and the results of evaluating this outcome. 
 
1.2 Structure of the Thesis 
The thesis is divided into two parts (documents): The Thesis and the Appendices. The 
Appendices document was submitted separately of the main Thesis document as it was 
submitted as secure document as it contains information about the participants in both the 
interviews and Delphi panel. Therefore, the Appendices were submitted as a secure 
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document to ensure the anonymity of the participants information, and adherence to 
Northumbria University regulations. 
 
The structure of this thesis is closely linked to the structure of the study itself. The thesis is 
divided into Parts and Chapters. The Parts reflect either a section related to the study (e.g., 
Part 1: Introduction and Part 2: Research methodology) or chapters related to a specific 
research stage (e.g., Part 3: Investigate and Part 4: Explore). The chapters listed in each Part 
are related to one another and form a specific part of the study. Each part has a specific 
colour, which will be the same as the chapter names in the header of each page.  
 
The naming of the titles and sub-title heading was styled to ensure that the reader knows 
the current chapter and position. So, each heading starts with the chapter number (e.g. the 
first title in Chapter one is 1.1). Table 1.1 visualises the different parts of the study and the 
associated chapters: 
Part 1 Chapter 1: Introduction 
Introduction  
Part 2 Chapter 2: Methodology Introduction 
Research Methodology Chapter 3: Case Studies Methodology 
 Chapter 4: WearCare II Observation Methodology 
Chapter 5: Delphi Method Methodology 
Part 3 Chapter 6: Theoretical Frameworks of Adherence 
Investigate Chapter 7: Design Thinking 
 Chapter 8: Medical Technology Innovation 
 Chapter 9: Case Studies Interviews 
Part 4 Chapter 10: WearCare II Project 
Explore  
Part 5 Chapter 11: Delphi Method Application 
Assess  
Part 6 Chapter 12: Discussion of Findings 
Discussion and Conclusion Chapter 13: Introducing a Suggested Design-Focused Adherence 
Canvas 
 Chapter 14: Conclusion and Potential Contribution to Knowledge 
Table 1.1 A visualisation demonstration of the structure of the study 
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1.3 Research Aims and Objectives 
This research has two main aims. The primary aim is to investigate how design thinking can 
improve patient adherence in self-administered treatment technology. The secondary aim is 
to identify the factors that affect patient adherence during the design of the self-
administered treatment technology. The two aims form the main hypothesis of the study, 
which is that building a Design-Focused Adherence Canvas can improve adherence in self-
administered treatment technology. 
 
To this end, the following objectives will be achieved: 
• Investigate the current design processes applied in medical technology innovation 
and how adherence factors are considered during the development process. 
• Explore the contribution of design thinking in the development of the treatment 
intervention and how the process is used to consider adherence factors, especially at 
an early design stage.  
• Assess the impact of considering adherence factors during the design process on 
patient behaviour and the expected outcome of the treatment intervention.  
 
The above three main objectives contribute to building three areas of knowledge: 
Investigate, Explore and Assess. Below are the details of each area: 
• The first area of knowledge, Investigate, includes investigating both literature studies 
and primary data (interviews) to explore the theoretical adherence framework, the 
design process for self-administered treatment technology and how adherence is 
considered during the design and development process. 
• The second Area of knowledge, Explore, includes building an understanding of the 
adherence factors and how they are considered at an early stage of the design 
process. This stage presents a triangulation of knowledge from the previous one, and 
it will feed into the following stage, Assess. 
• The third Area of knowledge, Assess, is covered during the Delphi method procedure 
in order to reach an agreement between panellists on the adherence factors that are 
most important to consider during the design of the treatment technology. The 
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usage of the assessment procedure is linked to study time limitations. This will be 
discussed later (Chapter 14: 14.3.2 Delphi Study Limitations). 
 
Over the course of addressing the above aim and objectives, the questions below were 
prepared to guide the research in the following stages 
 Information about the study objectives and the knowledge that will be result from 
achieving each objective is discussed in more detail in later chapters of this study. 
 
1.4 Contribution to Knowledge 
This research claims two contributions to knowledge: 
• An adherence framework that identifies factors that affect patient-administered 
technology treatment adherence and their level of importance. 
The existing adherence theories and frameworks don’t consider the specific forms of 
medical technology interventions. This finding presented the first gap in literature. 
The interviews with case studies (Chapter 9: Case Studies Interviews) and Delphi 
method (Chapter 11: Delphi Method Application) contributed to formulate the first 
claim above. 
• A design-focused adherence canvas, based on the adherence framework (1st 
claim), which is a practical resource that records how adherence factors are 
being considered and their level of importance. 
Existing adherence theories don’t provide a practical mechanism for companies to 
consider adherence in their product or service. This finding presented the second 
gap in knowledge. The interviews with the case studies, the observation of WearCare 
II project (Chapter 10: WearCare II Project), and the Delphi method have contributed 
to formulate the second claim above. 
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1.5 Definition of Terms 
This study explores two main domains of knowledge: medical science and design science. To 
ensure the accuracy of the terms and their precise definition, the below section will: 
1. Highlight the definition of key terms used in this study, and  
2. Highlight how these definitions are used in the context of this research to reflect the 
nature of the research to explore the role of design in improving adherence in self-
administered treatment technology. 
The below definitions are categorised into two main sections—medical terms and design 
terms—to differentiate between the two domains of knowledge. 
 
1.5.1 Medical Terms 
The below definitions are related to the medical and health terms that will be used during 
this research.  
 
1.5.1.1 Adherence, compliance, concordances and more 
Literature studies have shown confusion between both the conceptual and operational 
definitions of adherence. As a result of this confusion, terms such as ‘compliance’, 
‘concordance’, ‘cooperation’, ‘mutuality’ and ‘therapeutic’ alliance were used 
interchangeability to define adherence (Horne, 2006). However, the shared element 
between these definitions is that they describe coordination between the patient and 
clinicians (Haynes, 1979). These different terms were reviewed in this study to identify the 
most relevant term that fits with the research aims. 
 
Adherence 
The World Health Organisation defines adherence as 'the extent to which a person's 
behaviour—taking medication, following a diet, and/or executing lifestyle changes, 
corresponds with agreed recommendations from a health care provider' (Sabaté, 2003, p.3). 
However, this definition limits adherence to three aspects of medical intervention, 
eliminating other aspects such as medical technology treatments. Cramer et al. (2008, p. 46) 
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introduced a more inclusive definition of patient adherence: 'the extent to which a patient 
acts in accordance with the prescribed interval and dose of a dosing regimen'.  
 
Compliance 
Haynes (1987, p.13) provided the most cited definition of compliance: 'the extent to which a 
person's behaviour [in terms of taking medication, following a diet, modifying habits or 
attending clinics] coincides with the medical or health advice'. While this definition aligns 
with the literature definition of adherence, the term 'compliance' reflects subservience 
(Bosworth et al., 2005) and passive reaction (Jette, 1982) from the patient. This superior 
attitude presents one of the reasons that caused a recent shift toward the term adherence 
(Martin et al., 2010).  
 
Concordance 
The term 'concordance' implies that both the patient and physician discuss and come to an 
agreement about the prescribed treatment (Aronson, 2007). A concordance can be defined 
as 'the consultation process, in which doctor and patient agree on therapeutic decisions 
that incorporate their respective views, to a wider concept which stretches from prescribing 
communication to patient support in medicine taking' (Horne et al., 2005. p. 12). The 
American Institute of Medicine defines the patient-centred approach as respecting patients' 
needs and preferences to improve the healthcare system, especially of patients with chronic 
diseases (Levinson, 2011, p. 823).   
 
The term 'concordance' is usually confused with adherence and compliance. It is likely that 
this is because words like concord, accord, or agreement have been used as synonyms for 
compliance and adherence (Aronson, 2007). Horne et al. (2005) highlighted that term 
'concordance' is confused and incorrectly used as a synonym for the term 'adherence'. 
 
Based on the above literature, the term 'concordance' reflects the communication and 
conversation between the patient and clinician. Accordingly, the term 'concordance' can 
represent one of the factors that affect patient adherence such as communication (Haskard-
Zolnierek & DiMatteo, 2009; Martin et al., 2010; Martin, & DiMatteo, 2013) rather than 
defining the whole picture of the term 'adherence'. 





The term ‘cooperation’ is used interchangeability with adherence and compliance. Previous 
studies tended to use this term to eliminate the passivity (Jette, 1982) and subservience 
(Bosworth et al., 2005) implied by the term ‘compliance’. While the term ‘cooperation’ 
includes patient adherence to the medication, it is more than just this. The cooperation 
between the patient and clinician can extend to a wide range of activities in time and place 
during the treatment intervention. 
 
Mutuality 
Mutuality refers to the relationship between patients and service providers that is based on 
experience, respect and collaboration (Henson, 1997). The term 'mutuality' reflects the 
unique experiential characteristics of the relationship between the patient and clinician 
(Smith & Newton, 1984). Based on this definition, this relationship can have a positive 
impact on patient adherence to the treatment (Martin et al., 2010). Similar to cooperation, 
mutuality reflects the broad range of the patient-clinician experience that extends beyond 
patient adherence to the treatment. 
 
Different terms are used to describe patient adherence to a prescribed treatment; according 
to the above exploration of the definitions of these terms, 'adherence' was selected 
because it most accurately represents this part of the patient-clinician experience.  
 
1.5.1.2 Patient Empowerment  
Self-determination theory is a cornerstone of patient empowerment as it aims to enable the 
patient to make decisions and solve problems (Bosworth et al., 2006). Patient 
empowerment provides a model of medical treatment that widens the scope of traditional 
healthcare systems to include the psychosocial aspects of patient experience, such as 
emotional, social and cognitive factors (Arnold et al., 1995). The evolution of medical 
technology and digital health—for example, e-health and web-based interventions—
contribute to the extension of the role of patient empowerment and self-efficacy 
(Samoocha et al., 2010). Therefore, this study focuses on medical treatment technology. 




1.5.1.3 Treatment and therapy  
As this study aims to investigate patient behaviour toward medical technology, two terms 
have been explored to define this patient experience: 'treatment' and 'therapy'. According 
to the Merriam-Webster dictionary (2020), 'therapy' is defined as the dose or solution used 
to address a specific disease. On the other hand, 'treatment' is defined as the whole 
experience related to taking the medication. The word 'treatment' has a broader meaning 
that includes not only the medication but also the medication management and the 
regimen associated with it. In accordance with the above, this study will use the term 
'treatment' to refer to the medical intervention and the environment associated with it. 
 
1.5.2 Medical technology  
There are a wide range of applications for medical innovation in the healthcare sector, 
which vary from treatment, monitoring or diagnosis solutions. This study focuses on medical 
technology innovation as it has an important impact on different aspects of the healthcare 
system including how it works, professional practice and the participation of patients in the 
treatment decision (Timmermans & Berg, 2003). The broad implementation of medical 
technology can bring varied benefits to the healthcare system. Healthcare technology has a 
wide range of medical devices that includes treatment devices, monitoring devices (Lehoux 
2009) and communication technologies (Heath et al., 2003). Furthermore, medical 
technology is not only limited to physical devices, but also extends to digital and mobile 
systems (e-health), which can provide cost-effective, flexible and efficient solutions 
compared with the traditional interventions (Istepanian et al., 2006). 
   
Medical technology contributes much to medical science and practice. It covers a wide 
range of equipment designed for the diagnosis and treatment of diseases (Moore & 
Zouridakis, 2004). The term 'medical technology' is broad and includes both medical devices 
and also the information technology associated with them. The application of medical 
technology includes the production of medical devices and diagnostic technologies such as 
digital imaging, instruments and test kits, surgical tools and implanted devices (Canadian 
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Healthcare Manager, Suppl. Health Research & Innovation, 2013). The coverage and the 
decisions to adopt medical technology fundamentally affect medical innovation (Institute of 
Medicine and Committee on Technological Innovation in Medicine, 1994). 
 
Another definition of 'medical technology' was presented by De Miranda et al. (2005) as 
they defined it as usage and the application of energy forms to the body systems. The 
energy forms include physical forms such as magnetic energy, thermal energy, electrical 
energy and chemical energy. The implementation of these forms involves using medical 
devices such as x-ray machines, electrocardiographs, precision lasers and printed sensors. 
While this definition provides a solid understanding of medical technology from the energy 
perspective, it lacks the use of other physical forms, such as the implementation of 3D 
printing technology, in creating medical devices.  
 
To position the term 'medical technology' in relation to its scientific contribution to the 
medical industry, a clear understanding of what medical science is required. Vandenbroucke 
(2008) indicated two types of views of medical science; one view emphasises discovery and 
explanation, and the other emphasises the evaluation of the intervention. The first view 
focuses on the discovery and explanation of diseases, while the second view focuses on the 
evolution of the discoveries and how it reflects on patient welfare. Based on those two 
views of medical science, medical technology is closely linked to medical science and may 
contribute to medical science knowledge from different perspectives. Accordingly, this 
study will adopt both the broad scope of the definition by the Canadian Healthcare 
Manager, Suppl. Health Research & Innovation (2013) while also considering the later 
definition by De Miranda et al. (2005) from the perspective of a diversity of energy usage. 
 
1.5.2.1 Medical technology vs Health Technology 
 
'To believe that doctors and hospitals help keep people healthy is plain 
rubbish,' Lord Platt (Hegde, 2011, p.1). 
 
The usage of the term 'medical' instead of 'health' in this research is based on both the 
difference in definition and the research scope. The terms 'health' or 'healthcare' refers to 
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the prevention of diseases in general and promoting health welfare within the community. 
Healthcare does not provide a cure to a specific disease. Instead, it aims to encourage 
people to live a healthy life. While healthcare focuses on public health, there are many 
applications that promote personal health such as mobile applications for weight loss and 
healthy lifestyle tracking devices. In contrast, 'medicine' or 'medical care' focuses on 
individuals who already suffer from a specific disease. In this case, the medical care focuses 
on diagnosing, treating and monitor patients suffering from a specific disease such as the 
mobile applications and insulin pumps used to treat Diabetes (T.H. Chan, N/A). 
 
Based on the above, the term 'medical technology' will be used in this study because of the 
primary focus on adherence to treatment technology regimens for chronic diseases. The 
definition of this term will also reflect the type of case studies used to explore the design 
processes in SMEs working in the medical technology industry.  
 
1.5.3 Self-Administered Treatment  
As the term implies, self-administered treatment refers to treatment intervention that is 
administered by the patient. However, the level of dependency is essential to this study. For 
example, Scogin et al. (1990) defined the self-administered treatment as 'any therapeutic 
intervention that was presented in a written or audiotaped format and was designed to be 
implemented by the client'. This definition excluded therapeutic interventions that are 
administered by therapists or require therapeutic consistency contact. The above definition 
also excluded any form of communication between the patients and clinicians, which is one 
of the essential factors that influence adherence to treatment intervention as will be 
discussed later in 4.1.6 Treatment and Treatment Support. Accordingly, in this study, the 
term 'self-administered treatment' will include treatment interventions that are either fully- 
or partly-administered by the patients themselves. 'Partly-administered intervention' refers 
to a level of communication between the patient and the clinician. This relationship can be: 
1) before the treatment to guide the patient in the use and administration of the treatment; 
and 2) during the treatment in order to follow-up with and provide consultations to the 
patient. Alternative strategies such as self-administered treatment can provide a solution to 
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overcome challenges faced by the UK health system, such as increasing number of 
appointments, short of staff and long waiting lists (Leigh & Flatt, 2015).  
 
Glasgow and Rosen (1978) indicated four levels of communication between the patient and 
the therapist: 
• Self-administered treatment, which is entirely administered by the patient with 
possible contact from the therapist for an assessment. 
• Predominantly self-help, which includes which includes introduction to the 
treatment and materials and learning to the treatment, introduction to materials 
and learning how to self-administer the treatment. 
• Minimal contact with some involvement of the therapist. 
• Therapist-administered treatment, which is entirely administered by the clinician. 
•  
With the development of online communication tools, communication between the patient 
and the clinician is becoming more accessible and affordable. This communication can be 
done through telephone, online chat and mobile applications. Literature studies have shown 
significant benefits for self-administered treatment such as its effectiveness (Bandura, 
1977), cost, affordability, convenience and suitability for some patients, especially those 
who do not want to take medications (Mains & Scogin, 2003). 
 
1.5.4 Treatment and Treatment Support 
This research focuses on two related medical technologies: treatment devices and 
treatment-support devices. The treatment devices are used as direct intervention to cure 
diseases or the health problem. The treatment support devices are used to facilitate the 
treatment to patients. While the support devices are not treatments themselves, they can 
be used to facilitate the delivery of the treatment, help patients to adhere to the usage of 
the treatment or improve patients' experiences with the treatment itself.  Accordingly, the 
treatment support technology may have an impact on the patient adherence. Therefore, 
this research will consider both types of devices. 
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1.5.5 Regime and Regimen  
While the term 'regimen' is relatively straightforward in medical science, experts from other 
fields may confuse it with the term 'regime.' According to the Cambridge Dictionary (2020), 
the word 'regime' is used to refer to a particular government or political system run by the 
government. Also, it can mean a particular way of operating a business or organisation. In 
addition to Cambridge's definition, the Merriam-Webster (2020) defines 'regime' as a 
regular pattern of occurrence or action, and the characteristics of a specific behaviour or 
natural phenomenon. 
 
On the other hand, the term 'regimen' is defined in the Cambridge Dictionary (2020) as a set 
of rules and regulations related to health, food or exercise in order to improve health. In the 
Merriam-Webster (2020), 'regimen' is defined by a systematic plan (e.g., diet, treatment, 
therapy or medication) designed to improve health. The treatment regimen is defined by 
the treatment plan that aims to improve and maintain the patient's health (AIDSinfo, 2020).  
In this study, the term 'regimen' will be used to refer to the treatment plan used to improve 
patient health. This plan is either administrated by patients or clinicians. 
 
1.5.6 Efficacy and effectiveness  
The term 'efficacy' refers to the treatment intervention conducted under ideal or controlled 
circumstances. In contrast, 'effectiveness' refers to the treatment intervention in real-world 
conditions. In clinical trials, it is impossible to conduct pure efficacy or pure effectiveness 
studies (Flay, 1986; Singal et al., 2014). Accordingly, the efficacy studies test whether the 
experimental therapy generates specific therapeutic effects. The effectiveness studies aim 
to quantify the effects of several factors on the total therapeutic effect (Ernst & Pittler, 
2006). The efficacy trials expect to facilitate different factors in order to achieve the main 
target of the trials; therefore, the intervention should be ready, there should be clear idea 
about the population and patients’ adherence to the treatment intervention. For example, 
real-world conditions such as poor access to intervention and poor patient adherence make 
the highly-efficacious results less effective (Singal et al., 2014). 
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In this study, both terms are used based on the two definitions given above. Further usage, 
such as the theory of self-efficacy (e.g., Chapter 6: Theoretical Frameworks of Adherence), 
will be defined in the context. 
 
1.5.7 QALY (Quality Adjustment Life Year) 
The QALY (Quality-Adjusted Life Year) is a generic method of measurement that aims to 
measure both the quality and quantity of patients' lives. The QALY measurement is used to 
assess the outcome of a specific medical intervention by examining its impact on increasing 
the years' patients may live in good quality (Love-Koh et al., 2015). As highlighted in figure 
1.1, a long life lived with chronic disease can be equal to a short life lived with good health. 
The QALY is calculated by the number of the life years lived multiplied by the weight of the 
quality of life where 0.00 means death and 1.00 is the best health level (Arnesen & 
Norheim, 2003). 
 
1.5.8 Design Thinking 
Literature studies conducted in the latter part of the 20th century contributed to defining 
the term 'design thinking'. One example was conducted by Peter Rowe, a professor of 
architecture at Harvard School of Design, in 1987 (Dorst, 2010; Nixon, 2016). Rowe intended 
to 'account for the underlying structure with those rather private moments of "seeking out", 
on the part of designers' (Rowe, 1987. p.1). Dorst (2012) defines design thinking as a 
practice that can be used to resolve issues with a broad approach in professional design 
practice and can be implemented to solve both business and social problems. In his article in 
the Harvard Business Review, Brown (2008) defined design thinking as the usage of 
designers' methods to address the people's need for solutions that are technically feasible 
and business viable.  
 
Lawson and Dorst (2013) highlighted three types of thinking in design: 1) convention-based 
design thinking, where the response to the design challenge is based on the conventional 
wisdom; 2) situation-based design thinking, where the response to the design challenge is 
based on the study of the situation and the response is customised based on this particular 
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situation; and 3) strategy-based design thinking, where the response to the design challenge 
is based on a planned and effectively designed process that reflects the interpretation of the 
design situation. In addition to the above, more types of design thinking were introduced by 
Dorst (2010), such as choice-based and experience-based thinking, developing new 
schemata and refining the design arena. Strategy-based design thinking will be used in this 
study to examine the linkage between design thinking and strategic management. 
 
However, Barsalou (2017) highlighted that design thinking involves the cognitive science 
perspective as its nature may change based on how the situation is seen from an 
explanatory perspective. Designers tend to change their design styles based on a reflective 
process, which makes it a challenge to find an absolute definition of design thinking. there 
isn't a single canonical form of Design Thinking, and that practices vary across projects and 
design teams 
 
In this study, the earlier definition of design thinking by Dorst (2010) was used with the 
focus on the strategy-based type of design thinking. The linkage between design thinking, 
business viability and technological feasibility will also be considered. 
 
1.5.8.1 Creativity and Design Thinking  
There have been several attempts to define creativity generally (Boden, 1996) and 
particularly in design (Gero & Maher, 2013). Hokanson (2007) suggested that creativity is 
the process that generates new ideas. Several studies have suggested that creativity has 
different levels that relate to the difficulty of the problem or novelty of the resultant 
solutions (Brown & Chandrasekaran, 1983; Gero & Rosenman, 1990; Westerberg, 1989; 
Gero & Maher, 2013). Creativity plays a crucial role in the design process, as it is necessary 
to achieve innovation (Mumford and Gustafson, 1988; Amabile, 1996; Howard et al., 2008). 
Literature definitions of 'innovation' have closely linked creativity to innovation, especially 
where ideas are transformed into commercial value (Thompson and Lordan, 1999; Culley, 
2002; Cox, 2005). From the design thinking perspective, creativity is an essential factor in 
the co-evolution of the problem and solution spaces (Dorst & Cross, 2001) as it has a pivotal 
role that leads to framing and reframing problems (Schön, 1983). According to the above, 
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creativity plays an essential role in the design thinking process and is a pivotal driver of 
innovation. Therefore, this study will take into consideration the creative aspect of the 
design thinking process. 
 
1.5.8.2 Innovation 
'Innovation' is one of the most commonly used terms in different disciplines, yet many 
confuse it with 'invention'. While invention is the occurrence of a new idea, innovation is 
the first commercialisation of the idea. Although both are closely linked, there is a time lag 
between the two. It may take a long time to transform inventions into innovations (Rogers, 
1995), which reflects the different requirements needed to transform ideas into innovative 
products or services (Fagerberg, 2004). 
 
Bassant (2013) indicated that innovation is about change that can take a wide range of 
forms, from simple, incremental improvements of the product or service to radical changes, 
which may involve a varied level of risks and benefits. Innovation does not happen by 
accident. While the organisation may get lucky once, in order to repeat it, an organised and 
structured approach must be applied. Drucker (2002, p. 5) indicated that 'in business, 
innovation rarely springs from a flash of inspiration. It arises from a cold-eyed analysis of 
seven kinds of opportunities'. These opportunities include unexpected occurrences, 
incongruities, process needs, industry and market changes, demographic changes, changes 
in perception and new knowledge (Drucker, 2002). 
 
Keeley et al. (2013) defined innovation as the process that creates a new, viable offering 
through understanding problems and providing solutions. This definition has four main 
characteristics: 
•    While innovation may involve invention, it also requires activities other than simply 
creating new ideas, such as understanding the consumer's needs. 
•    Innovation should provide a return value for the enterprise. To achieve innovation 
viability, it should sustain itself and return its weighted cost of capital. 
•    Innovation can vary from small improvements to radical changes. Most innovations are 
improvements based on previous advances. 
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•   Innovation is not limited to the product or the service. It should extend its role to cover 
new ways of doing business. 
 
The innovation process provides a result to the design process. It starts with creativity as a 
generator of new ideas and ends with an innovative product or service that is a result of the 
design process inside the enterprise (Cox, 2005). From the medical technology perspective, 
innovation has three dimensions: consumer-focus, technology and business model. 
Consumer technology innovation aims to put the consumer at the heart of the development 
process by creating solutions that are more effective, more convenient and less expensive 
than current solutions. Technology innovation focuses on developing medical devices, 
diagnostic systems and drug delivery systems that are less expensive, less painful and less 
disruptive. Business model innovation aims to build a less fragmented healthcare system 
that solves the integration problem between all the stakeholders (Herzlinger, 2007). While 
this study aims to investigate innovation in the medical industry from the technological 
perspective, other dimensions of innovation in the industry will also be considered because 
all the three aspects of innovation lie under the umbrella of strategic design thinking 
interest and come together in the medical industry. 
 
1.5.8.3 Small and Medium Enterprises (SMEs) 
The definition of SMEs differs from country to country. These definitions vary based on a 
number of factors, the most important being the number of employees. Lukács (2005) 
defined SME as an independent business that is managed by its owners or part-owner. SMEs 
have a small market share. Until 1996, SMEs were defined solely by the number of 
employees, for example, micro-enterprises (1-9 employees), small enterprises (10-99 
employees) and medium enterprises (100-499 employees). In 1996, a new definition was 
introduced by the European Union for SMEs; the definition was based on the following 
criteria (European Commission, 1996): 
• The total number of employees 
• The annual volume of turnover 
• The total assets of the enterprise 
• The ownership or the degree of independence 
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According to the above, the SMEs were categorised as shown in Table 1.2. 
Category Headcount Turnover 
Medium < 250 £ 35.2 Million 
Small < 50 £ 8.2 Million 
Micro < 10 £ 1.7 Million 
Table 1.2 The categorisation of SMEs based on the European Commission definition 
Based on the UK Gov website (2012), SMEs need to meet two out of the three following 
characteristics: 
• Employees: Less than 250 
• Turnover: Less than £25m 
• Gross assets: Less thank £12.5m 
The UK definition is based on the turnover of the SME, as £25m is the lowest level of the 
definition of a Mid-Sized Business (MSB), which has a turnover range of between £25m - 
£500m. Based on the above definitions, the study will adopt the UK definition of a SME and 
will focus the research sample characteristics on the SMEs.  
1.5.9 Characteristics of Design and Medical Innovation 
To identify how design can contribute to medical innovation, the research aims to explore 
the characteristics of the design thinking process and how it stands apart from other 
development processes.  
 
De Mozota (2003) tried to identify the nature of design from the etymological approach by 
pointing out how design merges intention (need) with drawing (creativity). This definition 
aligns with the International Council Societies of Industrial Design (ICSID)'s definition of 
design. The ICSID highlighted two main characteristics of design:  
1) Aim: Design is a creative practice that aims to create an object, process, service or 
other outcomes, and  
2) Task: Design seeks to discover and assess the current situation to reach an improved 
state, such as enhancing global sustainability, giving benefits and freedom to people, 
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supporting cultural diversity and giving products and services an aesthetic form by 
appreciating the complexity (De Mozota, 2003; Manzini, 2006). 
 
The above two definitions appreciate two main characteristics of design: 1) creativity, form 
and aesthetics of the product or service; and 2) moving from one status to an improved one 
(addressing needs). These characteristics were highlighted in Tim Brown's definition of 
design thinking as: 1) a human-centred approach; 2) innovative; 3) addressing people's 
needs; 4) producing a product that is aesthetically desirable; 5) viable technologically; and 7) 
feasible from the business perspective (Brown, 2011). 
 
Cox (2005), Culley (2002) and Thompson and Lordan (1999) highlighted the nature of design 
as an innovative process that transforms creative ideas into innovative products. Cox (2005) 
saw design as a process that links creative new ideas and transforms them into innovative 
products and services. Therefore, design and innovation can’t disconnect from each other, 
innovation is an outcome of the design process. Other definitions for design targeted the 
nature of design and how designers think to transform intangible ideas into physical 
products or services. Dorst and Cross (2001) and Dorst (2018) pointed out the problem 
frame/solution frame nature of design. According to the above literature, the below 
characteristics highlight the nature of design: 
a) A creative process that is used to transform creative ideas into innovative products. 
b) Acknowledges uncertainty and the move between both problem space and solution 
space. 
c) Human-centred, as it addresses people's needs in the context of use. 
d) Considers the aesthetical features of the product. 
e) Considers the business-related aspects of the product. 
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1.6 COVID-19 Impact on Research 
In February 2020, the world was hit by the SARS-CoV-2 virus causing COVID-19 virus 
outbreak, which disrupted almost all industries as well as the healthcare systems in every 
country, including the UK. This outbreak impacted this study in the following ways: 
• The outbreak lockdown occurred during the Delphi method; this moderately 
delayed, by an average of two months, the response time of the panellists. 
• Panellists working in the NHS or companies closely related to it were given longer to 
respond to each round. 
• My research plans were disrupted, especially at the beginning of the outbreak in 
February and March. 
  
1.7 Conclusion and Summary 
This chapter has presented the initial research aims and objectives. Information about the 
research’s significant contribution to knowledge was provided. Additionally, the definitions 
of the terms used in the study were reviewed and clarified to ensure an accurate reflection 
of their meanings and interpretations. Finally, the impact of COVID-19 outbreak on the flow 
































Chapter 2: Methodology Introduction 
 
This chapter introduces the general 
methodology and research design of this 
study. It will review the research scope, 
philosophy and approaches. Then, it will 
highlight the research strategy, methods 
and process required to achieve the results 
of the strategy. Finally, research ethics will 
be discussed. 
Key Topics: 
2.1 Research Scope 
2.2 Research Philosophy 
2.3 Research Approaches 
2.4 Research Methods 
2.5 Research Strategy 
2.6 Data Triangulation 
2.7 Research Process 
2.8 Research Ethics 
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This part of the thesis outlines the methodologies used in each of the research stages. The 
first chapter covers the high-level elements of the research methodology such as the 
research scope, strategy, and plan. This chapter presents the base of the following chapters 
who discuss the research. 
2.1 Research Scope 
The research aim of this study is to explore how design thinking can improve patient 
adherence to self-administered medical technology treatment developed by small and 
medium enterprises (SMEs). To explore the research’s aim further, the healthcare 
challenging state was overviewed as following: 
Healthcare Burden 
Public spending on healthcare is a burden on many countries, including the UK. In 2006, at 
least 5 per cent of the UK’s GDP was allocated to the healthcare system (Natarajan, 2006). 
This amount has been increased to 8.4 per cent in 2011 (Chang et al., 2011).  Although some 
countries try to overcome this increasing pressure by facilitating private healthcare 
insurance, this solution may lead to inequality in the services offered (Timmins, 2005). The 
fact that the NHS provides equal healthcare service to both public and private patients 
(Oliver, 2005) increases its expenditure. The three main factors that cause this growing 
pressure are: 1) the financial load caused by ensuring that public sector wages remain 
comparable to those in the private sector; 2) increasing demands for healthcare; and 3) an 
increasingly elderly population (Emmerson et al., 2000).  
Adherence 
The adherence factor plays an essential role in different patient interactions with the 
healthcare system, including diagnosis, monitoring and treatment (Bosworth et al., 2006; 
Nunes et al., 2009; Sabaté, 2003). An estimated 20% to 30% of patients do not adhere to 
their treatment regimens (Viswanathan et al., 2012), and this increases to between 30% and 
50% among patients with chronic diseases (Barnett, 2014; Nunes et al., 2009; Sabaté, 2003). 
Failure to reach a significant level of adherence can cause serious complications, including 
death (Aldeer et al., 2018; Viswanathan et al., 2012). Accordingly, this research focuses on 
the impact of adherence to treatments on: 1) the outcome of treatments; 2) the accuracy of 
treatment efficacy; and 3) evaluations of treatments during clinical trials. 
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2.2 Research Philosophy 
To clearly state how this research philosophically addresses the phenomena studied, the 
philosophical approach to the study should be clearly defined (Saunders et al. 2008); 
therefore, this section provides an overview of the relevant research philosophies. In 
general, there are three philosophical approaches: ontological, epistemological and 
axiological (O’Gorman & MacIntosh, 2014; Saunders et al., 2008; Quinlan et al., 2019). 
Considering the nature of the study, the following provides a summary of the research 
philosophies and approaches that align with the nature of the research scope. 
 
2.2.1 Ontology 
Part of the branch of philosophy called Metaphysics, Ontology refers to research activities 
that aim to understand the ‘what is’ (Welty, 2003. p. 11). Ontology is a philosophical 
approach developed by the ancient Greeks and discussed by positivists such as Descartes 
through which the researcher aims to understand the nature around or the phenomena 
(Crotty, 2003); as Cocchiarella (2007) notes, ‘Ontology = the study of being as such’ (p. 3). 
Ontology informs two views of the nature of ‘reality’: objectivism and subjectivism. 
Objectivism regards phenomena as external to and independent of social actors. In contrast, 
subjectivism claims that the perceptions and actions of social actors form the world around 
them. Subjectivism and interpretivism are closely linked. Research that uses the interpretive 
approach explores the definition of the social phenomenon (Epstein, 2018). This is 
important because the researcher needs to understand the factors which affect 
participants’ beliefs and attitudes towards the phenomena being researched in order to 
accurately interpret the collected data (Wilson, 2010). Accordingly, the ontological approach 
will be utilised in this study to understand the adherence factors in the literature. 
  




Epistemology is one of the oldest branches of philosophy. It comes from the Greek word 
‘episteme’, which can be translated as ‘knowledge’. Epistemology is concerned with what 
constitutes acceptable knowledge, such as how we see and deal with social phenomena. In 
this philosophical tradition, the researcher asks questions, such as ‘how’, that reveal 
knowledge (Steup & Ram, 2020). In this study, the epistemological approach will be widely 
adopted to understand the knowledge related to different elements of the research such as 
the theoretical frameworks of adherence and the design process.  
 
The epistemological approach aligns with the study’s scope and research design. Therefore, 
it is used in this study to reflect the study’s phenomenological approach of understanding 
the phenomena (e.g. adherence) as they appear in our experience (Husserl, 2012). Smith 
(2018) suggests the phenomenological approach can be applied to understanding: 
• The appearance of phenomena; 
• The phenomena as they appear in our experience; or 
• How we experience the phenomena. 
 
Accordingly, phenomenology studies conscious experience as experienced from the 
subjective, or first-person, point of view (e.g. the point of view of the representatives of 
SMEs). While the research adopts a phenomenological epistemology perspective, the 
ontological approach cannot be ignored, especially in the early stages of the study where 
the phenomenon is defined. The ontological approach helps clearly explain the nature of 
the study elements. In this regard, the adoption of ontological realism can be considered a 
practice of critical realism (Fletcher, 2017). 
• In addition to the overview of the related research philosophies above, how the 
data is handled during the research is crucial to clearly defining the researcher’s 
position. As such, the below offers an overview of the different research 
approaches related to the current study 




Axiology is concerned with the nature of value and ethical issues within research, as well as 
the researcher’s values and how these affect the study. Some approaches, like positivism, 
consider the research process to be value-free (Wilson, 2010). The way the researcher 
regards the values related to the research plays an essential role in how research ethics are 
considered during the research process (Saunders et al., 2008). The axiological approach will 
be adopted in the study in relation to the communication with the participants and the 
management of the data, which was described in the research ethics application.   
 
2.3 Research Approaches 
The approaches to how the collected data are considered within the study affect the 
research outcome. Below is a brief of the research approaches related to this study (Denzin 
& Lincoln, 2011; O’Gorman & MacIntosh, 2014). 
 
2.3.1 Positivism 
In this approach, the researcher regards social phenomena as objective reality and 
acceptable truth so that data collected from the research can be used to build a generalised 
theory. Accordingly, only observable phenomena can give rise to credible data. In this 
approach, the researcher uses previous research to build a hypothesis that can be tested. 
Positivism (also known as logical positivism or subjectivism) has three characteristics:  
• Phenomenological: It distinguishes between the external world and the researcher 
who is observing it. 
• Empirical: It uses observable evidence to establish ‘knowledge’. 
• Objective: It separates the scientific knowledge from the researcher’s perspective, 
feelings, beliefs and values (Mäki, 2008; Payne & Payne, 2004; Williams, 2000). 
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However, positivism has faced criticism in the 20th century, especially with the rise of post-
positivism movements that are inspired by scientific theories, such as the theory of 
relativity, which suggest that events in the world are not isolated from each other, but are in 
fact connected and unified. (Liamputtong, 2019). 
 
2.3.2 Realism 
Realism is similar to positivist approaches and is related to scientific enquiry. It shares the 
phenomenological nature of the epistemological position in that it holds that what our 
senses show us is real and true, and that objects exist independently of the human mind. In 
this approach, the reality of phenomena can be seen from two perspectives:  
• Direct realism: In this perspective, we experience the world through our senses, 
which represent phenomena accurately. 
• Critical realism: In contrast, critical realism maintains that reality experienced 
through our senses can be deceiving; thus, phenomena need to be observed from 
different perspectives to validate their accuracy (O’Gorman & MacIntosh, 2014). 
While realism shares the phenomenological nature of the positivism, it is less fixed from the 
empirical perspective, in that it does not consider the truth of a theory essential to ensuring 
its accuracy (Bhaskar, 1998).  
 
2.3.3 Interpretivism  
The interpretive approach acknowledges the complexity of social phenomena. The 
researcher needs to be able to identify the role of human beings as social actors and 
differentiate between social phenomena which involve people and those which include 
objects. In this approach, the term ‘social actor’ is crucial to creating the need for 
interpretation: the person is considered an actor on a stage, which means that he or she 
interprets phenomena and transfers the knowledge to the researcher through the research 
methods adopted (O’Gorman & MacIntosh, 2014). The interpretivist approach is closely 
linked to phenomenological philosophy as it appreciates the subjective nature of describing 
phenomena. 
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In this research, the data collected reflected the experiences of the research sample. 
Therefore, the interpretivist approach will be adopted. However, during the early stage, a 
realist approach was used to handle the initial definitions related to the research 
phenomenon (e.g. adherence, design thinking and medical innovation). A realist approach 
was used to clearly define the different elements in the research. While these elements 
could be defined with a different approach in other studies, they were accepted as objective 
truth to focus on the main aim of the research. 
 
According to the above overview of research philosophies and related approaches, the 
phenomenological epistemology approach was adopted in this study to understand the 
phenomenon of adherence and the factors affecting it. This understanding is based on an 
interpretive phenomenological approach, which was adopted in the study to understand 
the phenomenon (adherence) and its relationship with the social actors (patients) based on 
the feedback from the latter, including researcher observation. That said, the research 
showed evidence of the objective and ontological philosophical approach, especially in 
relation to understanding the phenomenon of adherence, based on the theories outlined in 
the literature that aimed to investigate the factors which affect it, as highlighted earlier. 
 
2.4 Research Methods 
In order to determine the most suitable type of data to collect during the research, three 
main approaches were explored: 1) qualitative; 2) quantitative; and 3) mixed methods. Each 
type is described below (Creswell & Creswell, 2017): 
• Qualitative approach: This approach aims to understand how participants see and 
describe a specific social phenomenon from their subjective points of view. The 
researcher’s role is to interpret the meaning of the data to build general themes. The 
nature of this research requires an inductive approach and acknowledges the complexity 
of social phenomena (Rocco & Hatcher, 2011). 
• Quantitative approach: In this approach, the researcher aims to examine the 
relationship between measurable variables. The collected numerical data are analysed 
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using statistical methods. This type of approach has assumptions that are tested 
deductively (Rocco & Hatcher, 2011). 
• Mixed methods approach: This approach combines qualitative and quantitative data. 
The development of this approach is based on the assumption that the combination of 
qualitative and quantitative approaches helps to build a complete understanding of a 
phenomenon (Creswell & Creswell, 2017). 
 
Mixed methods will be utilised over the course of this study. While the Investigate 
(Chapter 9: Case Studies Interviews) and Explore (Chapter 10: WearCare II project 
observation) stages will be using qualitative data, the Assess stage (Chapter 11: Delphi 
Method Application) will adopt both qualitative and quantitative approach. 
 
2.5 Research Strategy 
The research strategy scopes a research design plan to achieve its main aims. To this end, 
the following research strategies were examined in order to identify the most suitable 
among them (Creswell, 2017; Denscombe, 2010): 
• Survey research: This provides a quantitative description of the phenomenon by 
studying a sample of the population linked to it. The main aim of this strategy is to build 
a generalisation from the sample (Fowler, 2009). 
• Experimental research: This is another quantitative strategy that aims to experiment 
with a specific practice, such as a treatment, and explore how this influences the 
outcome of the experiment (Keppel, 1991). 
• Case study research: This aims to build an in-depth analysis of a case study bounded by 
time and activity. The researcher collects data about the case study and the people 
involved in it (Yin, 2011). 
• Ethnographic research: This aims to understand the social behaviour of a social group 
and explore the shared patterns of behaviour and how these affect the cultural group in 
its natural environment (Creswell, 2017). 
• Grounded theory research: This aims to build a generalised theory about the 
phenomenon from the point of view of the participants. This method involves multiple 
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stages of data collection and analysis until the saturation point is achieved (Charmaz, 
2014). 
• Phenomenological research: This is linked to philosophy and psychology. The study 
explores the phenomenon from the description of the individuals involved in it. This 
research strategy involves conducting interviews with the participants in order to 
explore and analyse their experience (Creswell, 2017). 
• Mixed methods research: This involves the processing of both quantitative and 
qualitative data during the study (Creswell, 2017). However, various definitions were 
introduced based on the properties of the tool and the target of using it. The mixed 
methods were introduced as a systematic integration between quantitative and 
qualitative data, sequential or simultaneous use of qualitative and quantitative data, and 
two or more methods. while there are different views of mixed methods, the target of 
using it as almost the same that is building a more elaborated understanding of the 
phenomenon (Johnson & Onwuegbuzie, 2004). From the perspective of the sequence 
and integration of both qualitative and quantitative methods, Creswell (2017) defined 
main models. The first is convergent parallel mixed methods, in which the research 
starts with quantitative data and then moves to qualitative data in order to analyse the 
phenomenon comprehensively. The second is explanatory sequential mixed methods, in 
which the researcher starts the research by collecting and analysing quantitative data 
before collecting more detail using qualitative research. The third method (Exploratory 
sequential mixed methods) is similar to the second, but in reverse order: the researcher 
starts with qualitative research, after which the data are analysed before the 
quantitative analysis is carried out. 
• Action research: This involves making a practical contribution to the research activity. In 
this type of research, the participants play an essential role as they are practically 
involved in changing or affecting the current state of the situation being studied. The 
other two characteristics of this research are its practical nature and the importance of 
the feedback loop tin changing the current phenomenon (Denscombe, 2010). 
• Systematic review: This research aims to gain objective insight into the phenomenon 
and evaluate the effectiveness of the research intervention (Denscombe, 2010). 
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Based on the brief overview of research strategies above, this study applied a mixed 
strategy approach, as follows: 
• The core strategy of the research is adopting phenomenological philosophical approach 
due to the nature of the social phenomenon studied. However, from the perspective of 
the methods used, the research adopts a multiple mixed methods approach (interviews, 
observation, and Delphi method). The case studies step includes interviewing companies 
working in self-administered medical treatment technology as described in details in 
Chapter 9: Case Studies Interviews. Then, the observation method was used to observe 
how adherence is considered in an early stage of designing the medical technology 
(more details about the setup and usage of this method in Chapter 10: WearCare II 
Project). Finally, Delphi method will be used to collect panellists’ agreement on 
adherence factors that can affect the usage of self-administered treatment technology. 
During the Delphi process, both qualitative and quantitative methods will be used (more 
details about the process is in Chapter 11: Delphi Method: Instrument Design and 
Application). 
• The exploration of case studies was considered from a phenomenological approach as 
the collected data reflected the participants’ points of view and reflections on the 
practice conducted during the development of the medical solution examined in this 
study. 
• In terms of the type of data collected throughout the study, an explanatory sequential 
mixed method was applied. The early stages depended on the qualitative data collected 
through interviews, reflection on practice and observation. In the later stages (2nd round 
of the Delphi method), quantitative data were collected through a triangulation process 
using the Delphi method, as highlighted later in this chapter. 
 
And based on the research approaches, this research adopted a mixed-method approach, 
collecting both qualitative and quantitative data as follows: 
• Secondary data was collected from the companies, their products and the clinical trials 
conducted for these products, including both qualitative and quantitative data. For 
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example, the qualitative data included feedback from patients about the product, while 
the quantitative data included the percentage of patients that adhere to the treatment 
regimen. 
• Qualitative data was collected in stage one (interviews, stage two (observation), and 
stage three (1st Delphi round). The aim of stage one and two is to explore the design 
process and how adherence is considered in the process from different perspectives and 
build a clear understanding of the companies’ experiences from a phenomenological 
interpretive perspective. The aim of the qualitative data (collected using open-ended 
questions) in the 1st round of the Delphi method (stage 3) is to identify the factors that 
affect patient adherence in self-administered medical technology treatments. 
• Quantitative data will be collected in the second and third rounds of the Delphi method 
(stage three) to identify the consensus between the panel members. 
 
2.6 Data Triangulation 
The data triangulation strategy refers to the use of mixed methods or data sources to 
understand the phenomenon related to the study (Patton, 1999). This strategy was not part 
of the initial study plan, yet it evolved organically from the main structure of the research 
design, which used three qualitative research methods in addition to the desk research. The 
knowledge accumulated as study moved from one stage to the next presented an excellent 
opportunity to triangulate data in order to better understand the research topic. 
Understanding the role of triangulation in the study requires a review of the different types 
of data triangulation. Triangulation can take four forms (Denzin, 1978; Nancy et al., 2014; 
Patton, 1999): 
• Method triangulation: This type uses multiple research methods to collect data 
about the same research topic. For example, it may include interviews, focus groups 
and observation. 
• Investigator triangulation: In this type, two researchers independently investigate 
the same phenomenon and use the data collected by both to understand the 
phenomenon.  
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• Theory triangulation: In this type, different theories are used to interpret or 
understand the same data. Exploring the data from different perspectives may 
contribute to a better understanding or confirmation of the findings. 
• Data-source triangulation: This type involves collecting data from two types of 
targeted population or research samples related to the main study. The collected 
data are then analysed from both sources to see the problem from multiple 
perspectives. For instance, the study can use data from both patients and clinicians 
about the same health issue. 
Two types of triangulation have been utilised throughout the study: 
• The stages before the Delphi method in Stage 3 (Assess) aimed to explore the 
phenomenon from multiple perspectives. Therefore, the data was triangulated 
between these stages and the Delphi method. Accordingly, both method and data-
source triangulations were applied. Three methods were used (desk research, 
interviews and observation) to triangulate data in the Delphi method. The three 
main data sources used in the data triangulation were secondary data, case studies 
SMEs and the post-graduate students working in WearCare II Project.  
• Both method and data source triangulations were used over the course of the 
research when proceeding from one step to the next. For instance, the secondary 
data collected via the desk research was used to refine the target of the interviews 
with the SMEs. Similarly, the data collected and analysed from the interviews were 
used to formulate the target of the observations.  
The first three steps investigate and explore the design process, and how adherence is 
considered during the design process. Each step presented a view of the phenomenon from 
a different perspective. Accordingly, the triangulation of data contributed to building 
knowledge that was assessed in the final stage. 
2.7 Research Process 
As part of the research methodology, data was collected from case studies to analyse 
companies’ experiences of developing treatment technologies. The sample companies offer 
both partially and fully patient-administered treatments. As adhering to the regimen is 
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challenging in self-administered treatments, this study focused on adherence and how it is 
considered during the development process, testing and clinical trials. 
The research methodology was influenced by the study’s main aim and the data required to 
make the planned contribution to knowledge (Denscombe, 2010). The phenomenological 
interpretative nature of the research directed the choice of research method toward 
qualitative methods (Kothari, 2004). However, quantitative data were also considered in 
order to build a clear understanding of the nature of the case studies, the results of the 
clinical trials and the information about the use of patient-administered products (Creswell 
& Creswell, 2017). To structure the research workflow, the process was divided into ‘Stages’ 
and ‘Steps’. The Stages reflect the main aims of the research are 1) Investigate; 2) Explore; 
and 3) Assess. The steps represent the research activities: 1) Desk; 2) Field; 3) Analysis; 4) 
Action; and 5) Assess.  
Within the Investigate phase, Steps 2 (Field) and 3 (Analysis) were considered ‘mapping 
steps’ as the data collected from the interviews was mapped onto the literature on 
adherence-related theories.
 
Fig 2.1 The research process diagram 
 
2.7.1 Stage One: Investigate  
The Investigate stage builds an understanding of each case study, its development process, 
consideration of patients’ adherence and data collected from companies and clinical trials. 
This stage had three Steps: 1) desk research; 2) field research; and 3) analysis, as follows. 
 
2.7.1.1 Step 1: Desk research  
In the first Step (Desk), secondary data was collected from the company itself using 
documents shared by the company. Additional secondary data was collected from publicly 
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available information from the AHSN, National Institute of Health Research (NIHR) and NHS 
archives, clinical data results and published papers and articles. This step played a key role 
in the research as it helped the researcher to: 1) ensure that the company and its product 
aligned with the scope of the study; and 2) learn important details about the company, such 
as its size, structure, products, stage of product development and involvement in the 
healthcare innovation system in the UK. The data collected from this step played a crucial 
role in developing the questions asked during the semi-structured interviews in each case 
study.  
 
2.7.1.2 Step 2: Field research 
In Step two (Field), primary data was collected from each case study through interviews. 
This step builds a clear understanding of the companies, their products, their design 
processes and how they consider adherence. To meet this goal, the qualitative approach 
was regarded as the most suitable. To explore the research that may be used in this step, 
three methods were considered: 1) focus groups, group interviews and interviews (Gibbs, 
2012). Both focus groups and group interview methods were excluded as: 1) they do not 
ensure the security of information which companies demand; 2) participants’ answers can 
be influenced by the other participants in the focus group; 3) the accuracy of the collected 
data cannot be guaranteed; and 4) there were time and location limitations on gathering 
different founders of a single company or founders of different companies in the same place 
at the same time (Gubrium & Holstein, 2012). Accordingly, the most suitable method was 
the interview.  
 
Three main types of interviews were considered: 1) structured; 2) non-structured; and 3) 
semi-structured. Structured interviews proceed by asking attendees pre-defined questions 
that are not altered during the interview. This type does not provide the researcher with the 
flexibility to adapt the interview questions based on the course of the discussion. Non-
structured interviews do not use pre-defined questions, which reduces their benefits 
(Gubrium & Holstein, 2012). Semi-structured interviews provide the researcher more 
flexibility as the questions can be adapted to the specific situation either before or during 
the interviews, which gives the researcher the chance to maximise the benefits of the 
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interview by altering the course of questions to learn more about the specific company’s 
experience (Harrell & Bradley, 2009; Rabionet, 2011). Accordingly, the semi-structured 
interview was adopted in this research to maximise the benefits of the discussions with 
companies. This type of interview allowed the researcher to predefine questions but also to 
elaborate on and alter them in order to explore every interviewee’s unique experience in 
greater detail through online meetings via Skype. The meeting method was chosen based on 
the time and availability of each company’s founders. Each interview lasted from one to two 
hours and was recorded. The interview transcripts were created using the Otter application 
on iPad. Due to the possible mistakes in the transcriptions, the transcribed manuscripts 
were reviewed and compared with the audio narration. Transcribing mistakes in the 
interviewees’ answers were corrected to ensure accurate description for the answers.  A 
backup audio recording version was created using the Apple iOS Memo application. While 
interview questions were previously prepared and shared with interviewees, they were 
altered, changed or modified based on the nature of the conversation during the interview.  
 
The interviews were conducted in two batches—each batch consisted of three companies. 
Three companies were initially invited for interviews, after which their data were analysed 
(or partially analysed) before moving on to the second batch. This sequence helped to 
identifying exciting discussion points that could be discussed with companies in the next set. 
Further details about the observation setup in this research are covered in Chapter 4: 
WearCare II Observation Methodology. 
 
2.7.1.3 Step 3: Data analysis 
In the third step, Investigate stage, the data collected from the interviews were analysed. 
Different data analysis methods were explored. They differed in how they consider and 
interpret the data collected from the interviews, as follows (Denscombe, 2010): 
• Content analysis: In this method, the interview data are broken into smaller 
components, such as words and lines. The researcher then develops relevant categories 
from the analysed data. As Vaismoradi, Turunen, & Bondas, (2013) highlighted, the 
content analysis considers the common issues in the data (Green & Thorogood, 2004) 
and tends to quantify the data (Braun & Clarke,2006), which be considered a limitation 
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for applying the method in this study. Accordingly, this method is not the most suitable 
especially for exploring the detailed qualitative data about the companies’ experience. 
• Theme analysis: The researcher analyses the data and assigns codes (keywords) to each 
part of the interview, which may range from one word to a whole paragraph. The codes 
are then sorted into relevant categories which contribute to building hypotheses or 
inductive concepts. As this method aims to create a generalised theme or hypothesis 
that can be assessed, it presented a suitable approach for this study. Vaismoradi, 
Turunen, & Bondas, (2013) indicated that the thematic analysis aims to identify common 
themes in one or more interviews (DeSantis & Noel Ugarriza, 2000). Thematic analysis 
tends to quantify details bubbling out of the coded content (Braun & Clarke, 2006). 
According to the above. 
• Discourse analysis: This method claims that the data gathered from the conversation 
during the interview should not be taken at face value; instead, the analysis should focus 
on the implied meaning of the words. There exists a debate about the reliability of this 
approach, because it cannot be proven that the analysis definitively represents the real 
meaning of the conversation. Therefore, it was not a suitable analysis method for the 
study. 
• Conversation analysis: This method is a variant on discourse analysis as it focuses on the 
sample activity through the language used. It is influenced by the cultural backgrounds 
of both the participants and the researcher. As this method tends to explore everyday 
activities, it was not suitable for this research, which focused on a specific corporate 
experience through the development of medical technology. 
• Narrative analysis: This approach explores the topic through narrative. The participants 
share their experiences in the form of a story using different media. This approach did 
not fit this research as the professional nature of the participants may be a barrier to 
their sharing their experiences in narrative form. 
Based on the brief comparison of the four methods of analysis presented above, thematic 
analysis was deemed the most suitable form of data analysis to use in this study to 
understand the current state of design’s contribution to product development and the 
consideration of adherence within the context of development and testing in companies.  
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In general, there was an overlap between steps because of the nature of the research 
timeline. The interviews were analysed using thematic analysis to identify the shared 
themes related to adherence among the case studies. The research was conducted using 
NVivo software version 12 for Mac. The anonymity of the case study participants and the 
confidentiality of the information were both considered during the thematic analysis and 
are discussed in more detail in Chapter 3 (3.4.1 Anonymisation of Data). Both step two 
(Field) and three (Analysis) form a mapping phase as the collected data from both Desk and 
Field research were mapped onto the literature related to the consideration of adherence 
during the development process (Taylor et al., 2015).  
 
2.7.2 Stage Two: Explore  
The second stage in the research process is the Explore stage, which involves observation 
for the WearCare II group project, a post-graduate project run for the MA Design students 
at Northumbria University.  Details about the project and the Explore stage will be covered 
in Chapter 10: WearCare II Project. The project aims to design a medical solution to improve 
people’s lives, so the students worked in groups to address the design challenge. Part of the 
limitations of the first stage is that the interviews with companies highlighted were already 
established and their products either in prototype stage or already delivered to the health 
market.  The deployment of the observation method was decided because it provides the 
researcher the opportunity to observe the sample in the field (design practice room) and be 
able to observe sample’s actions, practice, and their description for their project (Sapsford, 
& Jupp, 2012). 
 
The second stage explores product ideas in an early design process’s steps and how 
adherence is considered in this early part of the design process. This stage presented an 
opportunity to explore the consideration of adherence from different perspectives. The 
students were observed on weekly basis during the academic semester one 2019.  The data 
of their progress in developing the design idea and the consideration of adherence factor 
were taken via notes by the research. During the weeks that the researcher didn’t attend, 
groups were asked to fill an online questionnaire to document their activities. 
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2.7.3 Stage: Assess 
Due to the research timeframe limitations highlighted in Chapter one: Introduction, testing 
the findings out of the previous stages is not feasible within the resources of this PhD study. 
Instead, the Assess stage identifies the level of agreement on the adherence factors that 
should be considered in the design and development of medical technology self-
administered treatments. Delphi method will be used to identify the consensus (Keeney, 
Hasson, & Mckenna, 2010) of a panel that represent academic and professionals such as the 
NHS, AHSN, CPI, Philips, medical innovation companies and Northumbria University. The 
total number of the Delphi panel is 15 panellists. 
 
The eDelphi will be used in the Assess stage to ensure the flexibility who are located in 
different locations in the UK (Hasson, & Keeney, 2000).  
The Delphi process ran in three rounds; the first round will be an interview conducted 
through written online questionnaire using open-ended questions about the factors that 
affect patient adherence to self-administered medical technology treatment. The second 
round will be an online questionnaire that is collecting rating answers about the adherence 
factors. The final round will be similar questions as the second round with one different is 
that the answers from the previous round will be displayed anonymously to the panellists to 
give them the chance to change their minds. The answers from the first round will be 
evaluated through inter-rater reliability process which will be tested using Cohen Kappa 
(Cohen, 1960; Krippendorff, 2004). The significance of the final questionnaire’s answers will 
be evaluated using Wilcoxon Signed Ranks Test (Taheri & Hesamian, 2012). 
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2.8 Research Ethics 
The research ethics for this study were submitted with submission reference 10186. Below 
is a summary of the ethical information related to the level of risk, data management and 
data anonymity. 
2.8.1 Research Risk 
The research level of risk was considered to be “medium” as it met the university guidelines 
below: 
• It included non-vulnerable adults, represented by the company founders;  
• It did not include sensitive personal information; and 
• It did include secondary data that are not in the public domain. These data are 
related to the companies and the products, including commercially sensitive 
information. 
 
2.8.2 Research Data Management 
Some of the data collected in this research may be commercially sensitive, such as internal 
company information that is not shared publicly. Therefore, the confidentiality and security 
of the data was considered. Data collected during the study were stored in a secure place: 
the printed data under lock and key, and digital data on Google Drive. 
 
2.9 Summary and Conclusion 
This chapter discussed the study research methodology and elements that affected the 
research design stages. The philosophical approach and research strategy were discussed in 
addition to determining how they would affect the study. Additionally, the way that the 
research methods that were used in the study fit with the research aims and objectives was 
discussed. The research methodology for each of the research methods highlighted in the 
research design in this chapter will be discussed in detail in the chapters three, four and five 
that follow. 

















Chapter 3: Case Studies Methodology  
 
This chapter discusses the research 
methodology related to the case studies 
interviews. It discusses the design of the 
research instrument, case study 
recruitment, sampling techniques and the 
administration of interviews. The 
interviews’ questions will be highlighted 
and mapped onto the main research 
questions.  
Key Topics: 
3.1 Aims and Objectives 
3.2 Sampling Technique 
3.3 Selection and Invitation for Companies 
3.4 Case Studies Recruitment 
3.5 Interviews Data Collection  
3.6 Coding and Content Analysis 
3.7 Summary and Conclusion 
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To explore the role of design in improving patient adherence to self-administered treatment 
technology regimens, this research explored SMEs working in medical technology 
innovation in the UK to: 1) learn about their products; 2) explore their product designs and 
development processes; and 3) investigate how adherence was considered before, during 
and after the product development process (PDP). The scope of the research, as highlighted 
earlier in this chapter, defined the specific characteristics of the companies considered as 
candidates for the research plan as follows: 
• Small and medium enterprises (SMEs); 
• Developing medical technology treatment; and 
• Developing treatments which are fully or partially self-administered by the patient. 
Accordingly, the above three aims formed the scope of the research, that is, SMEs working 
in patient-administered treatment technology.  
 
3.1 Aims and Objectives 
In this part of Phase one (Investigate), interviews were conducted as part of the research. 
These interviews aimed to: 1) investigate the state of medical technology innovation; 2) 
explore the role of design in developing innovative treatment technology; and 3) 
understand how adherence is considered during this development. 
 
To realise this aim, the following objectives, which are also present in the main research 
questions of this study, were considered:  
• Explore the current state of SMEs working in working in the medical technology 
innovation sector, including building an understanding of the barriers and 
opportunities they face. 
• Explore how design thinking characteristics are adopted during the design and 
development of the treatment technology (including barriers to and opportunities 
for its application). 
• Explore how adherence is considered during the design and development of the 
treatment solution. 
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• Explore how treatment products are considered in the clinical trials, including how 
adherence is considered during evaluation procedures. 
 
3.2 Sampling Technique 
To build an understanding of the recruitment of case studies, an overview of sampling 
techniques was conducted in order to determine the most suitable strategy for the current 
research. Overall, sampling falls into two main types: probability sampling and non-
probability sampling. Probability sampling uses normal distribution statistical theory to 
ensure the researcher has no influence on the selected sample, and each element in the 
population has an equal chance of being represented (Etikan & Bala, 2017; Taherdoost, 
2016). In contrast, non-probability sampling tends to build an exploratory sample, and the 
researcher may be involved in the selection process, for example, if specific criteria or aims 
require it (ibid). According to the above two classifications of sampling, the objective of this 
research was met by a non-probability sample. To identify the sampling technique which 
best aligned with the scope of the present research, the researcher explored the different 
non-probability sampling techniques and narrowed the choice to the following methods: 
• Quota sampling 
• Purposive sampling 
• Expert sampling 
• Snowball sampling 
• Convenience sampling 
 
The nature of this research played a crucial role in the choice of the sampling technique 
used to identify the case studies. This research focused on three main goals:  
1) Investigating the current state of SMEs which are developing self-administered 
medical technology treatment interventions by building an understanding of how 
they operate, the role design plays in product development and considerations of 
patient adherence; 
2) Exploring how design thinking can contribute to improving patient adherence; and  
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3) Assessing the adherence framework and gaining consensus as to its viability. 
Sampling was used as an exploratory technique for a current phenomenon 
(Denscombe, 2010) with acceptance of the current state of reality (White, 2013). 
This consideration dictated the use of non-probability sampling techniques in this 
research. There are five sample techniques, as outlined below.  
 
3.2.1 Quota sampling 
In this sampling technique, the main two considerations are: 1) easy access to the 
population; and 2) convenience, as the researcher is guided by visible characteristics that 
help in selecting the sample from the population. The selection process continues until the 
predetermined quota is reached (Kumar, 2014). The researcher has the freedom to choose 
the criteria used to select which participants will fill the quota, such as first to meet or last 
to visit a specific place (Denscombe, 2010). The foremost advantage offered by this 
technique is a low cost, as it does not require a sampling frame or information about the 
sampling, such as numbers and location. The disadvantage of using this technique is that the 
results collected from this sample cannot be generalised to the whole population, as there 
may be other elements in the population with unique characteristics for the participants in 
the population (Kumar, 2014). 
This research had a clear idea of the sample companies involved in the research process 
regardless of the number of companies in the population. Therefore, quota sampling was 
excluded from the sampling techniques used. 
 
3.2.2 Purposive sampling 
Purposive sampling, also known as judgemental sampling, is based on the principle that the 
most useful data can be collected by focusing on a small sample which possesses specific 
expertise (Denscombe, 2010). In purposive sampling, the participants are selected based on 
their relevance to, and knowledge of, the topic, which qualifies them to produce the most 
valuable data (Kumar, 2014). This sampling technique is suitable to create an exploratory 
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sample as the experts will have the ability to provide quality information about, and insight 
into, the research topic (Denscombe, 2010).  
In medical research, this sampling technique can be used to study groups with rare diseases 
or a specific ethnic group. In grounded theory research, a special type of sampling is called 
theoretical sampling. In this type, 20-40 people are selected who can contribute to evolving 
the theory. Data collection and analysis are conducted in parallel until the saturation point is 
reached (White, 2013). 
In this research, purposive sampling was the main technique used to select the case studies 
involved in the research. During the collection of data, the selection was based on the 
following criteria: 
• Size: Small- and medium-sized companies. 
• Scope: Developing medical technology treatments that are fully or partially self-
administered by patients. 
• Location: United Kingdom. 
The above criteria were the main target when the researcher started to search for 
companies though healthcare system archives or by attending medical innovation events. 
 
3.2.3 Expert sampling 
This technique is very similar to judgemental sampling. The only difference is that expert 
sampling requires participants to be experts in the field of the study. This sampling 
technique is applied by identifying people with expertise in the area, obtaining their consent 
to participate in the research and moving to data collection (Kumar, 2014). In this research, 
the participants represented each SME in capacities such as founders, co-founders, CEOs or 
managers. While they presented knowledge of the healthcare business in the UK, they did 
not necessarily have the expertise as regards the scope of this study, which was adherence 
within self-administered medical technology treatment. 
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3.2.4 Snowball sampling 
This technique is also known as network sampling. The researcher contacts a small number 
of participants from the population who are then asked to locate other participants, who in 
turn nominate others. This process continues until the target number of participants is met 
or the saturation point has been reached (Denscombe, 2010). This technique is useful when 
the researcher has little knowledge about the population. As a small number of participants 
are contacted, they can guide the researcher to more participants (Kumar, 2014). There are 
disadvantages to this technique, such as the sample being affected by the choices of some 
individuals biasing the decisions of other participants (Kumar, 2014; White, 2013). In this 
study, the snowball technique was used by asking participants in the case studies to 
recommend other potential candidate companies that met the research aim. During 
meetings with healthcare organisations, such as the Academy of Healthcare Sciences 
Network (AHSN), National Institute of Health Research (NIHR) and National Health Service 
(NHS), and medical innovation companies at different events, the researcher asked them to 
recommend case studies. While those organisations and companies were not candidates 
themselves, the core principle of the technique, which is asking for nominated samples for 
the study, still applies. 
 
3.2.5 Convenience sampling 
In some situations, it is difficult for the researcher to access the sampling frame. For 
instance, it may be difficult to find people with the relevant experience, or there may be 
time limitations on reaching the targeted sample. In this situation, the researcher selects 
available participants who meet the selection criteria. Accordingly, the sample selection in 
this method is based on two main factors: accessibility and convenience. In healthcare, this 
sampling technique can involve patients attending a specific clinic or receiving a particular 
medical intervention (White, 2013).  
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In this study, time limitations have little impact on the selection of case studies involved in 
the research. The qualitative nature of the research directed the researcher to focus on 
relevance to the topic rather than the number of case studies involved. 
 
3.2.6 Summary of Sampling Techniques Used in the 
Study 
In section 4.2 above, probability and non-probability sampling techniques were reviewed to 
identify the most efficient sampling method. The applied techniques include the following: 
• Purposive sampling: This was the main technique used in the study, as the scope of 
the research was clearly defined as SMEs developing self-administered technology 
treatments. The relevancy and knowledge of the participants were of higher priority 
than the number of participants. The timeframe of the study did not affect the 
sample selection process. 
• Snowball sampling: This was used during the recruitment of case studies in both 
direct and indirect ways: directly, by asking companies to recommend other SMEs 
with the same criteria, and indirectly, by asking healthcare experts to recommend 
case studies for the research. 
•  
3.3 Selection and Invitation for Companies 
Companies vary in terms of their size and operation. Therefore, a clear comprehension of 
the companies interviewed is crucial to understand how adherence is considered during the 
design process. This being the case, targeted companies had the following characteristics: 
• Small and medium enterprises (SMEs). This size of companies plays an essential 
role in the national economy (Birch, 1989; Bommer and Jalajas, 2002; Lukács, 
2005; Nauwelaerts et al., 2012; Oke et al., 2007). SMEs contribute to around 50% 
of the UK’s GDP (Braams and Urlings, 2010). 
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• The company operates in the UK, and therefore share the same operation 
ecosystem. 
• The firms focus on creating (fully or partially) patient-administered treatment (or 
treatment support) technology. 
• The companies have implemented and practiced design differently. For example, 
one company (YMX) systematically implement the design thinking process using 
the double diamond (Design Council, 2015) and MPPF (English, 2010). Other 
companies applied design characteristics without systematic design (thinking) 
process. This was driven by the design background or the professional design 
expertise (Cross, 2011) of the founder. For instance, one of the founders had no 
design background, yet he applied prototype iteration through testing the 
product with the patients themselves (ESA). In LW7 company, the founder had 
design and gamification background, however, he did not apply systematic 
design process paradigm. 
3.4 Case Studies Recruitment 
Based on the above, invitations were sent to companies which met the sample criteria. The 
following channels were used to search for companies: 
• Research collaborations with the School of Design at Northumbria University; 
• Recommendations from friends, colleges or companies; 
• Recommendations from healthcare organisations such as the AHSN, NIHR and NHS; 
and 
• Different healthcare innovation conferences such as the AHSN, Govconnect, NIHR, 
NHS trusts. 
Through those channels, companies were reviewed and filtered based on the research 
scope as follows: 
• National Institute of Health Care Excellence (NICE): 196 case studies overviewed; 
• AHSN network web archive: 119 case studies overviewed and filtered; 
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• Govconnect (Improving Patient Safety & Care 2019) event held 6th February 2019 at 
the Royal Society of Medicine, London: I visited each of the 29 attending companies 
and learned about their products; and 
• Adoption of Innovation (National Pipeline and our Local Experiences event held by 
the AHSN NENC 7 June 2018 at Chester-le-Street): I watched and overviewed nine 
companies. 
A total of 353 companies were overviewed and filtered based on the scope of the research 
(Table 3.2), of which 11 were contacted for collaboration. Of those: 
• Five agreed to collaborate in the research; 
• One agreed to collaborate but dropped out at an early stage of the study; 
• Three refused to collaborate; and  
• Two did not reply to the researcher’s emails. 
The companies who refused to participate were asked to clarify their reasons. They 
answered that either: 1) the company was small and lacked the resources, capacity and time 
to collaborate; or 2) they wished to avoid distractions for the development team. 
Alternatively, they gave no reason for their decision.  
Five of the recruited companies were micro- or small-sized companies and one was 
medium-sized. The process of inviting companies to join the study raises two interesting 
questions: 
1. Why is it harder to persuade some medium-sized companies to participate in 
research collaboration than smaller ones? 
2. Why do fewer companies offer self-administered treatment technologies than 
traditional pharmaceutical and surgical interventions?  
The above questions can be considered by future research to understand how such 
companies operate in terms of research and development and fill technological treatment 
gaps in healthcare.  
The first phase of this research consisted of three steps: desk research, field research and 
analysis. The aim of the field research was to explore how the companies working to design 
and develop (entirely for partially) self-administered treatment technology are working with 
a focus on two main elements: 
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• How these companies apply the PDP in the development their products; and 
• How adherence is considered during the PDP. 
To achieve this goal, the second step in this research was to meet with the companies and 
ask questions about the above two main points. 
Table 3.1 also shows the companies who received an invitation to join the research. The 
blue rows show confirmed case studies, the green rows show companies that never replied, 
the yellow row shows companies who dropped in an early stage and the orange shows the 
companies who refused to collaborate in the study. 




 Confirmed case studies   Refused to collaborate    No reply   Dropped at an early stage 
Table 3.1. List of the case study companies considered in the study, their solution and their status in the study. 
*The interviewee did not provide information related to the source funding. 








Capital Solution Comments 
YMX 2009 11 9 500,000 Diabetic retinopathy and diabetic macular oedema   
ESA 2016 2 3 700,000 Catheter supporting vest for renal and oncology  
LW7 2017 1 1 196,000 Encourage physiotherapy for children with Cystic Fibrosis  
3AB 2015 5 1 35,000 Treatment adherence support and behaviour change  
DE7 2018 2 1 N/A* 
Treatment for sleeping problems either as a disease or a syndrome for mental health 
disease including dementia 
 
Z5W   3 1   Treatment and behaviour change for patients with dementia 
Dropped in an early stage with no given 
reason. 
 C01 2011 7 60   Insomnia and anxiety Rejected with no given reason, 
 C02         Non-invasive treatment for cluster headaches 
Small company that did not have the 
resources and capacity at this time. 
 C03         
Teach, change behaviour and manage treatment for chronic diseases: COPD, Cardio and 
Diabetes 
Did not want to cause distract the design 
and development teams as they were in 
a very busy period. 
 C04 2016 2 13   Behaviour and lifestyle change for diabetes 2 (app + monitor device)  
 C05         Cardiac, cancer and pulmonary rehabilitation program (app + monitor device)  
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  Technology Self-administered Medical Solution     









YMX   ✔   ✔ ✔ ✔ ✔   ✔ ✔ ✔ 
ESA   ✔   ✔ ✔   ✔      ✔ ✔ 
LW7 ✔ ✔     ✔ ✔     ✔ ✔ ✔ 
3AB   ✔     ✔   ✔     ✔ ✔ 
DE7   ✔   ✔ ✔ ✔       ✔ ✔ 
Z5W   ✔   ✔ ✔ ✔ ✔     ✔ ✔ 
 C01 ✔       ✔ ✔       ✔ ✔ 
 C02   ✔ ✔   ✔ ✔         ✔ 
 C03 ✔     ✔ ✔   ✔   ✔ ✔ ✔ 
 C04 ✔ ✔   ✔ ✔ ✔     ✔ ✔ ✔ 
 C05 ✔ ✔   ✔ ✔ ✔     ✔ ✔ ✔ 
 
 Confirmed case studies   Refused to collaborate    No reply   Dropped at an early stage 
Table 3.2. List of case studies with a focus on the nature of their product considered in the study. 
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In Table 3.1 highlights the characteristics of each treatment solution presented by the 11 
companies. The characteristics indicate the nature of the treatment intervention based on: 
• Technology: The type of technology used in the intervention—either software or 
hardware or both.    
• Self-administered: The level of patient administration for the intervention. 
• Medical Solution: The type of solution: treatment, treatment support, diagnosis or 
monitoring. While the study focused on treatment and treatment support, some 
products included one or more of the other solutions.  
• Educational (behaviour change): Some interventions include educational (or 
behaviour) change features which can have a positive impact on adherence.  
• Patient-centred: The product focuses on addressing the patient’s needs. 
Together, the two tables show the following: 
• Regarding the technology used, the majority of the companies depend on either 
software or hardware in developing the final treatment solutions. Many of these 
companies build their product solution to replace pharmaceutical solutions. 
• Patients can fully administer most of the solutions. However, some products may 
need partial involvement of clinicians for installation, monitoring or both. 
• Almost all the companies target changes in patients’ behaviour, especially in chronic 
diseases where the technology has to be used over an extended period. 
 
3.4.1 Anonymisation of Data 
The data collected from the case studies includes private corporate information. Different 
case studies highlighted that they would like this information to remain confidential and not 
be shared with other case studies for various reasons, including competitiveness, 
production plans, the current state of development and collaboration with other partners. 
Accordingly, the data collected from the case studies were anonymised and names and 
contact information were excluded. The names of the companies were anonymised by 
giving them a random code generated through (https://www.randomcodes.co.uk). The 
generated codes for the six companies are: 
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• Company 1: YMX 
• Company 2: ESA 
• Company 3: LW7 
• Company 4: 3AB 
• Company 5: Z5W 
• Company 6: DE7 
 
Companies who did not participate in the study (because they were rejected, did not 
respond to the invitation or dropped out from the course) were given the code name C01-n 
Table 3.1 provides details of the companies invited to participate in the research, including 
size, target market and product. Some cells were left blank with the aim to be filled during 
the first interview with the company. Understanding the company information and the 
nature of the product yields essential information that can drive the interviews and analysis 
of the collected data—for example, the current stage of product development. 3.5.2 
Participants Dropped from the Study 
 
Although there were initially six confirmed case studies, one company (25W) was dropped 
from study due to not responding to my email communications. Two meetings were 
conducted with 25W’s founder, and we agreed to move forward and collaborate in the 
research. I subsequently tried to contact the founder multiple times though email and 
Twitter to arrange a meeting for the first interview; however, I received no reply. 
Accordingly, I had to drop the case study to move on to the next stage of the research. This 
decision was due to the time limitations of the research. 
 
3.4.2 Participants Dropped from the Study  
Although there were initially six confirmed case studies, one company (25W) was dropped 
from study due to not responding to my email communications. Two meetings were 
conducted with 25W’s_ _founder, and we agreed to move forward and collaborate in the 
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research. I subsequently tried to contact the founder multiple times though email and 
Twitter to arrange a meeting for the first interview; however, I received no reply. 
Accordingly, I had to drop the case study to move on to the next stage of the research. This 
decision was due to the time limitations of the research. 
 
3.4.3 Consent and Permission 
All the companies’ interviewees signed the consent form, which was approved by the 
University Research Ethics committee. Permission to record audio was also granted by all 
the five companies during the face-to-face and online interview sessions. 
 
3.5 Interviews Data Collection 
To achieve the goal of the interviews, the interview questions were designed to elicit 
answers that could contribute to answering the main research goals. The table below lists 
each interview question, the purpose of asking it and how it maps onto the main research 
questions. Tables 3.3 to 3.6 show the main questions and how these questions are linked to 
the primary research aims.  
  




Table 3.3 Group one: General questions about the company. 
Table 3.4 Group two: Questions related to the design process inside the company. 
  
Group 1: General Questions Associated Research Questions  Purpose 
Tell me more about your company: date of establishment, 
size, number of employees, branches and capital. 
1) What are the characteristics of the case study? Understand the company’s size, nature and age. Ensure it 
meets the research aim criteria. 
How is your company integrated with the healthcare system in 
the UK? 
1) What are the characteristics of the research case 
studies? 
Appreciate the level of the company’s involvement in the 
UK healthcare industry. 
Explain to me your product and its current state, and how 
patients self-administer the treatment. 
1) What are the characteristics of the case study? Learn about the product and the stage of its development. 
Group 2: Design Process Questions Associated Research Questions  Purpose 
How did you find out about the health problem? And how did 
you come up with the solution (product)? 
1) How does design influence innovation of patient-
administered treatment technologies? 
2) What are the current development processes applied in 
medical technology? 
Understand how the problem was initially discovered and 
how the solution (product) was defined. 
What type of research was carried out? And what is the 
product development process? 
1) What are the current development processes applied in 
medical technology? 
Learn about the exploration stage and the types of 
research used to define the product details. 
What factors did you consider during the development 
process? 
1) What are the current development processes applied in 
medical technology? 
Identify the patient- and business-related factors 
considered during the product development process 
(PDP). 
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Group 3: Design Benefits Associated Research Questions  Purpose 
How do you describe the development process from the 
innovation perspective? And what are the barriers? 
1)What are the current development processes applied in 
medical technology? 
Identify the level of appreciation of design inside the 
organization. 
What factors influenced the product development? And how? 1)What are the current development processes applied in 
medical technology? 
2) What are the barriers to and opportunities for adopting 
design thinking? 
Understand the factors and the people that influence the 
PDP both inside and also outside the company. 
Table 3.5 Group three: Questions related to the perceived benefits of design. 
Group 4: Patient Adherence and Clinical Trials Associated Research Questions  Purpose 
Can you explain the status of the product from clinical trials? 1) How do treatment technologies are considered in clinical 
trials or alternative procedures? 
Learn about the clinical trials applied to the product (if 
any) and the factors considered during it. 
10. What barriers did the development process face and 
affected patient compliance with the treatment? 
1) How does adherence is considered in product 
development and clinical trials?  
Learn how the company ensure patient adherence during 
the clinical trials and as an approved treatment in the 
market. 
How did the patients got involved in the development? 1) How does adherence is considered in product 
development and clinical trials?  
Understand the clinical trial process and how it is used 
during the PDP. 
What mechanism is/was used to evaluate adherence during 
long-term usage? 
1) How do treatment technologies are considered in clinical 
trials or alternative procedures? 
Understand if the company understand the correlation 
between long term treatment and adherence, and what 
are the procedures used to maintain it. 
How did non-adherence affect the results of the clinical trials? 
And what are the adherence factors considered during 
the clinical trials? 
1) How do treatment technologies are considered in clinical 
trials or alternative procedures? 
Understand the impact of non-adherence on the results 
of the clinical trials or product testing procedures. 
Table 3.6 Group four: Questions related to patient adherence and involvement in the design process.
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The interview questions shared with the case studies were categorised into four groups:  
• Group 1: General Questions  
• Group 2: Design Process Questions 
• Group 3: Design Benefits 
• Group 4: Patient Adherence and Clinical Trials 
Tables 3.3 to 3.6 maps the interviews questions to the main research questions and the 
purpose of each item. 
 
The order of the interview discussion differs in this chapter from how it actually unfolded; 
for some questions, the way questions were asked was influenced by the previous 
company’s answers. However, this order does not affect the discussion or answers. 
 
The transcript was read several times in order to identify the information shared by each 
case study and to do thematic analysis to identify the content strands and merge them into 
themes. Detailed information about the application of content analysis is available in 3.6 
Coding and Content Analysis. 
 
This stage aimed to investigate how companies consider adherence during the design 
process. The findings of this stage and the following stage (Wear Care project observation) 
were triangulated during the first round of Delphi method, which was covered in the Assess 
stage of this research. Accordingly, no reliability procedures were applied to the content 
themes generated from the interviews’ thematic analysis. At the first round (Interview) of 
the Delphi method, data collected from the panellists (including companies’ 
representatives) was analysed using thematic analysis. Then the inter-rater reliability test 
was applied to ensure the two inter-raters in my interpretation agreed with the content and 
that this agreement was not due to chance. 
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3.5.1 Data Collection 
This section covers how the data collected from interviews was managed an analysed. All 
the interviews were recorded, and transcripts were generated using the Otter application 
on mobile and desktop. Backups of the audio conversations were recorded using the Voice 
memos application on iPhone. As the interviews are semi-structured, during the talks, 
questions were altered or skipped. Items were added to the discussion to: 
1) Let the interviewee elaborate specific points; or  
2) Ask for further information related to the research topic. 
 
The interviews were conducted through face-to-face and online meetings with the 
companies’ representatives. The representatives were usually the founders and co-
founders. In one interview (YMX), the interviewees were team members who had deep 
knowledge of the company’s history and progress. 
 
The meetings were held either at the company’s location, on the university’s campus or 
online through Skype. An interview with one company (LW7) was held online through Skype 
due to distance and time limitations. Two companies’ interviews were held in the 
companies’ locations in Durham (YMX and DE7). Finally, two interviews were held in other 
locations: a Northumbria university’s meeting room (3AB) and a social meeting place in York 
(ESA). 
 
The duration of the interviews ranged from one to two hours. The length of the interview 
depended on the interviewee’s answers and the elaborated discussion after the original 
answer. One interview (YMX) was slightly more than two hours in length (two hours and 
eight minutes) because the interview was held with two representatives of the company; 
one with experience in the business side (interviewee one), and the other with experience 
in the technology side (interviewee two). 
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3.5.2 Management of Interviews 
The process of administering the interviews included travelling to the interviewees, 
arranging online interviews and also facilitating the recording, backup and transcription of 
both the questions and the answers. I used several tools to record, document and transcribe 
the interviews which ensured the interviews were recorded clearly and accurately, taking 
extra care when meeting with companies’ representatives in different environments with a 
variety of noise conditions. I also had administer interviews held with company 
representatives with whom it was hard to conduct in-person interviews due to factors such 
as distance and time limitations. 
 
3.5.3 Technology Utilisation 
To document the interviews, I used several software tools to ensure that the recorded 
sound was clear and could be heard accurately. The tools used include the following: 
Apply Quicktime software: I used it for recording the online interview (via Skype). I recorded 
only the audio of the sessions for documentation and transcription purposes. 
Otter: I used the app on an iPad to record the interviews and transcribe them in real-time. 
Otter app was the primary tool for transcription in all the interviews as it provided sound 
recording and accurate transcription even in places where there was unexpected noise 
Voice Memos: This is a built-in app for iPhone. I used this app for back-up recording; during 
each interview, Otter was used as the main recording tool while, at the same time, Voice 
Memo was used to record a back-up version of the interview in case there were any 
technical problems with Otter such as failing to record, accidental stoppage, poor audio 
quality or a poor internet connection. 
 
3.6 Coding and Content Analysis 
The interview transcripts were refined and added to Vivo (version 12) for content analysis. I 
reviewed the transcript of the interviews three times as follows: 
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1) The first time was to review the interviewees’ answers and fix any transcript issues;  
2) The second time was to analyse content and explore the generated themes; and  
3) The third time was to analyse the answers and explore the ways the companies 
considered adherence in the design process.  
 
NVivo software for macOS was used for content analysis. All the transcripts were imported 
to NVivo from Otter. Minor modifications were made to the imported documents such as: 
• Highlighting each question with bold text to quickly identify it and the answers. 
• Fix incorrect transcription. This fix was mostly necessary for the transcription of my 
speech due to my accent 
• NVivo allowed me to store all the interviews, the recorded audio and the codes in 
one project, which made the management of the process much easier. 
Reliability and validation are crucial factors needed in order to maintain consistency in the 
contents analysis and avoid biases (MacPhail et al., 2016). In this stage of the research, 
interviews represented the first stage of primary data collection. These data were 
triangulated with data collected in stage two. The analysis of the interviews case studies and 
workshop observation present an opportunity to explore adherence from different 
perspectives. Finally, in the Delphi phase, a panel of case study representatives, industry 
professionals, academics and clinicians had the opportunity to answer open-ended 
questions and scaled questions regarding how adherence factors into self-administered 
treatment technology.  
 
3.7 Summary and Conclusion 
The case study interviews step is part of the Investigate stage that aims to understand the 
design process in SMEs working medical technology treatment, especially the self-
administered interventions, and how adherence is considered during the design process. To 
this goal, sampling techniques were explored to determine the suitable technique for the 
research purpose, and both purposive and snowball sampling methods were utilised. As a 
result, 353 companies were reviewed against the studyd’s scope (SMEs working in the UK in 
developing “fully or partially” self-administered treatment “or treatment support” 
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technology). Out of the overviewed companies, 11 SMEs fall under the study’s scope. Five of 
the 11 SMEs agreed to join the research, which highlights two interesting questions that can 
be considered for future research:  
1. Why is it harder to persuade some medium-sized companies to participate in 
research collaboration than smaller ones? 
2. Why do fewer companies offer self-administered treatment technologies than 
traditional pharmaceutical and surgical interventions?  
The chapter covers the recruitment of the interviews sample, which involves the search for 
companies that meet with the research scope and inviting them to the study. The 
characteristics of each company was highlighted the anonymisation of the data was 
covered. The research ethics, consents, and the dropping for the study were also covered. 
 
The second part of the chapter involved the interview questions, the data collection from 
the participant including the management of the interview and recording the interviews’ 
transcripts for data analysis. The final part covers the data analysis including preparing data 
for analysis and the process of code analysis using Nvivo 12. 
 
 

















Chapter 4: WearCare II Observation 
Methodology  
 
This chapter discusses the methodology 
used in WearCare II observation project 
(Explore stage). The observation 
methodology will be reviewed to determine 
the suitable method to implement to 
achieve the goal of this stage. Description 
of how the data was collected and analysed 
will be overviewed. 
Key Topics: 
4.1 Stage Two: Explore (WearCare II 
Workshop Observation) 
4.2 Observation 
4.3 Reflection on practice 
4.4 WearCare II Project 
4.5 Observation Design 
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4.1 Stage Two: Explore (WearCare II 
Workshop Observation) 
Stage two explored how adherence is considered during the early stages of the product 
design process for SMEs. While the interviews provided an opportunity to learn about how 
companies consider adherence, the very early stage of problem/solution arena could not be 
observed. Accordingly, both step 2 (interviews) and step 3 (observation) explored the 
phenomena from different perspectives to construct the knowledge that would be assessed 
through the Delphi method and the study contribution to knowledge. The Explore stage 
provided an opportunity to observe how adherence is considered in the early stage of the 
design process. This was not possible in the previous step because companies had already 
developed their product (or product prototype). The findings from the observation in this 
stage were triangulated as part of a process of synthesis in the final stage (Assess).  
Project WearCare II was an assessed project for MA Design students at Northumbria 
University in semester one 2019/2020. This chapter describes the research observation 
design in order to achieve the aim of this chapter. In addition to the observation, reflection 
on the students’ action was part of the documentation of students’ practice during the 
semester. 
The nature of the Explore stage contribution can’t be properly perceived without clear 
understand to its role in the study and how the evidences related to the designers practice 
are strengths each other as the study evolve from one stage to another. Please refer to the 
Limitations section for more details about the nature of limitations. 
 
4.2 Observation 
The literature provides multiple definitions for the term ‘observation’. Gorman and Clayton 
(2005) have defined observation as the systematic recording of observable phenomena, 
while for Spradley and McCurdy (1980) it is the work of describing a culture that can lead to 
an ethnographic description. These definitions agree on the characteristics of observation as 
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a research method, such as direct observation of data (Baker, 2006). Elements in the social 
environment such as actions and interaction, are all observable. Observation is a tool to 
understand complex social situations, as highlighted by Bowling (2014).  
 
Observations can be classified based on three main categories: the nature of the data 
collected, the researcher involvement in the observed phenomena and if the sample know 
they are being watched or not. From the perspective of how the data is collected, 
observations can be either: 
• Quantitative (Structured): The observation aims to collect quantitative data. 
Accordingly, the data may be collected using a checklist or structured questionnaire.  
• Qualitative (Semi-structured or unstructured): The research aims to understand the 
phenomena in its natural setting, which reflects its phenomenological nature.  
Based on the epistemological phenomenological nature of the research, the observation 
collected qualitative data using note recording (Marks, & Yardley, 2011). 
 
Observations can be classified as either Over or Covert, depending on if the participants are 
aware they are being watched. During overt observation, the sample know they are being 
watched. In contrast, during covert observation, the participants do not know they are 
being watched. While overt observation brings with it the possibility that participants may 
change their behaviours when they know they are being watched, covert observation may 
be unethical, as the participants do not give their consent to be observed (Gray, 2013).  
 
The third observation categorisation below is based on the research participant and 
involvement in the social act, which includes two types (Gray, 2013): 
• Non-participant observation: In this type of observation, the researcher does not 
interfere with the phenomena and does not conduct any action that may change or 
affect the participants in the study. Although this method aims to eliminate bias and 
the effect of the researcher on the study, the isolation of the research from the flow 
of the observation is not 100 per cent. The method limits how much the researcher 
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affects the observations, yet the interpretive nature of qualitative data forces the 
researcher to be involved during the interpretation of the social act. 
• Participant observation: In this type of observation, the researcher is involved in the 
social act. The participatory nature of this approach brings with it the risk of biasing 
the act being observed, and the flow of the study is affected by the researcher as 
much as any of the other participants in the social act. However, this type provides 
the researcher an opportunity to practice and take part in the phenomena, which 
can improve the reflection on the practice and therefore the qualitative outcome. 
 
Gray (2013) defined four main roles for the observer (Figure 4.1) based on two main 
categories of observations: confidentiality and participation. These roles are: 
• Announced participant 
• Announced observer 
• Undercover participant 
• Undercover observer 
 
 
Figure 4.1 The role of the observer in each of the observation types. Source: (Gray, 2013). 




These roles relate to the practical role of the researcher. In participant observation, the 
researcher acts as a participant, which brings with it unique advantages. Undercover 
participation and observation grant the researcher confidentiality, which may be needed 
depending on the nature of the involvement in the social act.  
 
In this research, the participants were aware of the study as it was part of the module 
description and plan. Furthermore, in terms of the collected data, the qualitative data was 
addressed and collected, which aligns with the epistemological nature of the study. The 
collection and documentation of data are described in Chapter 10: WearCare II Project. 
 
4.3 Reflection on practice 
The notion of reflective practice in design was discussed by Schön (1983). He highlighted 
that designers construct the design word between two spaces: the problem space and 
moves to find the solution space. During this process, designers practise an experimental 
action and reflect on the practice and its results (Schön, 1983). In this research, reflection on 
practice applies to the information collected from interviews with companies. These data 
are used to formulate the questions that will be asked of the teams involved in the project, 
and the interpretation of their practice. 
 
4.4 WearCare II Project 
WearCare II was a student project conducted by post-graduate master students at 
Northumbria University School of Design during Semester One of the academic year 
2019/2020, in collaboration with Northumbria University and Centre for Process Innovation 
Limited (CPI) and AHSN Network North East and North Cumbria (NENC). In this practice, 
seven groups were assembled, each consisting of 2-4 students from different disciplines. 
WearCare II project was introduced to the students, which aimed to design a patient-centric 
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medical innovation solution. The project focused on patient adherence, healthcare system 
and economic perspectives (Aldeer et al., 2018; van Dulmen et al., 2007; Viswanathan et al., 
2012). During this project, the students were asked to consider patient needs, the NHS, 
technology, value networks and change factors. While developing their solutions, students 
followed a design thinking process using the Design Council Double Diamond model (Design 
Council, 2015) and the Multiple Perspective Problem Framing (MPPF) (English, 2007a, 
2007b, 2008). 
The aim of observing the WearCare II project was to 1) explore design characteristics, 
especially in the problem space and solution space (2015), and 2) explore how the solution 
for medical problem evolved in each of the observed groups, keeping in mind team 
members’ backgrounds. 
To analyse the data collected from observation, three main methods were explored: 
• Description as analysis: This method depends on transforming observation (e.g. 
written, visual or audio) into a written text that describes the situation as it happens 
(Flick, 2013).  
• Inductive analysis: An approach such as grounded theory is applied to analyse 
qualitative observation data. The research starts with a specific situation to build an 
inductive generalised conclusion (Charmaz, 2008)  
• Constructionist analysis: Unlike inductive analysis, constructionist analysis aims to 
identify the meaning-making processes that people use to create their social worlds 
using spoken and written language (Flick, 2013) 
 
The observation in the WearCare II project sought to explore the phenomenon rather than 
reach an inductive conclusion. Therefore, inductive analysis was excluded from the 
considered methods. Instead, the research used description as analysis and constructionist 
analysis as described below: 
• The main observation analysis tool was description analysis. Each group’s progress 
was observed and documented using notes to map design characteristics onto each 
group’s practice.  
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• Constructionist analysis was used to understand the design practice based on how 
each group used words to describe their progress. As Cross (2011) highlighted, some 
designers may find it challenging to describe the development of their design 
solutions. Therefore, my industrial experience in the design field was used to 
underpin the description of design practice for each group. 
4.5 Observation Design 
The primary methodology in this stage was observation. I used participant observation 
(Denscombe, 2011) to observe and document the students’ practice (Baker, 2006; Gorman 
& Clayton, 2005) within their teamwork (Spradley & McCurdy, 1980) as well as their 
reflection on that practice, as will be described in detail later in this chapter. Once the 
observation was completed, the collected data was analysed using both inductive and 
constructionist analysis (Charmaz, 2010; Flick, 2013) as highlighted earlier the Chapter 2: 
Methodology Introduction. This methodology involved reflecting on the practice as part of 
the observation analysis that was used to analyse the observation data. This analysis 
involved reflecting on the findings from the interviews in the first stage (Schön, 1983). 
 
4.5.1 Aims and Questions 
WearCare II project provides an opportunity to observe how teams progress from the 
problem space to the solution space, and the consideration of adherence factors. Therefore, 
the aims of the Observation stage were to:  
1) Explore the design practice at an early stage of the product design (problem space) 
(Dorst, 2018); and  
2) Explore how adherence is considered in the problem space and how it is represented 
in formulating the problem definition and possible solutions. 
 
The above two aims map onto, and contribute to answering, the following two study 
questions:  
1) How does design influence innovation in patient-administered treatment 
technologies?; and  
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2)  How does adherence is considered in product development and clinical trials? 
 
Teams needed to be aware of patient adherence and the significant impact it has on the 
accuracy of the health practice outcome. At the beginning of the semester, I introduced 
adherence and its impact to the students and provided ideas about the factors that affect 
adherence. 
As highlighted in the Limitations section of this study (Chapter 14: 14.3.2 WearCare II 
Observation Limitations), observing the SMEs as they develop the product was not possible 
due to: 1) the companies had already developed the product or a high-fidelity prototype of 
the product, or 2) the limited timeframe of the study, compared to the long-term process of 
developing medical technology. The WearCare II project presented an opportunity to 
observe how a solution evolves based on exploring the problem space during the practice 
conducted by the class groups. 
 
4.5.2 Methodological Approach 
The observation aimed to understand a complex phenomenon involving human practice, 
which is the team working together to understand the problem space related to the health 
project. This phase aimed to observe and understand their practice with a focus on the 
consideration of adherence to self-administered technology. Therefore, the suitable 
philosophical approach was constructionism, which aligns with the main epistemological 
phenomenological approach of the study. Accordingly, each of the participants’ 
interpretation for the data is based on number of factors such as experience and 
background (Jones et al., 2013). 
 
The workshop was conducted within an educational environment. Therefore, the 
observation was semi-structured. While there were questions which were already prepared 
and planned, the sessions were flexible to consider altering questions or asking additional 
ones in order to further explore the groups’ practice and project development (Gillham, 
2008). The questions that had prepared for the groups are: 
• What is the current stage of your idea development? 
• What is the problem addressed? 
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• How do you use the design process and reflective practice to explore the problem 
space?  
• How did you consider adherence in the project? 
 
The observation took the form of participant observation, therefore, ideas and highlighted 
thoughts were exchanged with the different teams during the conversation between the 
research and team members (Gillham, 2008; Iacono et al., 2009). 
4.6 Findings and Summary  
This chapter discussed the research methodology used in the Explore stage (WearCare II 
observation). The main research method used is the observation with considering the 
reflection on practice. This research practice aims to observe the design process at an early 
stage, and adherence is considered. Toward this goal, the observation research method was 
overviewed to decide the research tool design and planning. The research questions that 
need to be addressed were also overviewed, and the limitations related to this research 
method. 
This chapter briefly introduces the WearCare II project, which was used to apply the 
observation stage. The findings of the Explore stage contribute to building the big picture of 
the research outcome. 
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The final stage is Assess (Delphi method). Data observed from different perspectives was 
triangulated and fed into a Delphi method aimed to assess the integrated findings from the 
previous steps’ analysis. This practice contributes to the main aim of the study, which is to 
explore how design thinking can contribute to improving adherence to self-administered 
treatment technology. As the stages before the Assess stage identified design and other 
factors that affect adherence to self-administered treatment technology, these factors were 
assessed using the Delphi method.  
 
5.1 Assessment Methods 
The decision to implement an assessment process rather a testing stage was due to the 
timeframe of the design, development and usage of a treatment device, which is much 
longer than this study’s timeframe. Accordingly, the assessment was implemented at the 
last stage of the research. The decision to use the Delphi method was related to its 
properties as a tool that can be used to measure the consensus of the panellists and support 
the anonymity of the panellists. Generally, two main decision-making methods were 
explored to decide which is suitable for the study: the Delphi method and the analytic 
hierarchy process (AHP), as follows. 
 
5.1.1 Analytic hierarchy process 
Several research methods are used to determine future actions through decision making, 
such as analytic hierarchy process (AHP), which is used to measure priorities through the 
comparison and judgement of experts (Saaty, 2008). This tool and similar tools aim to make 
decisions by focusing on prioritising choices. Therefore, AHP was not applied in this study. 
Similar tools were investigated, such as the decision-making paradox, analytic network 
process and hierarchical decision process. 
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5.1.2 Delphi method 
In this stage, two main factors dictated the use of this research method: 1) the 
confidentiality of information shared by the companies (Keeney et al., 2011); and 2) the 
target, namely assessing the proposed framework. Based on these two factors, the Delphi 
method was chosen to obtain a consensus about the factors that affect adherence in self-
administered treatment technology. 
In the Delphi method, two or more rounds of questionnaires are shared with professionals 
on an experts’ panel. Firstly, a questionnaire asks the experts their opinions about the 
research topic, using open-ended questions. The answers are analysed by the researcher 
and sent back to the experts in the form of statements or questions. The experts rank the 
elements in the second questionnaire. The saturation point in the Delphi method is 
achieved once a consensus among the experts is reached (Hsu & Sandford, 2007). 
There are several types of Delphi method which are used depending on the aim of applying 
the tool and the technical characteristics of the practice (Keeney et al. 2011). More details 
about the different types of Delphi method and the selected type are discussed later in 2.1 
Types of Delphi Method. 
5.1.2.1 Delphi Questionnaires 
To explore the level of consensus of the expert panel on adherence factors that can form a 
proposed Adherence Canvas, three initial rounds of questionnaires are considered (Keeney 
et al., 2011). 
• The first round consisted of a questionnaire about the adherence factors. The 
questions in this round were dictated by the research phases conducted in Stage 
one: Investigate, and Stage two: Explore.  
• The second round of the questionnaire posed questions based on the answers 
received in the first round. 
• The third round of the questionnaire was based on the second round and sent to the 
experts, along with the answers to the previous questions, to allow them to explore 
the responses of the rest of the panel and revise their own if needed. 
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The results of the Delphi method were used to confirm the adherence framework and 
introduce it for further research investigations, which may include testing or evaluating it 
for application in both product development and evaluation. 
 
5.2 Application of The Delphi Method  
The Delphi method is a research tool that is based on building consensus amongst a group 
of experts (panel) through a series of rounds. Each round involves a specific research 
method that varies based on the type of Delphi method (e.g. questionnaire, interview or 
focus group). During the last round, the panel members can review the results of the panel 
and build a consensus opinion about the study (Hasson et al., 2000). Delphi was initially 
developed by the RAND Corporation for scientific and technological forecasting and used by 
the United States Armed Forces (Manley, 2013). Since its introduction in the early 1960s 
(Gordon, 1994), it has been widely adopted in a variety of areas including policy-making, 
environment, social sciences, business, industrial research and medical and health research 
(Gibson, 1998; Hasson et al., 2000; Kirk et al. 1996; Williams & Webb, 1994). Medical and 
health research is the largest and most recent field to adopt this method (Gordon, 1994). 
 
5.2.1 Types of Delphi Method 
 There are three main types of Delphi method: classic (traditional), decision-making, and 
policy (Linstone & Turoff, 1975; Manley, 2013). Most of the different varieties of the 
method is based on the traditional method (Manley, 2013). Several types of Delphi method 
can be identified, according to the aim of applying the tool and technical characteristics of 
the practice, as follows (Keeney et al., 2011). 
• Classic Delphi: This is the most common method, which consists of three or more rounds 
and can be administered by email. 
• Modified Delphi: This method replaces the first postal (or email) questionnaire with 
face-to-face or focus groups. 
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• Decision Delphi: This method differs from the classic type only in that it is used to make 
decisions. 
• Policy Delphi: This method is used to agree on future policies. 
• Real-time Delphi: In this method, the experts meet in an experts’ session room. 
• E-Delphi: This method differs from the classic Delphi only in that it uses a web-based 
questionnaire. 
• Technological Delphi: This method is similar to the real-time Delphi, with experts using 
technology to immediately respond to the questions. 
• Online Delphi: This method focuses on discussing arguments without the need to 
achieve consensus. 
• Disaggregate Delphi: This method aims to agree on uses cluster analysis. 
 
The type adopted in this study is the e-Delphi method because: 
1. The experts are usually short of time and it is hard to ensure regular meetings with 
them. So, it is flexible in terms of sharing and collecting data through digital platforms 
(e.g. email and Surveymonkey.com) to obtain consensus on the adherence factors that 
can be considered in the medical technology treatment; and  
2. Similar to the Classic Delphi, the first round can include open-ended questions which 
present an opportunity to allow panellists to share their experiences related to patient 
adherence. The eDelphi inherits the same limitations of the Classic Delphi, such as the 
amount of data collected from round one.  
This study adopted the e-Delphi method because of its flexibility and feasibility, especially 
during the Covid-19 national lockdown in early 2020. 
 
5.2.2 Delphi Rounds and Questionnaire Design 
The Delphi panellists were asked a specific number of questions during each round. The 
number of rounds in Delphi studies can vary from two to ten rounds (Errfmeyer et al., 1986). 
However, most studies have between two-three rounds (Day & Bobeva, 2005; Milevska-
Kostova & Dunn, 2010). The saturation point is where the research receives the maximum 
benefit from the sample and further rounds are meaningless. Therefore, reaching the 
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saturation point was considered when deciding on the number of rounds. While reaching 
the saturation point is normally achieved in the second or the third round, the decision of 
the number rounds was also affected by the study’s time limitation (Keeney et al., 2010).  
In traditional Delphi, the first round is usually an open-ended questionnaire that is the 
cornerstone of the research, as the data collected from the panellists in round one 
represents that crucial data used to construct the following rounds (Milevska-Kostova & 
Dunn, 2010). In round two, the data collected in round one is used to create 5-point Likert 
scale questions in order to create an anonymised questionnaire that explores the level of 
agreement between the panellists on the collected data. In the third round, the same 
questions are presented again, along with anonymised answers from the previous round, in 
order to allow experts to change their minds in ways which may affect the final agreement 
of the panel (Keeney et al., 2010).  
 
5.2.3 Limitation of the Method 
Similar to classic Delphi, one of the significant limitations of the open-ended questionnaire 
in e-Delphi is the amount of data collected and analysed (Gibson 1998; Hasson et al., 2000). 
A large amount can produce an extensive questionnaire in round two, which panellists may 
find time-consuming to complete (Keeney et al., 2011; Linstone & Turoff, 1975). As a result, 
the percentage of panellists participating in round two may fall relative to the number of 
panellists who completed round one. Therefore, the round one questions were limited to 
five and were targeted to collect data related to the adherence and factors that should be 
considered during the development of treatment technology. 
 
5.3 Delphi Panel 
The selection of the panel in Delphi was a crucial factor in the success of this stage (Linstone 
& Turoff, 1975). Therefore, the choice was based according to their expertise. Two criteria 
governed the panel selection: 
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• Panellists had to work in the UK healthcare system in the UK; for example, they could be 
company founders, experts working in healthcare organisations such as NHS, AHSN or 
NIHR, or academic experts; and/or  
• Design experts had to have an understanding of the challenges within the healthcare 
system, for example, to be academic design experts with knowledge of the design 
process from one side or the healthcare system on the other. 
Accordingly, the panel included case study founders, medical professionals, founders of 
medical research bodies in the UK such as AHSN and NIHR, design practitioners and 
academics. In general, the expertise involved included: 
• Medical psychology behaviour change (adherence) 
• Design for health technology 
• Healthcare system 
• Decision making 
• Medical innovation 
 
5.3.1 The Anonymity of the Panel 
Anonymity of the panellists is essential to achieve the goal of the Delphi method because it 
reduces the occurrence of biased opinions and psychological influance (Linstone & Turoff, 
1975). In this study, the identity and contributions of the panellists remained anonymous 
during the Delphi method process. Only the PhD supervisors and the researcher knew the 
identities of panellists and knew how they answered. We were also the only ones to follow-
up with them regarding completing the survey or to engage in any further communication 
related to their answers.  To avoid biased decisions, the names of the panel members were 
removed and replaced by serial codes P1 to P15, as listed in Table 5.1. The names of the 
experts who declined to join the panel or did not reply to the invitation were removed and 
replaced with codes P16 to P29, as listed in Table 5.2. 
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5.3.2 Size of Panel 
The literature studies did not find any specific recommendation about the number of 
experts in the panel (Keeney et al., 2011). Some researchers suggested a small panel of less 
than 15 participants (Cavalli-Sforza & Ortolano, 1984; Delbecq et al., 1975; Malone et al., 
2005; Novakowski & Wellar, 2008; Richey et al., 1985; Strasser et al., 2005; Turoff, 1970). 
Others recommended a larger panel of between 15-100 participants (Doughty, 2009; Miller, 
2001; Rowe & Wright 1999), while still others suggested the panel to include hundreds 
(Back-Pettersson et al., 2008; Cyphert & Gant, 1971; Kelly & Porock, 2005; Meadows et al., 
2005; Okamoto, 1999) or even thousands of participants (Aichholzer, 2001; Barnette et al., 
1978; Drennan et al., 2007; Farrell & Scherer, 1983; Grundy & Ghazi, 2009; NISTEP, 1997; 
Jung-Erceg et al., 2007). In my research, the panellists’ experience was considered a higher 
priority than the size of the panel. Table 5.7 shows the panel candidates, their expertise, 
affiliation and expertise. 
 
5.3.3 Recruitment of the Panel 
Panel member recruitment was based on the criteria highlighted earlier in the Delphi Panel 
Members section, as follows:  
• A personal connection or the panellist is already a partner in the research as a case 
study; 
• A representative of the Medical and health research organisations such as the AHSN, 
NHS and NIHR; 
• Recommended designers with expertise in health technology; and/or 
• Recommended faculty members in the School of Psychology at Northumbria 
University. 
I reviewed the prospective participants’ profiles, affiliations and positions in order to 
identify how their opinions might add value to the Delphi study. The total number of 
panellists considered was 28. From the nominated panellists, the participants were filtered 
as below:  
1. Two were excluded as they did not have the required expertise; 
2. Four replied that they were too busy to be part of the panel; 
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3. Two did not reply to my invitation email. Those panellists are excluded because one 
of their team had already agreed to be part of the panel; and 
4. Six members did not reply to my invitation email or repeated follow-up messages. 
Based on the above, the confirmed number of participants on the panel was 15. These are 
the panellists who received an invitation to answer the first-round questionnaire. Table 5.1 
shows the 15 confirmed panellists and their expertise. Table 5.2 shows the initial candidates 
who didn’t join the panel and the reason of exclusion. 
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P1 Founder Case study  ✓ ✓   ✓   ✓ 
P2 Co-Founder Case study    ✓ ✓ ✓   ✓ 
P3 Founder Case study    ✓   ✓   ✓ 
P4 Founder Case study    ✓   ✓   ✓ 
P5 Clinical Operations 
Manager 
Case study  ✓ ✓ ✓ ✓ ✓ ✓ 
P6 Innovation Manager AHSN NENC   ✓ ✓ ✓ ✓ ✓ 
P7 Innovation Manager AHSN NENC   ✓ ✓ ✓ ✓ ✓ 
P8 Senior Strategic 
Marketing Manager 
CPI   ✓ ✓ ✓ ✓ ✓ 
P9 Founder and CEO GraftWorx ✓ ✓ ✓ ✓ ✓ ✓ 
P10   James Cook University Hospital 
– NHS 
✓ ✓ ✓ ✓ ✓ ✓ 
P11 Founder Movement Inc. ✓ ✓ ✓ ✓ ✓ ✓ 
P12 Head of Design Strategy 
& Design Innovation 
Philips ✓ ✓ ✓ ✓ ✓ ✓ 
P13 School of Health and Life 
Sciences, Northumbria U 
Academic (medical psychology). 
School of Health and Life 
Sciences, Northumbria 
University 
✓           
P14 School of Health and Life 
Sciences, Northumbria U 
Academic (medical psychology). 
School of Health and Life 
Sciences, Northumbria 
University 
✓           
P15 CEO and Co- Founder ORCHA ✓ ✓ ✓ ✓ ✓ ✓ 
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  Position Affiliation Experience Mapping  Comments 












































































P16 Co-Founder Case study ✓ ✓ ✓ ✓ ✓ ✓ 
Removed: the company is represented 
by another expert 
P17   Case study ✓ ✓ ✓ ✓ ✓ ✓ 
Removed: the company is represented 
by another expert 
P18 Business manager AHSN NENC      ✓ 
Removed because of irrelevant 
experience  





CRN      ✓ 
Removed because of irrelevant 
experience  





✓ ✓ ✓ ✓ ✓ ✓ Could not get in touch 
P22 Director NIHR ✓ ✓ ✓ ✓ ✓ ✓ Busy 
P23 







✓ ✓ ✓ ✓ ✓ ✓ 
Agreed then could not move forward, 








   ✓ ✓ ✓ 





   ✓ ✓ ✓  No reply back 
P27 
School of Health 




✓ ✓ ✓  ✓   Busy 
P28 
School of Health 




✓ ✓ ✓     No reply 
P29 University of Oxford 
Professor of 
primary care 
✓ ✓ ✓  ✓   No reply 
Table 5.2 List of the panel candidates who were not involved in the study and the reasons. 
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5.3.4 Invitation to the Panel Members 
After preparing the candidates’ list, an invitation email was sent to each candidate in order 
to introduce the research brief and research aims as well as to provide a summary of the 
Delphi method process and what was expected from each member. A copy of the message 
sent to the panellists is shown in Appendix 11.7. 
5.4 Ethical Approval and Consents 
This study was conducted under the Ethical Approval Regulation of Northumbria University. 
Panellists were asked to sign a consent form that was already approved by the university 
ethics committee (Appendix 1.1). Approval to join the study was collected through email 
invitations (Appendixes 11.7) and communications between the panellists and me. 
 
When the panellists visited the online questionnaire hosted on SurveyMoneky.com, the 
header of the questionnaire displayed a welcome message and information about the 
current round’s survey. The brief indicated that, by clicking Ok and filling out the survey, the 
panel member gave consent to use their and data in the study. 
 
5.4.1 Storage of Delphi Data 
The storage of data related to the Delphi method stage followed the same regulations used 
throughout the study. A copy of the questionnaire and its responses was stored on the 
SurveyMonkey.com website database. I was the only one who had access to these data. The 
survey was shared with each of the panellists through a URL. The link was only shared with 
the experts who agreed to contribute to the study. I accessed and the questionnaires and 
data from my Apple computer, which was secured by a password and my fingerprint. 
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5.5 Process Management  
The panel management represented a critical activity that ensured that the aim of the 
Delphi process was achieved. Accordingly, the process of managing the panel was as 
follows: 
1. Identify the experts that could join the panel and provide insights and opinions 
related to adherence factors that affect self-administered treatment technology. 
2. Build a list of candidates and map their different expertise onto the selected panel. 
The list (Table 5.1) includes: panellist name, position, affiliation, expertise, email and 
organisation represented (e.g. research case study, NHS or AHSN). 
3. Email candidates to invite them to join the Delphi panel. In this email, information 
about the research was provided, including the Delphi method, planned timeline and 
required time commitment, along with a brief about the study’s panel. 
4. Ask the candidate to sign the research consent form and send it to me. It was then 
archived based on the research ethics regulations.  
5. Select a sample of the candidates to share the first-round questions and get 
feedback. 
6. Share the first round (open-ended qualitative questions) with all the panellists. The 
panellists were expected to answer the questions and send their responses back 
within one week. 
7. Once the panellists answered the first-round questionnaire, the data was organised 
and analysed. At this point the inter-rater reliability process started, which involved 
hiring, managing and communicating with the inter-raters. 
8. Based on the results from the analysis of the first round, I wrote the second-round 
questions and created the questionnaire on SurveyMonkey.com. 
9. Once the second-round answers were collected and analysed, the third-round 
questions were created, which included the same questions as the second round but 
also showed the panellists the sum responses from the previous round and their 
answers. The process involved creating a separate questionnaire (with a unique URL) 
for each panellist to ensure the anonymity of their responses. 
• Once the data was received, it was analysed using the Wilcoxon test to define 
the level of agreement without the chance factor between the panellists. 
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5.5.1 Instrument Design: Questionnaires 
The Delphi method aimed to explore the level of consensus amongst the panellists. Three 
initial rounds of questionnaires were planned (Keeney et al., 2011). The design of the survey 
aimed to achieve the following:  
• Collect opinions from panellists related to adherence factors and how adherence is 
considered while designing medical and health treatment technology. 
• Build a consensus on the different factors and their impact on patient adherence. 
The Delphi study consisted of three rounds, as follows: 
• The first round consisted of an open-ended questionnaire to collect qualitative data. 
• The second round consisted of a quantitative questionnaire.  
• The third round sought consensus on the questions from the second round. 
The results of the Delphi method were used to confirm the adherence framework’s factors 
and introduce the framework for further research investigations, which included testing and 
evaluating it for application in both product development and evaluation. 
 
5.5.2 Questionnaire Timeframe 
The Delphi method, which ran from March until May 2020, represented the last stage in this 
study. I understood the panellists’ time was limited, so I planned a specific time between 
each round to provide a chance for the panellists to reply with answers and allow myself the 
time to analyse the data. The timeframe was as follows: 
• A sample of three panellists were shared the test questions in order to evaluate the 
responses. This stage took around one week. 
• Panellists were asked to complete each round’s questionnaire within a specific time 
period (one-two weeks). Another two weeks was given to analyse each round.  
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5.6 Implementation of Delphi methodology 
According to the design of the research methodology, the application of the Delphi method 
represents the third stage of the research, the Assessment stage. This stage aims to identify 
the consensus of Delphi panellists on the adherence improvement a proposed Adherence 
Canvas. The model is a result of analysing the earlier steps:  
• Completion of the literature studies related to treatment adherence.  
• Interview of the five case studies.  
• Observation of the WearCare II project; and  
• Completion of the open-ended questionnaire in the first round of the Delphi study. 
 
5.6.1 Technological Utilisation 
The eDelphi method presented an opportunity to facilitate the Delphi study and to 
overcome the limitations of time (both of the study and of the panellists) and place (as they 
were located in different cities around the UK and Northern Ireland). The questionnaire 
rounds were designed and created using Surveymonkey.com (a website to design, create, 
distribute and analyse questionnaires). A link for each round was generated and shared with 
the panellists; this web-based questionnaire allowed them to answer the questions.  
The links were shared with the panellists through email before each round. 
 
5.6.2 Pilot Delphi Round 
‘Pilot test’ refers to the practice of sharing the first-round questions with a sample of the 
panellists (Gordon, 1994; Mitchell, 1991; Novakowski & Wellar, 2008). Although the pilot 
testing step has been viewed as optional (Moore, 1987), the majority of the literature 
highlighted various benefits of applying it (Miller, 2001). Some of the benefits of 
implementing a test stage of the first Delphi round include: 
• The data collection is an opportunity to gather sufficient data from the panellists. 
Accordingly, implementing a testing step develops good practices and reduces the 
risk of missed chances (Teijlingen & Hundley, 2001) 
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• Identify any inaccuracies and lack of clarity in the wording used in the questions 
(Turoff, 1975), especially in the open-ended questions. 
• Test the administration process (Jillson, 1975). This process involves tasks such as 
sending the invitation emails, reminders, collecting and organising panellists replies 
(Keeney et al., 2011). 
 
In this study, the pilot round was shared with a sample of panellists in order to test the 
wording of the questions, the round’s administration and the feedback from the panellists. 
The sample selection was based on the following criteria: 
• Understanding the nature of the research and the research method used; and 
• Being able to test and provide comments regarding the design of the open-ended 
questions. 
 
According to the above criteria, four panellists were selected to receive the questionnaire. 
For this sample, I sent an invitation email (see Appendix 11.7) to participate in the pilot 
study. Then, in a separate email, I highlighted why their contribution to the sample was 
significant and encouraged them to provide feedback regarding the questions and process. 
Panellists were given around a week to answer the questions and share their comments. 
Some of the comments received were: 
• The questions are wordy and need to be more straightforward. 
• The usage of terms may not be precise, especially for the panellists without 
knowledge of the medical psychology theoretical terms used to describe patient 
behaviour. 
 
5.7 Timeline of the Delphi Phases 
Table 5.3 shows a summary timeline of the Delphi phase and how it was administered 
between the researcher, the inter-raters and the panellists




 Researcher Panellists Inter-raters Tool Used 
Pre-Delphi 
activities 
1. Define the aim of the Delphi study phase  
2. Design and plan the Delphi study phase 
3. Design round one questionnaire 
  MS Word 
1. Search for potential panellists 
2. Evaluate and filter panellists 
3. Build an invitation list of the panellists 
   
1. Contact the panellists 
2. Design the questionnaire on 
SurveyMonkey.com 
3. Invite the approved panellists to round 
one 
  SurveyMonkey.com – MS Word – Email 
Pilot Delphi 
activities 
Select pilot round panellists    
Share with the panellists sample questionnaire   SurveyMonkey.com – MS Word – Email 
 Pilot panel answers the 
questionnaire and provide 
comments 
  
Consider the comments and improve the questionnaire   SurveyMonkey.com – MS Word – Email 
Round One Invite the entire panel to round one questionnaire    
 Panellists answer round one 
survey 
  
Follow-up with panellists   Email 
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Collect, organise and analyse the results   SurveyMonkey.com – MS Word – Email 
    
Contact any panellist for clarifications if needed Some panellists clarify their 
answers 
 Email – SurveyMonkey.com 
Table 5.3 Timeline of Delphi method process. 
 
 Researcher Panellists Inter-raters Tool Used 
Inter-rater 
reliability 
Content analysis   NVivo – MS Excel – SurveyMonkey.com 
Search and hire inter-raters    
Brief inter-raters about the research and their tasks   Email – Web-based chat 
  Inter-raters 
review and code 
round one data 
NVivo 
Collect the inter-raters’ content; analysis and organise   NVivo – MS Excel 
Calculate Cohin’s Kappa reliability   MS Excel 
Round two Create round two questionnaire   SurveyMonkey.com 
Invite panellists to answer round two   SurveyMonkey.com – Email 
 Panellists answer round two survey  SurveyMonkey.com 
Follow-up with panellists   Email 
Collect, organise and analyse the results   SurveyMonkey.com – MS Excel – SPSS 
Round 
three 
Create round three questionnaire. Same as round two with 
showing the panellists the sum results and their responses.  
  SurveyMonkey.com 
Invite panellists to answer round two   Email 
 Panellists answer round two survey   
Follow-up with panellists   Email 
Collect, organise and analyse statistics   SurveyMonkey.com – MS Excel – SPSS 





Apply Wilcoxon test   SPSS – MS Excel 
Analyse statistics and build a proposed Adherence Canvas   MS Excel 
Table 5.3 Timeline of Delphi method process (continued). 
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5.8 Summary and Conclusion 
This chapter provided a brief about the Delphi methodology that is part of the third stage of 
the study (Assess). Due to the limitations related to the study such as the timeframe of the 
study, testing the findings of the study was not feasible within a sample of live commercial 
product development. Accordingly, the Delphi method was deployed to assess the findings 
through the consensus of a panellists of professional in the fields involved in the study. The 
previous two stages highlighted two interesting findings:  
1. There is a lack of adherence theories that focus on self-administered treatment 
technology 
2. There is no practical framework for companies to evaluate the consideration of 
adherence factors in the design and production of self-administered treatment 
technology. 
According to the above findings, the Delphi method was designed to collect panellists’ 
consensus on adherence factors that affect patient adherence to self-administered 
treatment technology. Toward this aim, the Delphi method was designed and described in 
this chapter.  
 
As a conclusion of this chapter, the eDelphi was selected as the method that will be used to 
ensure flexibility and accessibility for panellist to contribute to the study. The eDelphi 
involves three rounds: the first round is an open-ended questionnaire, the second is a 
quantitative (Likert) survey, and the third round the same survey of round two with one 
difference that is showing the anonymised replies of the whole panel for panellists to revise 
their answers if they want. The panel selection and invitation were also discussed along with 
details related to the anonymisation and running the rounds with the panellists.  
The management of the process, storage of data, sending the invitations, and the timeframe 
of the process were also discussed. The application of the method and the results of the 











































Chapter 6: Theoretical Frameworks of 
Adherence 
 
This chapter explores the challenging 
problem of adherence, and its clinical and 
financial impact on the healthcare system. 
Furthermore, the impact of administration 
on treatment adherence will be discussed. 
The theoretical frameworks that consider 
how adherence is affected will be discussed 
in order to identify the factors that affect 
adherence and how it works. The 
relationship between adherence on the one 
hand and communication and technology 
on the other hand is reviewed in order to 
understand its impact on adherence. 
Finally, the variations in adherence for 
different diseases will be discussed.  
Key Topics: 
6.1 Adherence in Literature Review Search 
6.2 The Problem of Low Adherence 
6.3 Factors that Affect Treatment 
Adherence  
6.4 Theoretical Adherence Frameworks 
6.5 Communication and Adherence 
6.6 Patient Empowerment 
6.7 Patient Monitoring 
6.8 Information, Motivation, Strategy 
6.9 Adherence Factors in Different 
Diseases 
6.10 Behaviour Change 
6.11 Findings and Summary  
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This chapter investigates adherence as a challenging factor and burden for todays’ 
healthcare systems. Furthermore, this part explores the factors that influence patient 
adherence and behaviour change. Exploring these factors requires a clear understanding of 
the literature and theories related to the topic. This chapter explores the literature to 
answer the research question: what are the theoretical frameworks of treatment 
adherence? 
 
Baum et al. (2012) defined three types of adherence: adherence to a prescribed treatment, 
adherence to produce a clinical outcome, and adherence to behavioural treatments. 
However, there is a lack of studies that address adherence in relation to medical technology 
usage and particularly self-administered interventions. This lack is identified as a gap in 
knowledge that need to be investigated, especially with the varied nature of medical 
technology interventions and other treatments such as pharmaceutical and clinically 
administered therapies.  
 
van Dulmen (2007) stated that: ‘Many interventions to improve patient adherence are 
unsuccessful and sound theoretical foundations are lacking. Innovations in theory and 
practice are badly needed’ (p.1). The literature studies discussed in this chapter contributed 
to determining the research scope and the characteristics of the products that the case 
studies manufacture. This part of the research scoping focuses on the characteristics of the 
product based on the nature of the disease (chronic diseases) and the administration of the 
treatment (self-administered). 
 
6.1 Adherence in Literature Review Search 
The Desk Research stage explored adherence and its consideration in the self-administered 
treatment technology design. The results of this stage presented the base for the setup of 
the following steps in the research. Various sources were used to search for the literature. 
The keywords and phrases used in the search varied based on the target objective of each 
chapter. This chapter explored the psychological theories related to adherence. 
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The search through the literature was conducted through the following channels: 
• Northumbria University library website and its connected service (i.e. Shibboleth) 
• NICE (www.nice.com) 
• AHSN (https://www.ahsnnetwork.com) 
• Google Scholar UK website (https://scholar.google.co.uk). Also, it includes my saved 
library from previous research 
• Google search website (https://www.google.co.uk) 
• My previously saved library on Mendeley desktop application 
• Medical research using MEDLINE, PubMed, PsycINFO, EMBASE and The Cochrane 
Library  
• Design for Health conference publications 
• Design Research Society  
 
While conducting the research, related keywords were used to expand the possibility of 
exploring related literature as shown Table 6.1: 
Main search term Related terms 
Adherence Compliance, Concordance, Patient Involvement, Patients Centred 
Intervention, Mutuality 
Design Behaviour Change, Persuasive Design, Captology 
Design Thinking Design Process, Innovation Process, Human-Centred Design, 
Gamification 
Treatment Therapy, Intervention 
Health Technology Medical Technology 
Table 6.1 Literature review main search queries and related queries used in the search. 
 
The search for the above (Related terms) aimed to expand the findings from design, 
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6.2 The Problem of Low Adherence 
The low adherence is a challenging problem for healthcare systems (van Dulmen et al., 
2007). An estimated 20% to 30% of patients do not take their medications (Viswanathan et 
al., 2012). In prevention and disease management activities (e.g. diet, medical appointments 
or screening), non-adherence may reach 25% (Haskard-Zolnierek & Dimatteo, 2009). As a 
consequence of non-adherence, a gap can be identified between actual treatment success 
rates and those which are realistically achievable (Viswanathan et al., 2012). This gap may 
affect the accuracy of clinical trial results and, subsequently, the outcome of decisions 
related to the treatment. The adherence to intervention plays an essential role in 
determining the intervention’s effectiveness in improving patient health (Car et al., 2017). 
 
While there is a lack of practical mechanisms which consider adherence, there are some 
practices which consider adherence. van Dulmen et al. (2007) reviewed 38 systematic 
reviews of the effectiveness of adherence interventions and defined three practices: 1) 
there are effective practices to improve adherence without a supported theoretical 
explanation; 2) there are effective adherence interventions based on the behavioural 
theories; 3) there are acceptable models that are able to define non-adherence, however, 
they are poorly effective in improving adherence. 
 
6.2.1 Non-adherence in the Treatment of Chronic 
Diseases 
The nature of the disease plays an essential role on the level of adherence. The level of non-
adherence of patients with chronic diseases is between 30% and 50% (Barnett, 2014; 
Bourbeau & Bartlett, 2008: Nunes et al., 2009; Sabaté, 2003). Bowry et al. (2011) 
emphasised that improving the percentage of adherence can be far more effective in the 
treatment outcome than only improving the medical treatment itself. Accordingly, a 
widespread innovative solution is needed to improve patients’ adherence to prescribed 
intervention. For example, DiMatteo et al. (2000) highlighted that depression as a chronic 
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disease can be a main factor in patient’s non-adherence. The adherence drops by 27% from 
the normal ranges if the patient experiences symptoms of depression (Martin et al., 2005).  
 
There are number of techniques that are used to improve adherence in the treatment of 
chronic diseases, such as the Micro Electro-Mechanical Systems (MEMS) that uses 
embedded microprocessor technology to record the time and date of the opening of 
bottles. Another technique is counting the pills during physician visits. However, these 
practices have a weak effect on adherence (Saini et al. 2009). The latter technique may not 
be effective for medical technology due to the nature of the treatment and its 
administration.  
6.2.2 Impact on Clinical Outcome 
The failure to achieve a significant level of adherence can have serious consequences for 
patient health, including relapsing, morbidity, health status, hospitalisation and mortality 
(Aldeer et al., 2018; Baum et al., 2012; Viswanathan et al., 2012). Mennini et al. (2014) 
investigated the cost of poor adherence to anti-hypertensive therapy in five European 
countries (Italy, Germany, Spain, France and England) over a 10 year period. The study 
explored cardiovascular complications associated with hypertension (i.e. stroke, heart 
attack and heart failure). Improving patient adherence to anti-hypertensive therapy to 70% 
could reduce the cases of cardiovascular complications by 82,235 in the five European 
countries combined, with 6,553 fewer cases in England alone.  
 
Fitzgerald et al. (2011) conducted a retrospective longitudinal study to understand the 
impact of non-adherence to medication on hospitalisations and mortality from heart failure. 
The study indicated that fewer than 80% adherence can lead to risk of mortality and 
hospitalisation for the entire population. The level of adherence that is associated with 
health complications varies according to the disease. For instance, in HIV patients, a level of 
adherence lower than 90%–95% is associated with viral replications and consequences may 
result from this (Martin et al., 2005). 
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6.2.3 Impact on Cost and Workforce 
Poor adherence also results in financial and workforce burdens, such as increasing 
healthcare costs and a negative impact on healthcare workforce productivity (Bosworth et 
al., 2011; Conn et al., 2016). For chronic diseases, the financial cost to the EU healthcare 
systems was estimated to be Euro 110 billion in 2006, which represents around 10% of their 
total healthcare expenditure. In England, the drug cost is estimated to be around Euro 200–
300 million. This cost includes the burden of non-adherence to the medical intervention. 
Improving adherence can reduce the cost by an estimated Euro 36.2 million in England 
(Mennini et al., 2015). 
 
Cutler et al. (2018) assessed 79 individual studies which covered the cost of medical non-
adherence in 14 diseases. In general, the cost related to all non-adherence causes ranged 
from $5,271 to $52,341 annually. Ho et al. (2016) conducted a systematic review of studies 
related to the clinical and economic impact of non-adherence in depressive disorders. The 
review categorised the costs into drug costs and medical costs, where the latter referred to 
the physician costs. The study concluded that the cost of non-adherence to the medication 
was significantly higher comparing to the adherence to the treatment.   
 
Another example of the cost of non-adherence is located in Muduma et al. (2015), who 
found that improving the adherence in renal transplant recipients by adjusting the 
treatment of tacrolimus doses from twice- to once-daily could provide an estimated cost 
savings of £4,862 per patient over five years, based on the NHS reference reported costs in 
2014. This cost savings extends to mental health diseases such as bipolar disorder. The cost 
of non-adhering patients with this disease is higher compared with adhering patients with 
the disease: £4,796 vs £2,150, respectively (Hong et al., 2011). 
 
The failure to adhere to the medical intervention has direct and indirect impacts on the cost 
to the healthcare system. While the direct impact is the drug cost, indirect costs such as the 
complications associated with lack of adherence to the treatment can exceed the direct 
costs. For example, poor adherence to hypertension treatment may lead to a stroke, which 
requires hospitalisation and incurs rehabilitation costs (Baum et al., 2012).   
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6.2.4 Treatment Administration and Adherence 
Hospitalised patients have more factors that lead to improving adherence to the prescribed 
treatment because the intervention is administrated by clinicians. When the treatment is 
self-administered by the patients, the factors that improve adherence to the treatment 
regimen change, becoming more complex. In self-administered therapy, it is estimated that 
one-third of the patients adhere to physician directions while two-thirds do not adhere to 
the therapy (Becker, 1985).  
 
The risk of poor adherence in self-administered treatment continues to be one of the 
biggest challenges in the process of medication intervention. Hall et al. (2016) emphasised 
that the level of adherence to the self-administered cancer treatments (e.g. haematological 
cancer) varied, ranging between 76%–100%, depending on the definitions and 
measurements used. The study concluded that, to achieve high adherence to the treatment, 
a multi-component intervention strategy is required. In another study of self-administered 
chemotherapy, 43% of the patients met the non-adherence criteria defined by the study 
(Lebovits et al., 1990). The latter studies highlighted another aspect of understanding 
adherence, which is the measurement of adherence. A clear measurement of adherence is 
required in order to identify the impact of adherence on the treatment intervention.  
 
According to the above literature, the research scope from the perspective of the disease 
and its administration is as follows: 
• The focus on chronic disease is determined because non-adherence magnifies the 
impact of chronic diseases as time progresses. This causes increasing clinical 
complications and financial costs. 
• The focus on the self-administered treatment is determined because adherence 
decreases when patients administer interventions themselves. 
 
The above two points determine an increased level of non-adherence and subsequently its 
complications. 
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6.3 Factors that Affect Treatment Adherence  
There are many theories which explain the complex nature of adherence (Aldeer et al., 
2018). Different approaches have been taken to patient adherence, and the theories these 
approaches have been based on have varied on their scope and how the phenomenon was 
addressed. An exploration of these theories reveals that they can be divided into two main 
categories: factor-based theories and stage-based theories. The first category focuses on 
the factors that affect adherence, such as the social learning theories (Martin & DiMatteo, 
2013). The second category of theories focuses on the stages people move through in order 
to achieve the behaviour change or adhere to medical treatment, such as the 
transtheoretical model (Aldeer et al., 2018; Martin et al., 2010). An interesting observation 
from the investigated literature is that adherence theories do not consider the type of 
medical practice (e.g. treatment, monitor or diagnosis), nor the type of intervention (e.g. 
pharmaceutical drug or medical technology), nor the administration of the practice (e.g. 
clinically administered, self-administered or both). However, there is a clear appreciation of 
the idea that adherence factors impact patient behaviour differently depending on the 
disease (Bosworth et al., 2005).  
 
The factor-based category of theories is most relevant to the aim of this research, which is 
to understand the factors behind adherence. The theories in the second category (stages 
theories) focus on the cognitive process of behaviour change. The focus of this study is on 
understanding the factors that influence adherence which should be considered during the 
design process of the treatment technology. Therefore, the discussion in this chapter will 
focus on the first category. 
 
6.3.1 Factor-Based Theories 
Some theories which aim to explain behaviour change focus on the factors which drive the 
change. Those theories present an opportunity to understand adherence factors, both 
individually and also in relation to each other. I will identify this set of theories as factor-
based theories because they focus on the factors that affect adherence.  
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6.3.1.1 WHO Five Dimensions 
The WHO defined five dimensions which affect patient adherence. These dimensions 
acknowledge the complex nature of adherence (Aldeer et al., 2018). These dimensions 
include the following (Sabaté, 2003): 
1) Social and economic factors (e.g. economic level and poverty, education level, age, 
unemployment and high medication costs)  
2) Healthcare team and system-related factors (e.g. poorly developed service and poor 
medication distribution)  
3) Condition-related factors (e.g. illness-related demands and patient perception of 
risk) 
4) Therapy-related factors (e.g. side-effects and the availability of medical support)  




Figure 6.1 The WHO five dimensions model of adherence. Based on Sabaté (2003). 
 
The WHO model (Figure 6.1) is supported by clear definitions of different factor which affect 
patient adherence. However, this classification is very broad and includes many factors, 
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such as economical levels and healthcare team factors, which cannot be controlled by the 
companies working in the field of medical treatment technology. 
 
6.3.1.2 NICE Medical Adherence Guidelines 
The fifth factor (Patient-related factors) of the WHO model aligned with adherence variables 
is indicated in the National Institute for Health and Clinical Excellence (NICE) Medical 
Adherence Guidelines. The guidelines suggest that the causes of patient non-adherence fall 
into two intersecting categories: intentional and unintentional. The latter factors can be 
either perceptual, which motivate patients to continue the treatment (e.g. beliefs and 
preferences), or practical, which influence their ability to adhere to the advised treatment 
(e.g. limitations in capabilities and resources) (Bosworth et al., 2011; Chapman et al., 2015; 
Nunes et al., 2009). The above guidelines present a simple yet broad model. The model is 
suitable for companies which have already developed a clear idea about the factors that 
affect patient adherence amongst their target patients. 
 
Figure 6.2 The NICE definition for adherence factors. 
 
The psychology literature introduced theories targeting behaviour change and treatment 
adherence. Below, an overview of the literature theories related to adherence is presented 
in order to clearly identify the adherence factors.  
 
6.4 Theoretical Adherence Frameworks 
Different theories have been proposed to understand patient adherence to treatment or 
behaviour change. These theories are based on psychology research (Rosenstock et al., 
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1988). As highlighted earlier, adherence theories can be categorised based on how the 
adherence is addressed as a number of intersecting factors, or as a sequence of stages that 
leads to the continuation of adherence to the medical treatment. 
6.4.1 Stimulus Response Theory (SRT) 
Stimulus response theory (SRT) focuses on the stimuli of the event rather than on the 
physiological drivers. SRT theory views learning as the result of events that provide 
‘reinforcements’. For example, a person who is rewarded for a specific behaviour tends to 
repeat that behaviour in order to receive the reward. In contrast, a person who is punished 
for a specific behaviour learns the outcome and tends avoid that behaviour, as this reduces 
the tension incurred by the punishment (Rosenstock et al., 1988). Skinner and Champion 
(2015) explain SR theory by noting that the frequency of the behaviour is determined by its 
consequences. The immediate reward or punishment after the event is enough to drive the 
behaviour response without the need for mentalistic concepts. Based on this description, SR 
theory focuses on main two factors: 
• Immediate reward reinforcement 
• Immediate punishment reinforcement 
 
6.4.2 Social Learning Theory (Social Cognitive Theory)  
Bandura (1977) introduced social learning theory (SLT), which was later renamed social 
cognitive theory (SCT). According to SCT, behaviour results from external stimuli and can be 
explained by reinforcement (reward and punishment). In this theory, the behaviour is a 
result of mental processing activities (such as reasoning, decision making and problem 
solving). SCT points out that the drivers of behaviour reinforcements are social in nature 
(Bosworth et al., 2005) and behaviour is determined by two types of factor categories: 
• Expectations: Three types of expectations can drive behaviour: 1) expectations 
about environmental cues such as beliefs about connected events and the 
surrounding environment during the action; 2) expectations about the consequences 
of the action (outcome expectancies); and 3) expectations about one’s ability to 
perform the behaviour (self-efficacy). 
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• Incentives: An incentive is the value of a particular object or outcome (reward and 
punishment). For example, relieving pain can be a reward of taking painkillers or 
being healthy can be a reward of physical exercise. 
 
The above two theories highlight the social aspect of learning, as people learn by observing 
others perform the behaviour (observational learning). Practices informed by these theories 
can lead to higher adherence to the behaviour (for example, treatment intervention) 
(Bosworth et al., 2005). Furthermore, some shared factors can be noticed between SR 
theory and SCT, represented in the reinforcement of rewards and punishments, which are 
described more broadly in SCT as the expectations about the consequences of the action. 
 
6.4.3 Locus of Control Theory 
Rotter (1966) introduced the Locus of Control Theory, which suggests that in the presence 
of the same information people react differently either by learning different things or 
responding to reinforcement. 
 
The expected varied behaviour is affected by number of variables known as the ‘locus of 
control’. These variables can be categorised into two dimensions:  
• Internal locus of control: the reinforcement of the behaviour is internal to the 
person. For example, physical exercise rewards the person with good health. 
• External locus of control: external factors, such as luck, fate and chance, are the 
drivers of the reinforcements. 
 
Wallston & Wallston (1978) suggested that the influence of other people can be considered 
an external reinforcement of behaviour. Those influencers (powerful others) can be 
clinicians, consultants, or families. Different studies have used the Locus of Control Theory 
to improve the adherence to treatments and therapeutic recommendations such as HIV, 
smoke cessation programmes, and hypertension medication (Bosworth et al., 2005; Martin 
et al., 2010). 
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There is a shared border between the reinforcement factors in SRT, incentives in SCT theory 
and the Locus of Control Theory factors. Each of these three theories address stimuli factors 
from different perspectives. SR theory addresses it from the 
reward/punishment/reinforcement perspective. SCT presents the incentive as a broad 
factor that can include any stimulus to drive the behaviour change. Locus of Control Theory 
presents a more detailed categorisation which focuses on the location of the locus of 
control factors which drive the behaviour change. 
 
6.4.4 Self-Efficacy 
Bandura (1977) suggested that social learning is not a strong enough factor to make a 
person behave or react to reinforcement; the person must also be confident in her ability to 
perform the behaviour. This aspect is known as self-efficacy. Different studies have shown 
self-efficacy to be a significant factor in treatment adherence in, for example, smoking 
cessation and the ability of women to perform breast self-examination (Bosworth et al., 
2005). Four aspects affect self-efficacy: performance mastery, vicarious experience, social or 
verbal persuasion, and physiological cues perceived by the person. Self-efficacy focusses on 
the internal locus of control factors represented in the locus of control, which subsequently 
related to the incentive factor in social learning theory. 
 
6.4.5 Continuum Theories 
Several theories based on social learning theories have been produced. A subsection of 
these theories, known as continuum theories, assume that the variables which influence 
behaviour can be combined in one equation which can predict adherence behaviour. Below 
are some examples of continuum theories. 
 
6.4.5.1 Health Belief Model (HBM) 
The Health Belief Model (HBM) explains why some patients adhere to a specific regimen 
while the others do not. In this theory, the likelihood that a patient will adhere to a regimen 
is affected by the patient’s personal beliefs about the: 1) perceived susceptibility; 2) 
perceived severity; 3) perceived benefits; and 4) perceived barriers of the disease and 
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treatment. The influence of these factors depends on the demographic variables and 
psychological characteristics of the patient. The health belief model presents a point of 
intersection between two theories: Stimulus Response, and social learning (Williams, 2014).  
 
Different modifications were added to HBM. For example, Bandura (1977) introduced self-
efficacy as one of the barriers in the model. Other factors, such as health motivation, 
relevant personal attributes, susceptibility to the condition, general orientation toward the 
treatment and the characteristics of the relationship between the patient and the doctor, 
were also added (Bosworth et al., 2005). 
 
Factors from SR theory and SCT can be seen in HBM theory. For example, the punishment 
reinforcement in SR theory is represented in the HBM as perceived severity. The self-
efficacy factor in the modified version represents both self-efficacy theory and the 
incentives in SCT. The incentives reinforcement in SCT is represented in HBM as perceived 
susceptibility.  
 
6.4.5.2 Theory of Reasoned Action and Theory of Planned Behaviour  
Unlike theories which depend on exploring the factors that affect how well a person 
adheres to a treatment regimen, this theory suggests that the strongest predictor of a 
behaviour is the intention to engage in that behaviour. This intention is determined by the 
attitude toward this behaviour—for example, the personal evaluation of the behaviour—
and the subjective norm (the personal perception of how others feel about the behaviour). 
The theory of reasoned action was modified by Ajzen (1991) to include the perceived 
behaviour control. This third factor refers to the level to which the person feels in control 
when engaging in the behaviour. This last factor—perceived behavioural control—shares 
similar meaning with the previously discussed theories, such as the self-efficacy theory.   
 
Various studies have attempted to understand the factors which drive people to adhere to 
specific behaviours and have approached this from different perspectives. For example, 
Social Learning Theory discussed above tends to address adherence from the perspective of 
social learning and seeks to observe the change in behaviour based on internal and external 
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factors. Additionally, this perspective considers the predictors of adherence and what the 
factors are that drive the behaviour. The second type of theories address adherence from 
the perspective of the stages that one moves through in order to react to the thread and 
how the behaviour is addressed. An example of this is the Self-Regulatory Model of Illness, 
which describes how the patient’s behaviour change starts with situation stimuli (internal or 
external) which lead the patient to representation of danger or fear. The patient then tries 
to cope with the new changes and appraisal to evaluate the impact of the coping 
procedures. Another example are the Stages theories, which include Transtheoretical and 
Precaution Adoption Process Models, describe behavioural change as a process that occurs 
via progression through different stages.  
 
6.5 Communication and Adherence 
A wide range of literature studies have highlighted the positive correlation between 
communication with the patient and adherence to treatment regimen (e.g. Haskard-
Zolnierek & DiMatteo, 2009; Martin et al., 2010; Martin & DiMatteo, 2013). Effective 
communication between the clinician and patient can improve adherence by 19% (DiMatteo 
et al., 2012; Haskard-Zolnierek & Dimatteo, 2009). Although the importance of the patient-
physician relationship has long been understood, it was not until the 1960s and 1970s that 
studies explored the factors that affect the communication between patient and physician, 
and subsequently affect the adherence to the medication. Literature studies have addressed 
patient-physician communication from five perspectives: 1) the physician’s interpersonal 
skills; 2) the physician’s teaching skills; 3) the patient’s satisfaction; 4) the patient’s recall of 
instruction; and 5) the patient’s satisfaction with and adherence to the regimen. Studies 
that focused on the fifth perspective have indicated that the relationship between the 
patient and physician is significant. Korsch et al.(1968) highlighted number of elements 
related to communication between the patient and physician, including how friendly the 
physician is, how well the physician understands the patient’s concerns and the patient’s 
satisfaction (Bartlett et al., 1984). 
 
 Chapter 6: Theoretical Frameworks of Adherence  
 
 112 
Haskard-Zolnierek and Dimatteo (2009) presented a meta-analysis based 127 studies of 
patient-physician communication. A number of factors were found to affect patient 
adherence, including: 
1) Physician communication skills: physicians with good communication skills can 
improve patient adherence. 
2) Patient involvement in decision making.  
3) Discussing with the patient information about the treatment benefits and risks, as 
well as the barriers that may affect adherence to the treatment regimen.  
4) Building a rapport and trust with the patient, and providing support and 
encouragement for the patient. 
 
The third and fourth factors above align with the patient’s knowledge, which can be 
mapped onto different adherence theories, such as the patient-related factors in the WHO 
five dimensions of adherence (Sabaté, 2003) and the consequences in Social Learning 
Theory (Bosworth et al., 2005). Furthermore, those four factors are linked to the perceived 
susceptibility, barriers, benefits and severity in the HBM (Bosworth et al., 2005; Williams, 
2014). This involvement can extend to broader patient empowerment, a concept that aims 
to widen the patient experience to involve decision making, self-management and patient 
education (Anderson & Funnell, 2010). Various of studies have shown a positive relationship 
between patient empowerment and adherence (Delamater, 2006; Náfrádi et al., 2017).   
 
‘Communication’ refers to the adherence factors related to the patient’s communication 
with the outer world, including clinicians and friends, and how the patient perceives others’ 
opinions about the practice. According to the reviewed studies above, the following factors 
can be part of the communication section. 
 
6.6 Patient Empowerment 
Another benefit of the communication between the patient and the clinician is patient 
empowerment. A close connection can be found between patient communication and 
patient empowerment. The term ‘patient empowerment’ refers to the patient’s extended 
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capacity to make decisions and take responsibility for the consequences of these events 
(Aujoulat et al., 2007; Feste & Anderson, 1995; Funnell & Anderson, 2003; McAllister et al., 
2012). It is an educational process which encourages patients to self-manage their 
treatment regimens and achieve behaviour change (Anderson & Funnell, 2010; Feste & 
Anderson, 1995). 
 
Studies which have covered patient empowerment have highlighted the role of the 
healthcare system and tried to define the boundaries between patients and clinicians 
(McAllister & et al., 2012). These boundaries should be negotiated between both the 
patient and the clinician to ensure an effective outcome (Funnell & Anderson, 2003). The 
successful application of the patient empowerment concept can have a positive impact on 
patient adherence and participation in planning the treatment regimen (Powers & Bendall, 
2003). In self-administered treatment devices, patient empowerment plays an essential 
role, as patients are responsible for the administration of the treatment. However, the 
communication factor between the patient and the clinician is one of the most challenging 
factors, as it may be hard to maintain the self-administered treatment even though it is 
crucial to improve adherence. 
 
Gamble et al. (2011) have indicated that poor adherence increases the burden of controlling 
asthma. However, adherence improves after involving the patients in concordance meetings 
with the clinicians. 
 
6.7 Patient Monitoring 
As highlighted earlier, a number of external factors impact patient adherence and behaviour 
change, such as the external locus of control in the Locus of Control theory (Rotter, 1966), 
the environmental cue in SCT (Bandura, 1986) and the subjective norm in perceived action 
and planned behaviour (Ajzen & Madden, 1986).  
 
Health technology provides an opportunity for the clinician to monitor a patient’s data 
without the need for the patient to be in a hospital or a clinic during the monitoring. This 
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helps clinicians gain a better understanding of the patient’s disease and provide effective 
treatment (Car et al., 2017).  
 
6.7.1 Follow up and reminders in adherence 
Fenerty et al. (2012) conducted a meta-analysis study that systematically reviewed four 
randomised controlled trials (between 1999 and 2009) related to reminded intervention and 
how it may improve patient adherence. The study concluded that reminders may improve 
patient adherence to medication. However, this application cannot be generalised to 
different types of diseases and needs to be adapted for ‘alternative adherence-modifying 
strategies’ (Fenerty et al., 2012. p.127). 
 
Another meta-analysis conducted by Vervloet et al. (2012) explored the role of electronic 
reminders in improving adherence in the treatment of chronic diseases. In this study, a 
varied a number of electronic methods were used to remind chronic disease patients to 
take their daily medications. The study concluded that electronic reminders can improve 
adherence in the short-term. However, the long-term impact of electronic reminders is not 
clear. 
 
6.7.2 Adherence and technology 
Medical technology can provide an opportunity for the clinician to better observe patient 
adherence and improve it using different types of technologies. For instance, using the short 
message system (SMS) on a daily basis for a short period has been shown to improve 
patient adherence to anti-asthma medications (Strandbygaard et al., 2010).  
 
Using monitoring devices and strategies such as the Self-Reporting Adherence 
Questionnaires (SRAQ) can play a crucial role in improving patient adherence, especially for 
self-administered treatments (Bus et al., 2012; Shi et al., 2010). 
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6.8 Information, Motivation, Strategy 
The theoretical factors of adherence present challenges when identifying the factors 
underpinning adherence behaviour. This is because: 1) some factors are shared between 
theories or hold similar meanings, such as consequences (social learning theory), perceived 
barriers and benefits (health belief model), and threat appraisal (protection motivation 
theory); and 2) some factors are addressed from different perspectives in each theory. For 
example, the environmental cue in social learning theory refers to the external environment 
in which the patient is located while doing the behaviour. In the theory of reasoned 
action/planned behaviour, the concept of subjective norm holds similar characteristics 
compared with the environmental cue concept. 
 
A general classification of the nature of adherence factors is required if companies are to 
easily consider them. One of the most interesting classifications of adherence factors is the 
three-factor model presented by Martin and DeMattio (2013). In this model, the adherence 
drivers are classified into three main factors: information, motivation and strategy (I-M-S). 
The main aim of the model is to provide a practical guide for clinical action. Towards this 
end, the model addresses three main aims: 
• Ensure the patient has the right information related to how to adhere to the 
treatment, which includes listening to the patient’s concerns, encouraging patient’s 
partnership in decision making, building trust and empathy and enhancing recall. 
• Help the patient to believe in the treatment and commit to it by addressing different 
cognitive, cultural, social and normative factors. 
• Help the patient to overcome the barriers to treatment adherence and develop 
strategies for chronic disease management (DiMatteo et al. 2012). 
 
The above model presents a practical guide for clinicians to build a strategy to improve 
patient adherence by focusing on the general factors that affect adherence in the majority 
of diseases. This model was developed based on a meta-analysis study of the literature from 
1948 to 2001 (DiMatteo, 2004). The simplicity and adoptability of the model make it more 
efficient than following the theoretical factors of adherence. However, in the interest of this 
research, two observations should be noted: 
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• The model can work effectively with physicians, as they have experience with the 
diseases they specialise in and how patients adhere to the prescribed medication. 
However, for new companies working on delivering medical technologies, this model 
becomes challenging to adopt when manufacturing treatment devices and 
measuring the efficiency of adherence factors. 
• The I-M-S model considers the general factors that affect patient adherence in 
controlled non-technological treatment interventions. When the treatment is a self-
administered device, the adherence involves other factors, such as how the 
adherence will be monitored and measured. Furthermore, the model considers how 
the design and function of the medical device contributes to adherence to the 
treatment regimen. 
 
According to the above, in order to guide and measure how adherence is considered in self-
administered treatment devices, a more inclusive and achievable Adherence Canvas is 
required. This model should consider the nature of self-administered treatment devices and 
the contexts of their use.  
 
Figure 6.3 presents a visualisation of examples of 1) the theoretical frameworks of 
adherence, 2) the factors in each theory, 3) communication-related factors, and 4) design-
related factors. Furthermore, the figure links and re-orders the factors into categories as 
described below: 
• Examples of the adherence theoretical frameworks (blue) are presented on the 
right side. Some theories are linked to each other (grey lines). In some instances, 
the Social Learning theory overlaps with other theories, such as the Health Belief 
Model. For example, in the Social Learning theory, the expectancies factor refers 
to the expected outcome of the intervention, which aligns with the Health Belief 
Model factors of perceived barriers, benefits and severity. The expectancies 
factor in the Social Learning theory includes the environmental cue (sub-factor) 
that refers to the patient’s environment and its social and cultural impact on 
adherence. The environmental cue is described in Researched Action/Planned 
Behaviour theory as the subjective norm. 
 Chapter 6: Theoretical Frameworks of Adherence  
 
 117 
• In linking different factors and their relationship to each other, three main 
categories can be identified: Motivation, Knowledge and Communications. The 
latter category can map onto other factors that are not listed in the adherence 
theories but can affect patient adherence. The communication between patient 
and clinician can lead to a higher level of adherence as highlighted in the 
literature (Chapter 6: Theoretical Factors of Adherence) and case studies 
interviews (Chapter 9: Case Studies Interviews). Factors such as the 
environmental cue (Social Learning) and subjective norms (Reasoned 
Action/Planned Behaviour) have communication aspects as they involve social 
interaction.  
• In medical technologies, the patient experience extends beyond behaviour 
change factors to involve design aspects, as highlighted by the five case studies 
interviews (Chapter 9: Case Studies Interviews). The lack of linkage (grey lines) 
between the Experience category and the adherence theories confirms the 
design aspects’ lack of consideration in physical and digital treatments. 
 




Figure 6.3 Adherence factors linked to the theories on the left and the categories on the top right.  
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The theories cover adherence factors in general without considering that the factors that 
affect adherence may vary depending on the disease (Bosworth, Weinberger, & Oddone, 
2005). Other aspects can determine the factors which affect adherence, such as the nature 
of the treatment, patient demographics and the circumstances associated with the 
treatment regimen. Thus, while common factors can be used in general consideration, these 
factors may need to be refined as a clear understanding of the patients, treatment and 
disease becomes available.  
 
6.9 Adherence Factors in Different Diseases 
Theoretical Adherence factors aim to understand the factors that affect how patients 
adhere to a treatment regimen. However, the impact of adherence factors may vary 
depending on the disease. For example, a number of factors stand as barriers to adherence 
to weight loss and diet recommendations. The barriers affect patient adherence and 
therefore the patient’s ability to achieve the recommended goal, as well as to continue 
adhering to clinical recommendations after reaching the targeted weight. These factors 
include lack of income or resources, cultural factors, lack of motivation and especially 
patient knowledge, which may involve complex dietary information (Bosworth et al., 2005). 
 
The frequency of the doses is a significant factor that affects adherence in the treatment of 
chronic disease. This being the case, the likelihood of adherence to one dose per day is 
higher than the likelihood of adherence to an intervention that involves two or more doses 
per day (Saini et al., 2009). Another example is the statin therapy used for the prevention of 
cardiovascular disease. A number of factors affect patient adherence to the statin therapy, 
including:  
• Patient factors, such as comorbidities, financial issues, the constraints of adhering to 
the therapy and psychological issues. 
• Practitioner factors, such as knowledge and education, time limitations and poor 
communication skills. 
• System factors, such as lack of monitoring, financial barriers, and medication side 
effects (Bates et al., 2009). 
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6.10 Behaviour Change 
The desk search used design-related keywords such as “Behaviour Change” in place of the 
keyword “Adherence”, which are used more frequently in healthcare, medical, and 
psychological knowledge. Behaviour change was used along with “Design” and “Patient” 
keywords in the search query (Behaviour change, design and patient) to identify the 
literature related to the usage of design to drive patients’ behaviour change. Using the last 
query, the results reflected research about using factors such as motivation and 
gamification to drive behaviour change in patients with diseases such as cardiovascular 
diseases (Gallagher et al., 2019; Pfaeffli, 2016). The research results retrieved several 
applications, including the Behaviour Change Wheel (Michie, Van Stralen, & West, 2011). 
The Behaviour Change Wheel includes more details about the wheel and the COM-B model. 
The model has been used to develop interventions for cancer patients (Webb, Foster, & 
Poulter, 2016). The Behaviour Change wheel presented an interesting approach that 
presents a practical tool to consider behaviour change factors based on a COM (Capabilities, 
Opportunities, and Motivations) model. However, the following can be observed: 
1. It does not focus on self-administered health technology. So, several elements were 
not considered, such as usability, user experience, and product characteristics. 
2. While it provides a guide to different behaviour change factors, it does not provide a 
practical guide to evaluate these factors during the development process. 
3. It does not provide levelling feature that can be used to rate the importance of 
behaviour change factors. The feature is needed, especially with building a 
behaviour change strategy that involves more than one factor. 
 
Another type of literature addressed the outcome of behaviour change solutions rather 
than considering it, such as implementing mobile-health behaviour change interventions in 
cardiovascular disease self-management and using the behaviour change to encourage 
physical activities for cancer patients. In another study, The COM-B model improved self-
care adherence in heart failure patients (Herber et al., 2018). 
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6.10.1 Persuasive Design and Behaviour Change 
“Persuasive Design” is a design-related term that aims to use design as a persuasive tool to 
change behaviour. When searching using Google Scholar using the search query (persuasive 
design and patients adherence), the results mainly came from the medical and psychological 
publications similar to using the term “Behaviour Change”.  
 
The search for persuasive design showed results related to the usage of persuasive 
technology design to encourge patients to behaviour change. The observation shows a close 
connection in the search results related to using persuasive design to influence behaviour 
change (or adherence) to technology such as web-based intervention (Kelders et al., 2012), 
e-health design (Baumeister et al., 2019) and home health-monitoring systems (Rezai, 
Torenvliet, & Burns, 2014). 
 
Fogg (2009) presented the FBM, which connects both persuasive design and behaviour 
change. The model is built on three main elements: motivation, ability and behaviour 
trigger. The trigger to behaviour change occurs when the person receives a sufficient level 
of motivation and simplicity. In FBM (Figure 6.3), the motivators are factors that can drive a 
person to change behaviour, and these motivators include three factors that vary from high 





The factors above present the scale of motivation. For example, pleasure is linked to high 
motivation, whereas the pain is linked to low motivation. The scale of the ability (simplicity) 
refers to how simple is the change from the perspective of six factors: 
• Time 
• Money 
• Physical effort 
• Brain cycles 
• Social deviance 





Figure 6.3 Fogg Behaviour Model (Fogg, 2009) 
 
Fogg’s model appreciates the complex nature of behaviour change and relevant factors in 
driving behaviour change. Many attempts at persuasive design fail because of the lack of 
understanding of the factors that lead the behaviour change (Fogg, 2009). 
 
Another search query used as a synonym for “Persuasive design” is “Captology”, which 
refers to using computer technology as a persuasive tool. Both terms are used in design and 
technology domains. The results were not sufficient when a combination of keywords 
“Persuasive design”, “Captology”, “Adherence”, and “Behaviour change” were used. 
 
The search for the terms above has revealed that most of the literature is presented from 
the psychology, medical and healthcare perspectives. A lack of studies from the design 
scholars in this area, especially how the mechanisms that drive adherence are defined and 
considered during the PDP. This finding presented a sub-claim as highlighted in Chapter 14 
(14.2 Research Claims and Contribution to Knowledge). 
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6.11 Findings and Summary 
Adherence presents one of the major challenges that face healthcare systems, as it has 
direct impact on 1) the efficacy of the treatment results (or other clinical testing procedures, 
including focus groups and advisory groups) (Viswanathan et al., 2012); 2) the difference 
between efficacious and effectiveness trials results; and 3) the real-world results of using 
the product (Car et al., 2017). The scope of the adherence literature investigation in this 
chapter involves non-adherence in the treatment of chronic diseases (Barnett, 2014; 
Bourbeau & Bartlett, 2008; Nunes et al., 2009; Sabaté, 2003) and self-administered 
treatments (Becker, 1985; Hall et al., 2016; Lebovits et al., 1990) as they present a high risk 
of non-adherence occurrence, as discussed in detail in 6.2.1 Non-adherence in the 
Treatment of Chronic Diseases and 6.2.4 Treatment Administration and Adherence. 
 
A clear understanding of the theoretical models of adherence is required in order to explore 
its potential during the design process. Adherence theories have focused on either the 
factors that affect adherence or the steps that are taken toward the behaviour change. 
Factor-based theoretical models were overviewed to understand the factors that drive 
adherence and subsequently consider these factors in the design of the treatment 
technology. The other factors that affect adherence were discussed, especially the 
communication between patients and clinicals and the role of technology in improving 
adherence.  
 
Four main observations can be found from the literature overview of the theoretical 
frameworks related to adherence: 
1. The adherence theoretical frameworks did not consider providing, nor provided, a 
practical solution to consider adherence in the design and development of the 
medical intervention. 
2. The theoretical frameworks did not consider the special characteristics that make 
medical technology different from pharmaceutical treatments. As a result, factors 
such as user experience, aesthetic look of the treatment and functionality of the 
treatment were not considered to be part of the factors. 
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3. The adherence theoretical frameworks did not consider patient-administered 
treatment in proposing that adherence behaviour is affected by whether the 
treatment is clinically administered or self-administered by the patients. 
4. Communication-related factors were either not considered or not sufficiently 
considered. The theoretical frameworks overviewed did not consider the importance 
in communication and it is role in patient empowerment. 
5. There is a significant lack of the design literature about patient adherence especially 
in relation to providing solution for companies to consider it in the development of 
the healthcare technology. 
 
Understanding the theoretical factors of adherence provides an essential cornerstone in the 
design process for medical technology. Overviewing the literature about design thinking can 
lead to a better understanding of how adherence factors can be considered in the design 
process to develop patient-centred medical technology.

















Chapter 7: Design Thinking 
 
This chapter explores the literature on the 
design thinking process, focussing on the 
characteristics which can add value to the 
design of self-administered treatment 
technology. Furthermore, the value and the 
challenges of applying design thinking will 
be discussed from the perspective of its 
benefits for medical technology innovation. 
  
Key Topics: 
7.1 The Nature of Design Thinking 
7.2 Design and Creativity 
7.3 Design Thinking as a Process  
7.4 Voting in Design Process 
7.5 Design as a Driver for Innovation 
7.6 The Multi-Perspective Problem Framing 
(MPPF) 
7.7 Innovation in Small and Medium 
Enterprises SMEs 
7.8 Evidence-Based Design 
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The term ‘design thinking’ has been commonly used over the last two decades to refer to a 
tool that companies use to achieve innovation. However, the philosophical approach behind 
design thinking has been blurred due to the over-commercialisation of the term by those 
who lack a clear understanding of the core value behind it (Kimbell, 2011). This chapter will 
clarify the core value of design thinking. It will furthermore discuss why design thinking has 
been used as a framework to design and develop medical technology treatments.  
 
This chapter will explore design characteristics to identify the potential role of design 
thinking in driving innovation in medical technology SMEs. Over the course of this literature 
review, this chapter aims to answer the following two questions: 
• What are the characteristics of the design thinking process? 
• What are the barriers to and opportunities for adopting design thinking? 
 
Over the course of answering the above two questions, the main reasons behind focuses on 
design thinking as a process used to design and develop medical treatment technologies will 
be addressed.  
 
7.1 The Nature of Design Thinking 
Scholars have been interested in the nature of design thinking since the early 20th century, 
and especially in the rise of craftsmanship and initiatives that have sought to define design 
practice as either a science or an art. The philosophical approaches that inform design 
thinking contribute to the nature of the design process, especially in how it addresses 
problems.  
 
Simon (1968) defined design thinking, stating that: ‘the proper study of mankind is the 
science of design, not only as the professional component of a technical education but as a 
core discipline for every liberally educated man’ (Simon, 1968, p.83). Buchanan (1992) 
discussed John Dewey’s view on design as a liberal art, which Dewey described in his The 
Quest of Certainty:  
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‘The old centre of the universe was the mind knowing by means of an equipment of 
powers complete within itself, and merely exercised upon an antecedent external 
material equally complete within itself. In this new centre is indefinite interactions 
taking place within a course of nature which is not fixed and complete, but which is 
capable of direction to new and different results through the mediation of intentional 
operations.’ (Dewey, 1960, p.91). 
 
Dewey defined design thinking as a new liberal art, different from the traditional arts. This 
new definition, acknowledged by Buchnan, gave it an adaptive progressive nature. 
Buchanan described this ‘liberal art’ as an ability that exists in all people, but some are more 
talented in utilising it in professional practice. Furthermore, Buchanan described the term 
‘design thinking’ as expandable (Buchnan, 1992). Dewey’s and Buchnan’s descriptions of 
design thinking gives it a constructive pragmatic perspective which is a different view from 
Simon’s.  
 
Cross (2011) supported Buchanan’s and Dewey’s understanding of design in his description 
of design ability. Cross highlighted Rowe’s observations of architecture design case studies. 
Rowe observed architecture case studies of large buildings in major American cities. In 
Rowe’s observations, designers were found to regularly switch between solution concepts 
and problem exploration in the design process (Rowe, 1987). This nature of design is 
addressed by Schön (1938), who describes the process through which designers address the 
problem as ‘a reflective process’ or ‘a reflective conversation with the situation’ (Cross, 
2011. p.56). 
 
Dorst (2010) developed his definition of the nature of design thinking around the abductive 
nature of design. For Dorst, abductive reasoning is one of the reasoning patterns used to 
solve problems based on what we know and do not know. He highlighted three main 
patterns: 
• Deductive: Both ‘What’ (the elements of the system) and ‘How’ (how the elements 
work together) are known. Accordingly, the ‘Result’ can be accurately defined. 
• Inductive: The ‘What’ and ‘Result’ are known. Accordingly, the working principle or 
the process ‘How’ can be predicted. 
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• Abductive: Dorst defined two forms of abductive reasoning. In the first form 
(problem-solving), both ‘How’ (the working process) and the ‘Value’ that needs to be 
achieved are known. Next, the system element ‘What’ needs to be figured out. In 
this case, the missing part is the designed product or service. In the second form, we 
do not know ‘What’ or ‘How’ but we do know what we need to achieve (Result). 
Therefore, we need to find out (or create) working principles and the elements or 
systems needed to achieve the value.  
 
This nature emphasised the importance of testing in the design process, as designers need 
to test the different ideas (what) in the specific scenario (how) in order to achieve value. 
This process moves from the problem space to the solution space and back again. It builds 
an intuition within the designers, which shifts the creative nature in design toward creative 
solutions and testing and improving those solutions. 
 
7.2 Design and Creativity 
The literature studies discussed earlier (7.1 The Nature of Design Thinking) presented 
evidence that design thinking is a driver of creativity and supports creativity in the design 
practice (Buchnan, 1992; Cross, 2011; Dewey, 1960; Rowe, 1987). This aligns with the 
International Council Societies of Industrial Design (ICSID)’s definition of design. The ICSID 
highlighted two main characteristics of design:  
1. Aim: Design is a creative practice that aims to create an object, process or service, 
among others, and  
2. Task: Design seeks to discover and assess the current situation to reach an improved 
state, such as enhancing global sustainability, giving benefits and freedom to people, 
supporting cultural diversity and giving products an aesthetic form and appreciating 
the complexity (De Mozota, 2003; Manzini, 2006). 
 
The latter two definitions appreciate two main characteristics of design: 1) the creativity, 
form and aesthetics of the product or service; and 2) the move from one status to an 
improved one (addressing needs). These characteristics align with Tim Brown’s definition of 
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design thinking as 1) a human-centred approach; 2) innovative; 3) targeted to address 
people’s needs; 4) making the product desirable aesthetically; 5) technologically viable; and 
6) feasible from the business perspective (2011). Other definitions for design thinking 
indirectly highlighted its support for creative practice, such as Dorst’s (2012) definition of 
design thinking as a practice which can resolve issues with a broad approach and can be 
implemented to address both business and social problems. English et al. (2010) indicated 
that professional design practice resolves issues with a broad approach which reflects the 
multi-perspective approach to solving the problem. The unique opportunity to focus on the 
problem frame and understand the relationship between the problem frame and solution 
frame allows companies to leverage creative thinking and brainstorming in order to explore 
the problem space (Dorst, 2015). Keeping in mind the nature of medical technology, and 
how it originates from a clinician-administrated approach, the shift toward a patient-
administered treatment may present a challenge, especially when considering patients’ 
behaviours and experiences. The characteristics highlighted above can contribute to 
addressing this challenge in self-administered treatment devices, especially by addressing 
patient needs with creative solutions. 
 
7.3 Design Thinking as a Process  
Design thinking is a process that aims to identify innovative solutions through deep 
exploration of the problem space (Brown, 2011; Dorst, 2015) and move decisively to define 
the problem and evaluate prototypes in order to reach the final deliverable product (Cox, 
2005). This early definition of the problem doesn’t apply to wicked problems when the 
problem cannot be clearly defined until the end of the process (Coyne, 2005; Roberts, 
2000). Several design thinking models have been presented which reflect the nature of the 
design as a process (Cox, 2005; Dorst, 2012) such as the Double Diamond (Design Council, 
2015), IDEO D.School and IBM Design Thinking. While design thinking process models vary in 
the number of stages and how the process works, they follow similar sequential steps from 
exploring the problem, defining it, and move to developing of the solution such as the 
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Double Diamond (Figure 7.1). 
 
Figure 7.1 The diversion and conversion stages in the Double Diamond (Design Council, 
2015). Adopted from Dorst (2015).  
 
• The Diversion stage is where the ideas are explored in an inclusive environment. The 
nature of this stage remains the same in both the problem and the solution spaces, 
while the application differs. In the problem space, the diversion stage explores the 
problem from multiple perspective. In the solution space, the diversion stage aims to 
develop different prototypes and test them in order to reach a solution that is 
human-centric, viable from the business perspective and technologically feasible 
(Brown, 2011). 
• The Conversion stage aims to filter ideas, excluding the ones that do not contribute 
to achieving the business target. In the problem space, the conversion stage aims to 
refine the problem for the subsequent prototyping stage. The second conversion 
stage is delivery, where the prototypes are refined, and one design is selected to be 
processed. 
 
The Double Diamond in Figure 7.1 presents another characteristic of the design process, 
which is the iteration and prototype improvement (Design Council, 2015). Pugh (1990) 
presented the concept of ‘total design’, an iterative model in which the information is 
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shared with all the departments and from the early stage (Figure 7.2). The user is placed at 
the heart of this model in order to develop a product that meets consumer needs. In 
addition to the above benefits that design can add to the development of medical 
technology, challenges related to the adoption of the process need to be highlighted below: 
‘The design process is less scientific, and this may present a challenge to adopt the process 
in the current system as design process considers both user, technology, and business 
equally.’ (Design Council, 2007, p.8) 
 
Figure 7.2 An iterative model (total design) by Pugh (1990). Source: (Council, 2007). 
 
The world is evolving quickly, which makes it unrealistic to dictate a fixed methodology or a 
process. To this end, Cross (1994) was one of the first to look at this challenge from the 
engineering perspective. In Engineering Design Methods, he provided tools that help 
designers and engineers work together (Figure 7.3). While his model is related to 
engineering, his approach opens the door for further investigation into the integration 
between the design process and medical science.  





Figure 7.3 Cross (1994) for integrating both design and engineering. Source: (Council, 2007). 
This realistic look at the design process and how it works in real life companies is supported 
by Clarkson and Eckert’s (2005) model (Figure 7.4). In this model, the design process does 
not move rigorously toward product development and delivery. However, it faces 
‘constraints’ and ‘drivers’. Therefore, the process needs to be generic and adaptable in 
order to face development challenges (Council, 2007). Best (2006, p.114) indicated: ‘Design 
processes are difficult to standardise, in part because of their iterative, non-linear nature, 
and also because the needs of clients and users are so different.’  




Figure 7.4 Clarkson and Eckert’s (2005) model of adaptive design process. 
 
According to the above exploration of the design process, a number of values can be 
realised through adopting the design thinking process including: 
• Creativity: Several studies support the creative nature of the design process (Brown 
& Katz, 2011; Cross, 2011; Dorst, 2015; Kimbell, 2011; 2012). The divergent nature of 
the design process, especially in the Explore and Develop stages (based on the 
Double Diamond), encourages creative thinking and idea generation (Design Council, 
2015). According to Benkenstein’s (1998) innovation funnel model (Figure 7.5), the 
larger the mouth of the funnel, the more ideas are driven toward the R&D stage 
(Acklin, 2010). 
• Human-centric approach: Similar to creativity, several studies have highlighted the 
focus on human needs and on solving problems associated with those needs’ 
(Brown, & Katz, 2011; Giacomin, 2014; IDEO, 2015; Zhang & Dong, 2009). Design 
thinking focuses on the problem from three main perspectives: business, technology 
and human needs (IDEO, 2015). 
• Iterative process: The design thinking process is distinguished from many other 
approaches with the appreciation of iteration through prototyping and testing 
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(Ballard, 2000). The design process shares some of these characteristics with the 
lean process (Motwani, 2003). These characteristics contribute to building human-
centred products and services.  
 
Figure 7.5 Benkenstein’s innovation funnel model (Benkenstein, 1998). 
 
7.4 Voting in Design Process 
Voting is used by participants (i.e. design team) to determine the priority between a number 
of choices. Voting is utilised in a number of tools such as the affinity diagram, where 
participants vote for the priority of multiple elements or severity level of a number of 
problems such as software problems. (Alänge, 2009; Elmansy, 2016a).  Design sprinting is 
another method that utilises voting to select between a number of layout design options 
(Banfield, Lombardo, & Wax, 2015; Elmansy, 2016b). Design sprinting is an iterative lean 
practice (Knapp et al., 2016) that drives innovation through an experimental process, where 
participants create wireframes for the applications' UI. A voting session is then applied to 
collect an agreement on which is the wireframe that is selected and processed to create the 
final design (Magistretti, Dell'Era, & Doppio, 2020). Design sprinting is used to develop 
prototypes into products during action design research (Keijzer-Broers, & de Reuver, 2016) 
and design thinking (Magistretti, Dell'Era, & Doppio, 2020). 
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7.5 Design as a Driver for Innovation 
Cox (2005) defined the relationship between design and innovation. Cox indicated that 
design works as a process and catalyst to transform creative ideas into innovative products. 
This relationship works as an equation in which design describes the core process: 
 
Creative ideas —— Design ——> Innovative products 
 
Based on the above equation, design is the core tool (process) with which to achieve 
innovation regardless of the creative idea or the target market. Carpenter & Nakamoto 
(1990) defined design as an innovation that can add value, achieve profits and influence 
consumer preferences (de Mozota, 2003). 
 
Battistella et al. (2012) explored the theoretical relation between innovation management 
and design from the innovation management perspective, highlighting that innovation 
management no longer focuses on technology and innovation alone (Chandy & Tellis, 2000). 
Instead, value is driven by building human-centric products, services and experiences. This 
shift toward design-driven culture represents the new boundary of business innovation 
(Geels, 2004; McCracken, 1986; Verganti, 2008). It presents an approach which focuses on 
the subjective meanings people ascribe to the product (Krippendorff, 1989). Verganti (2008) 
highlighted that every product has a meaning that reflects why people need the product 
and what they need from the product.  
 
7.6 The Multi-Perspective Problem Framing 
(MPPF) 
Multi-Perspective Problem Framing (MPPF) is a theoretical approach introduced by English 
(2008) to address complex problems. It is based on De-Bono’s (1996) idea of breaking out of 
established ways of seeing in order to visualise new patterns that allow new design 
opportunities. The MPPF approach builds on radiant mind mapping techniques (Buzan, 
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1996) to create conceptual networks where new patterns and ideas can evolve. These 
patterns contribute to a new understanding of the problem, which leads to innovative 
solutions (Figure 7.3).  
 
Figure 7.6 Example of a radiant map from the WearCare II project (Source: team 2 final 
presentation). 
 
Radiant mind maps are utilised to build single perspective problem framing. Buzan (1996) 
introduced the radiant mind map as a diagram that includes a centre concept, such as an 
idea or a problem. Radiant mind maps start with a single centre of enquiry in the middle of 
the map and lead to single perspective problem framing. (Figure 7.4).   




Figure 7.4 Team 2’s integrated mind map from WearCare II project (Source: team 2 final 
presentation). 
 
7.6.1 Cornerstones and Utilisation of integrated mind 
maps 
Integrated mind maps simulate the brain’s ability to build connections. They have multiple 
centres of enquiry and branched ideas connect to develop complex patterns (Taylor, 2007). 
 
Integrated mind maps are used to frame value through the definition of Cornerstones of 
Innovation (English, 2007). This can be seen in Figure 7.5. 
 




Figure 7.5 The key cornerstones defined by the WearCare II project (Source: team 1 final 
presentation). 
 
Links that connect integrated mind maps help to define key cornerstones that can be used 
to identify potential value innovations. The cornerstones of innovation are used to frame 
design solution as highlighted in the value innovation case studies in Figure (7.6). 




Figure 7.6 Examples of the cornerstones of innovation and the application to a product 
(English, 2007, p.4). 
 
 
7.7 Innovation in Small and Medium 
Enterprises SMEs 
Two main reasons behind the decision to focus in this thesis on SMEs working in medical 
technology innovation are: 
1. SMEs make a key contribution to the world economy (Birch, 1989; Bommer and 
Jalajas, 2002; Lukács, 2005; Oke et al., 2007; Nauwelaerts et al., 2012). In the EU, 
SMEs represent 98% of the economy of member states combined. 93.2% (19.3 
million enterprises) are considered small companies with less than 10 people 
(Lukács, 2005). In the UK, SMEs contribute up to 50% of the national GDP, which 
motivates the UK government to support this sector and encourage its growth (Cox, 
2007; Oke et al., 2007).  
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2. SMEs are creative in nature. In these firms, creativity is transformed into innovation 
through design (Cox, 2007). As part of this, SMEs contribute to the economy because 
the technical nature of the companies supports innovation on both the 
organisational level and national level. This means that the jobs these companies 
create are related to innovative discoveries and ideas (Savlovschi and Robu, 2011). In 
addition, SMEs play an essential and unique role in inventing new technologies and 
improving existing ones (Almeida, 2004). Henderson (2002) highlighted that enter-
returners contribute to the economy on multiple levels, including creating new jobs, 
increasing local income and wealth and connecting communities with the larger 
global economy. In order to further understand the role of innovation in SMEs, both 
the benefits of and the barriers to innovation were examined. 
 
7.7.1 Benefits of Innovation in SMEs 
Several studies have shown the positive benefits of focusing on innovation in SMEs. These 
include administrative benefits, competitive advantages and increased profitability. A brief 
discussion of these benefits is presented below: 
• Profitability 
There exists a positive relationship between adopting innovation and achieving 
success in SMEs (Heunks, 1998). Studies have shown this correlation from the 
profitability perspective. Innovative companies have higher profitability, growth and 
market value than non-innovative companies (Cefis & Ciccarelli, 2005; Geroski et al., 
1993; Leiponen, 2000; Oksanen & Rilla, 2009). However, studies have highlighted 
that superior quality is essential for SMEs to maintain their success in the market 
(Cooper, 1990; Cooper and Brentani, 1991). Therefore, Cho and Pucik (2005) 
introduced the innovativeness-quality-performance model, which presented three 
factors that should be balanced in order to achieve profitability and growth (Cho, & 
Pucik, 2005). 
 
• Market competitiveness 
Cho and Pucik (2005) indicated that a firm’s ability to innovate and create high-
quality products can lead to it achieving high market value and sustained 
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competitiveness ability. In their report, Proter et al. (1999) showed that many CEOs 
agree that new ideas and innovation should be at the top of a company’s priorities if 
it is to achieve success in the market. Lawson and Samson (2001) indicated that 
putting innovation at the centre of organisational competitiveness can drive global 
competition and technological advancement. 
 
• SMEs and economic growth 
As highlighted earlier, SMEs play an essential role in economic growth. A large 
percentage of SMEs focus on innovative products, and this results in market 
competitiveness and contributes to economic growth. Additionally, SMEs face 
continuous pressures, such as competition from large companies and rapid 
technological change. As a result of these pressures, SMEs focus on improving their 
innovative capabilities (McAdam et al., 2004) and adopting strategic approaches and 
effective innovation management skills. These pressures and the competitive 
environment led to economic growth.  
 
7.7.2 Innovation Barriers in SMEs 
As highlighted above, SMEs can escape the market challenges especially the high 
competency through innovating (i.e. new products, services, or business models). However, 
Barriers cannot be ignored as it can stand the company and its goals. In, Figure 7.8, 
organisational barriers can be categorised into two types: internal and external barriers. 
Some barriers such as the financial barriers and unpredictable success are affected by both 
internal and external factors. 
  



















Figure 7.8 Internal vs external barriers (Larsen and Lewis, 2007; Nauwelaerts et al., 2012). 
 
• Financial barriers 
Financial barriers are among the top reasons behind SME failure and inability to achieve 
innovation (Larsen and Lewis, 2007; Madrid-Guijarro et al., 2009; Nauwelaerts et al., 
2012). This is because financial barriers are complex and include elements such as short-
term liquidity problems, insufficient working capital, insufficient funding, under 
capitalisation and poor financial management.  
 
• Marketing barriers 
Marketing skills are essential if innovative products are to be successful on the market 
(Foley and Green, 1995). Freel (2000) listed a number of factors that affect an 
organisation’s marketing: poor planning, lack of expertise, insufficient marketing 
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• Management barriers 
Larsen and Lewis (2007) highlighted some factors related to poor management, 
including management experience, skills, determination to carry out innovation plans 
and the ability to judge situations and make decisions. 
 
• Organisational Culture Barriers 
Changing a company’s culture to a design-driven one can stand as a barrier to adopting 
design thinking in the company’s process. Trompenaars & Pru'hommer van Reine (2004) 
call this phenomenon an ‘organisational culture dilemma’. In this state, there is tension 
between the design thinking innovation drive and the organisational drive. Table 7.1 
visualises the relationship between organisational culture dilemmas (Trompenaars & 
Prud'homme van Reine, 2004) on the top row and the expected tension in design 
thinking for innovation (Prud'homme van Reine, 2015; Prud'homme van Reine & 
Dankbaar, 2009) on the bottom row. The organisation culture dilemma here is specific 
vs diffuse culture.  














































































































Table 7.1 The organisational culture dilemmas. Modified from (Prud'homme van Reine, 2
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7.8 Evidence-Based Design 
Evidence-based design is a relatively recent trend, as it has developed in the last 25 years 
and is inspired by the evidence-based approach to decision making adopted in healthcare 
system (Ulrich et al., 2011). The term ‘evidence-based’ refers to the use of research 
evidence to both inform and validate design decisions. Sackett et al. (1996) defined 
evidence-based design as ‘the conscientious, explicit, and judicious use of current best 
evidence in making decisions’ (p.71). Evidence-based design is a growing trend in the 
healthcare system, especially in the field of space design and hospitals design (McCullough, 
2010). As this trend is relatively new, it has recently evolved to include consideration of 
design elements such as environment, visual design, safety and sustainability. 
 
Various methods have been introduced with which to measure the evidence in the 
evidence-based design. These include the Oxford Evidence-Based Medicine Levels method 
and the American Institute of Architects Guidelines for Healthcare Design method. While 
the former method is concerned with medicine interventions, the latter focuses on 
architecture and space design.  The general factors that affect patient adherence from the 
Healthcare Design Center suggests a level-based measurement system. These 
measurements aim to evaluate the credibility of the research evidence used to guide the 
design process. Table 7.2 shows the Health Environments Research & Design Journal (HERD) 
model, which consists of six levels which classify the rigorousness of the research conducted 
to dictate the design process (Stichler, 2010).  
  




  Level 1 Systematic reviews of multiple randomized controlled trials (RCTs) or 
nonrandomized studies; meta-analysis analysis of multiple 
experimental or quasi-experimental studies; meta- synthesis of 




Level 2 Well-designed experimental (randomized) and quasi-experimental 
(nonrandomized) studies with consistent results compared to other, 
similar studies. 
 Level 3 Descriptive correlational studies, qualitative studies, integrative or 
systematic reviews of correlational or qualitative studies, or RCT or 
quasi-experimental studies with inconsistent results compared to 
other, similar studies. 





Level 5 Opinions of recognized experts multiple case studies. 
 Level 6 Recommendations from manufacturers or consultants who may have a 
financial interest or bias. 
Table 7.2 The HERD Evidence Based Levels (Stichler, 2010). 
 
7.9 Summary and Findings 
This chapter provided an overview of the literature studies linked to the research scope, 
including the decision to focus on design thinking as a process which can add value to the 
design of self-administered treatment technology. Furthermore, the focus on SMEs was 
discussed as part of a focus on the size of the companies working in developing treatment 
technology. The characteristics of design thinking were discussed and how these 
characteristics provide benefits to the organisation. These benefits include creative problem 
solving as the driving force behind creativity as the company explores the problem from 
different perspectives. This approach helps drive innovation in the company culture, as 
highlighted by various literature studies. Another benefit of the process is the focus on 
human needs when considering the business viability and technological feasibility. In 
addition to the above benefits, several barriers which can hinder the benefits of the design 
process were identified. These barriers are either internal or external. Internal barriers 
include lack of skills, management structure and cultural barriers. External barriers include 
financial barriers and the unpredictability of success. These external factors can affect 
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internal linkages. For example, the unpredictability of success can hinder a company’s 
expansion if the internal team is not ready for the expansion or lack the experience to 
manage the company on a larger scale. Prud’homme van Reine (2017) introduced 
organisational culture dilemmas, which map onto the current organisational culture and 
how it hinders change opportunities.  The organisation’s cultural dilemmas reveal the 
internal culture as another possible barrier to the company’s intention to change. 
 
The above findings highlight several challenges that face the companies seeking to exploit 
the benefits of the design thinking process. This complex process happens to the company 
from the exploration stage to the final delivery. In relation to the adherence, the 
consideration of adherence factors is a complex and challenging practice because several 
factors affect patient adherence to the treatment regimen. As a result of this complexity, 
the consideration of adherence factors may change over the course of designing and 
developing the medical treatment. A mechanism is needed to ensure the consideration of 
the factors that affect patient adherence to the treatment regimen. 
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This chapter explores medical technology innovation in the UK healthcare system. Over the 
course of this exploration, the following questions reformed the objectives of this chapter 
and the main research questions: 
• What is the current state of innovation and medical technology? 
• What are the hinders and opportunities for innovation in medical technology? 
• What is the role of medical technology in driving patient empowerment? 
 
8.1 Medical Technology Innovation: 
Opportunity and Benefits 
Since the inception of the NHS in 1948 until today, it faces continuous challenges, not only 
because of the lethal diseases such as tuberculosis, diphtheria, and currently the COVID-19, 
but also the chronic diseases such as dementia, cancer, diabetes, and cardiovascular 
diseases. These events triggered the question how the healthcare system can be changed to 
address future challenges (Shapiro, 2010). While medical technology innovation can provide 
an opportunity for such a change (Wamble et al., 2019), the NHS is taking insufficient 
(Mayor, 2005) and slow (Kyratsis, Ahmad, & Holmes, 2010) steps toward the adoption of 
medical technology. 
 
Medical technology innovation is widely implementing in a large spectrum of healthcare 
sectors including but not limited to treatment, monitor, diagnosis, procedures, and drug 
prescriptions. Innovative technology has contributed to increasing the life expectancy and 
QALYs. Various studies have highlighted the positive impact of investing in medical 
innovation in increasing the health outcomes and Return of Investment (ROI) (Wamble et 
al., 2019). The benefits of adopting the medical technology vary based on the technology, its 
implementation, and administration. For example, telehealth is a technology which enable 
patients to meet virtually either through phone calls or video calls with their GP or 
physician. The technology has different advantages including (Eaton, 2019): 
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• Provides access to consultation for patients in rural areas or have medical conditions 
that prevent them from visiting the GP or admit to a hospital 
• More flexibility in time of appointment which reduces patients’ waiting time 
• Reduces the missing appointment problem as clinicians contact patients 
 
Edwards et al. (2014) conducted a survey to evaluate the telehealth intervention with 
patients with chronic diseases. The results have shown general interest in the telehealth 
service amongst the research sample regardless their age, chronic health condition, and 
access difficulties. During the widespread of the COVID-19, remote consultations (such as 
phone and video appointments) have presented an opportunity for patients to get 
consultation and reduce the risk of visiting the clinicians.  Greenhalgh et al. (2020) 
highlighted that the result of a randomised trials has shown high level of satisfaction among 
patients and clinicians regardless the disease progression and difference of the service. 
 
Another example is the self-administered app-based psychological interventions. Leigh and 
Flatt (2015) indicated that there is an increasing demand for the psychological 
appointments and services which is faced with decreased in resources, funding, and 
clinicians. 1 in 10 patients has experienced a wait of over a year, and 1 in 2 has a wait of 
over 3 months. 1 in 6 from the waiting list are expected to attempt suicide, and 4 in 10 
patients are expected to self-harm. Self-administered psychological app therapy can provide 
an opportunity for patients to access treatment programs by simply download the mobile 
app. However, patient adherence and engagement to the treatment is a key to achieve 
successful outcome. 
 
Grist, Porter, and Stallard (2017) highlighted that there is a lack of research evidence to 
support the effectiveness of the mental health apps for children considering its safety, 
efficacy, and effectiveness. 
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8.1.1 Unmet Needs 
Medical technology innovation contributes to addressing the so-called ‘unmet needs’, which 
is core strategy of Devices for Dignity’s (D4D) technology development process. D4D is part 
of the Health Technology Cooperative (HTC) that aims to ‘to deliver innovative medical 
devices to support patients with long term conditions, which preserve their dignity and 
independence” (Robertson et al., p.72). The clinical unmet needs refer to the lack of specific 
human functionality or aspects that require technological assistance. These needs aim to 
serve the roles below (McCarthy et al., 2015): 
• Unmet needs are a driver of innovation as companies find it an opportunity to address 
an unmet patients’ needs 
• The solution can start by identifying the problem in an existing technology 
• It focuses on potential technology ideas that can present a future solution 
• The unmet needs vary from being focused on one-person health issue or a need of large 
group of people 
 
The role of D4D in driving medical technology has been highlighted in this study during the 
interview with one of the case studies (ESA) covered in the Chapter 9: Case Studies 
Interviews. Figure 8.1 shows the D4D PDP. 
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Figure 8.1 D4D generic device development approach. Source (Robertson, Hawley, & Herons, 
2010) 
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The D4D Generic Device Development Approach is a practical example of the application of 
user-centred design in medical technology innovation in a number of specialised areas 
(renal technology, urinary continence management, paediatrics and assistive and 
rehabilitation technology). The focus on patient needs is part of the identification of unmet 
needs, which is the first step in the development process (Moody, 2015). 
As part of the focus on patients’ unmet needs, the process highlights the presence of the 
consideration of patients in four out of six stages of the process: Articulate/Identify Needs, 
Prioritise, Prototype and Evaluate (Heron, Tindale, & Hawley, 2010).  
 
8.1.2 Unmet vs Unrealised Needs 
The unmet needs model provides an opportunity for companies to establish their position in 
the market by addressing patients’ unmet problems on the one hand and by integrating 
with the healthcare system which is expected to provide support in terms of funding, 
experience, and partnership opportunities on the other. The opportunities that the model 
present is the unrealised needs. Unlike unmet needs, unrealised needs are solutions (or 
improvement) of situations that clinicians and patients don’t release it as a problem 
(McCarthy et al., 2015). They tend to see the problem only when they experience the 
solution of the current situation. While the unmet needs are obvious and required by 
patients and clinicians (pull), the unrealised solutions as not and usually pushed (or 
presented) to patients and clinicians through new technologies (push) as see in figure 8.2..  
An example for the unrealised needs is the self-administered chemotherapy pump (infusion 
pump). While there was a general acceptance for the clinician-controlled hospitalised 
chemotherapy sessions, the patient-administered pumps let patients get chemotherapy at 









Driven (Push)   
Figure 8.2 The unmet and unrealised needs. Source (McCarthy et al., 2015) 
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8.2 Barriers of Innovation in Healthcare 
The NHS is blamed for insufficient (Mayor, 2005) and slow (Kyratsis, Ahmad, & Holmes, 
2010) adoption of medical technology. A criticism that has backed by the House of 
Commons Health Committee. The British Healthcare system spends only 0.36 per cent of its 
GDP on medical technology, while the average of the European average is 0.55%. 
Furthermore, NHS trusts (around time 700 trusts) have inconsistent policies and practices in 
relation to the development of medical technologies (Mayor, 2005).  
 
Another barrier is the complex national policies either domestically or internationally. These 
complex regulations stand as a barrier for SMEs working in designing and developing 
medical technologies especially new companies who have no prior experience with the NHS 
regulatory process. The World Health Organisation (2003) advised to harmonise the 
regulation systems in order to reduce the cost and complexity for the companies working in 
medical technology development (Faulkner, 2008). For example, Grist, Porter, and Stallard 
(2017) highlighted that there is a lack of research evidence to support the effectiveness of 
the mental health apps for children considering its safety, efficacy, and effectiveness. 
 
Asthana, Jones, and Sheaff (2019) ran a study that examine the macro, Meso, and micro 
factors that affect eHealth innovation the NHS. The study concluded that barriers exists at 
all scales, yet at the top of the factors is the fragmentation of the healthcare system, which 
plays a significant factor in limiting the adoption and diffusion of the technology. 
 
Castle-Clarke, Edwards, & Buckingham (2017) highlighted a number of structural factors 
that obstruct the NHS making the most of the new innovations. These factors include the 
structure of the system which is based on a supply-driven and top-down approach to 
innovation. The model needs to be shifted toward co-production where clinicians and 
industry work together to find solutions. Other factors are related to the strategic planning 
of organisations such as the focus on the short funding rounds rather than the innovation 
impact.  
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Herzlinger (2006) introduced three types of innovations that are convenient to the 
healthcare system and target to improve it and make it cheaper: 
• Consumer Focused: The aim of this innovation model is to focus on addressing 
patients’ needs by creating effective, convenient, and cost-effective interventions. 
• Technology: This type of innovation focuses on the offering such as new treatment 
technology, drug system, and monitoring. 
• Business Model: The business model can involve patient or focus on the healthcare 
system such as supporting SMEs in developing medical technology, supporting 
telehealth systems, and helping SMEs to access evaluation mechanisms such as 
clinical trials. 
 
While the above types of innovation focused on the United States (US) healthcare systems, 
it provides generic types that can actually implemented in other systems such as the NHS. 
Additionally, he highlighted six factors (forces) that can improve or kill the innovation in the 
healthcare system. These factors include (Herzlinger, 2006): 
• Players – The stakeholders inside the healthcare system (e.g. patients, nurses, 
clinicians, managers, and decisionmakers) 
• Funding – The funding that can facilitate the innovation process or kill it as one of 
the big hinders 
• Policy – The current regulations and legislations required from companies to push 
their innovative technology to the medical use  
• Technology – The required technology to utilise the innovative solutions such as 
patients’ access to smart phones and suitable Internet connection 
• Customers – The level patient empowerment and concordance between patients 
and clinicians 
• Accountability – The cost-effective, safety, and effectiveness of the innovative 
product comparing with the other competitors in the market. 
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8.3 Medical Technology as a Driver of Patient 
Empowerment 
Medical technology plays an essential role in patient empowerment as it provides patients 
the opportunity to take part or self-administer the treatment intervention and educate 
patients about their condition and how to take control of their lives. The type of the 
technology intervention reflects how the intervention is empowering patients. For example, 
BabyCareLink is an online collaborative secured platform that supports infant families 
especially who are living in rural areas. Safran (2003) highlighted that 300 parents have used 
the platform more than 11,000 times in a period of 1 year. 85% of the platform visitors 
accessed it form home, work, library, or public places (Gray, et al., 1998). 
 
Ziefle, and Schaar (2014) indicated that the usage of technology can help older patients to 
be independent through self-administered technology. However, the research highlighted 
that human factors need to be considered in order to build a successful technology design. 
The intervention technology should consider a multidisciplinary implementation in order to 
consider the different aspects of the intervention. Additionally, solutions should consider 
the special needs of patients and provide tailored solution to fit with their needs. From a 
holistic perspective so the technology should be patient-centred an inclusive. 
 
8.4 Summary and Findings 
Medical technology innovation presents an opportunity for the healthcare system to 
overcome many of its current challenges not only in treatment but also other healthcare 
systems. From the patient’s aspect, medical technology can help patients to access to 
services much easier and faster such as the telehealth used in GP appointments. 
Additionally, it can help patients to self-administer their treatments. Medical technology can 
provide cost-effective solutions that help patients to avoid surgical interventions. 
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Innovation in medical technology should address both unmet and unrealised needs. While 
the unmet needs are already known by patients and the design process focuses on these 
needs, the unrealised needs cannot be seen as a problem until the design process 
investigate the problem space and provide a solution. The abductive nature of design 
thinking (7.1 The Nature of Design Thinking) can provide an opportunity to address both 
unmet and unrealised needs (Dorst, 2010). 
 
Having that said, the medical technology innovation faces challenges and barriers that 
standing against it and achieving innovation. Herzlinger (2006) introduced six factors that 
can drive the medical technology innovation or kill it. These factors are players, funding, 
policy, technology, customer, and accountability. 
 
A further benefit for the medical technology, especially the self-administered interventions 
is the patient empowerment, as it provides the opportunity for patients to take part in the 
treatment or diagnosis practice. Further discussion about the patient empowerment is 
covered in Chapter 6: Theoretical Frameworks of Adherence. 

















Chapter 9: Case Studies Interviews  
 
This chapter reviews the second step in the 
Investigate phase (Case Studies). In this 
step five SMEs were interviewed to explore 
the design process and how adherence is 
considered at this stage of the design 
process. This step involves a triangulation 
of the desk research data. 
Key Topics: 
9.1 SMEs Characteristics  
9.2 Employees’ Experience 
9.3 Integration with the Healthcare System 
9.4 Design Thinking Process 
9.5 Barriers of Product Design and 
Innovation 
9.6 Treatment Adherence 
9.7 Patient Communication and Adherence 
9.8 Findings and Summary 
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The second step in the Investigate stage involves interviews with five SMEs working in 
developing treatment devices to build a clear understanding of the design process 
implemented in the case studies to develop self-administered treatment (or treatment 
support) technologies and how adherence is considered during this process. Semi-
structured interviews were conducted with the case studies. The interviews included pre-
prepared questions that were altered, skipped, or expanded based on the discussion and 
information shared by the interviewees (Gubrium, and Holstein, 2012). The questions in the 
interview can be mapped to the main research questions, as highlighted in Chapter 2: 
Methodology Introduction. Part of the aim of these interviews to understand the design 
process used on developing treatment devices and how adherence factors are considered 
during the development of the treatment or during patient’s usage. A detailed description 
of the research methodology is covered in Chapter 3: Case Studies Methodology. 
 
This chapter provides an overview of all the five interviews based on the topics related to 
the research aims. Full details of answers for each case can be found in the transcript listed 
in Appendix 9.1.  Sections in this chapter focus on the themes across the interview data, 
map interview answers to the main research questions, and summarise how the main 
findings here will support later research stages (explore and assess). An italic font will mark 
the factors that have an impact on adherence. All the interviews were conducted with the 
companies’ representatives who are usually the founders of the business. One interview 
with YMX company included two of the team members, one with an speciality in the 
technology and the other with speciality in the business side. When talking about YMX 
answers, they will be referred as interviewee 1 and interviewee 2. 
 
The next section summarises the SMEs' characteristics. After that, sections focus on the key 
findings will be triangulation with insights from the literature (Chapters 6 to 8) to plan the 
remaining stages: Explore (WearCare project observation) and Assess (Delphi Method).  
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9.1 SMEs Characteristics  
This group of questions aims to identify the status of the companies based on their size, 
integration with the healthcare system, and information about the product. This group 
includes the following questions: 
• Tell me more about your company: date of establishment, size, number of 
employees, branches, and capital. 
• How is your company integrated with the healthcare system in the U.K.? 
• Explain to me your product and its current state. And how patients self-administer 
the treatment? 
Five companies participated in this research. Due to the anonymisation procedure, the 
names of the companies were removed and replaced with a coded name. More information 
about the anonymity of the case studies can be found in Chapter 3: Case Study 




The company is a SME run by one person who is the founder. The company was established 
in 2015 with a capital of £35,000. Company size varied from one to three members during 
the four years. Currently, there is only one member who is the founder of the company. The 
company funding was based on loans (£25,000) and other funding sources (£10,000). Most 
of the funding was spent on evaluation research and building multiple prototypes of the 
product.   
 
The company faced several barriers which affected the progress in the product 
development. These barriers include lack of funding, experience, and team dedication. The 
product is wearable that provides a sensory experience for patients who have long-term 
treatment goals. It helps them to break their big goals to small achievable ones with little 
reward once any of the goals are. The wearable product is very generic as it can be used 
with any disease especially the chronic ones, to motivate patients to adhere to long term 
treatment such as weight loss. 





The company established in 2018 and currently it has four employees in the USA and UK. 
The main product is a device to support sleeping quality. It is used to avoid pharmaceutical 
drugs while patients are sleeping. The treatment device sends electromagnetic signals that 
can improve the sleep quality. The technology that can help patients and people who are in 
a risk of Alzheimer’s or insomnia. The product is in the prototyping and testing stage, and it 
is part of research in a USA-based university. 
 
LW7 
The company was established in January 2017 as a pre-revenue medical technology start-
up. The founder is the only full-time employee. However, there are 18 sub-contracts and an 
advisory team working with the company. The capital is £196,000 raised by charitable 
sources. 
•  
“the difference between us and a limited company is we have an 
asset lock and the mission lock, which dictates how we may use our 
profits” LW7 Interviewee 
 
The description of the company puts it on the micro or small company. The company’s 
status as a community interest reflected on the funding channels and opportunities. The 
differences between this company type and limited liability companies include assets lock 
and mission lock, which dictates how the company uses the profit. 
•  
The product is a device that integrate with cystic fibrosis physiotherapy to encourage 
children to follow their physiotherapy intervention. The product aims to improve young 
patients’ adherence to self-administered therapy and help parents to ensure that they do 
the therapy correctly. The device is connected to a mobile game that rewards children when 
doing daily therapy. 
 




The company was established in 2009 (around 11 years old). The current number of 
employees is 9 and starting capital is £500,000. The number of employees has changed over 
the years based on the company status. The company provides a non-invasive treatment 
device for Diabetic Retinopathy (DR) and Diabetic Macular Oedema (DME). The treatment 
device replaces or reduce dependency on painful surgical intervention. However, adherence 
to a minimum usage time over the treatment regimen is required. While the company’s 
product is self-administered, current surgical intervention is clinically administered and 
requires admission to the hospital.  
 
The treatment is a wearable device that is fully administrated by the patients themselves. In 
some cases, such as first-time use, the product can be partially be administered so clinicians 
can follow-up the usage of the device, replacing it, or transferring the data from the device 
into the clinician computer to analyse it. 
 
The product can be considered patient-centric as it uses technology to address the patient 
problem, which is reducing or eliminating the need for invasive intervention. A second 
benefit is reducing the times that the patient needs to be in hospital. The third benefit is 
reducing the cost of traditional treatments and saves patients the burden of many 
unnecessary hospital visits. 
 
The treatment device has an educational aspect. It requires behaviour change as patients 
need to wear it for a long-term regimen. Table 3.1 in Chapter 3: Case Studies Methodology 
shows that behaviour change is a common feature between all the SMEs. Patient education 
affects adherence based on two perspectives: 
• Literature studies highlighted the importance of patient education such as the Social 
Learning and Health Belief Model theories. These theories highlight factors that can 
affect patient adherence such as expectancies and incentives in Social Learning 
theory, and perceived susceptibility, barriers, benefits, and severity (Bosworth, 
Weinberger, & Oddone, 2005).  
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• The other perspective is patient empowerment. Educating patients take them from 
the position of obeyers to an active partner in the decision-making process (Powers, 
& Bendall, 2003; Funnell, & Anderson, 2003; McAllister et al., 2012). 
 
As a result, the type of patient education, and the quality of the shared information plays an 
essential role in influencing patient adherence to the treatment regimen. 
 
ESA 
The company was established in 2015, the company includes two directors (founders) and a 
secretary. Until the time of the interview, the funds invested in the company was over 
£700,000. The company portfolio includes a number of tailored products for patients who 
require external catheter line such as young patients with renal and peritoneal dialysis. The 
product main aim is to fasten the catheter line to the patient’s body to avoid movement, 
which can lead to bleeding or infection. As a result, patients can live their normal life. So, 
patients, especially young patients, can play, exercise, and do other daily activates that 
require body movements without worrying about the catheter attached to their bodies to 
move or disattached. 
 
9.1.1 Contrasting the SMEs 
Companies vary in terms of their size, structure, funding, management, location, and 
integration with the healthcare system. The characteristics of four companies are those of 
micro- or small-size enterprises (ESA, LW7, 3AB, and DE7). While in the UK definition these 
companies can be considered a small company, other definitions put it in the micro-size 
category.  This variation in definition will not affect the interviews nor the analysis of the 
data. 
 
 One company (YMX) falls in the small- or medium-sized enterprise, yet its employees and 
capital changed over time, which makes its nature swing between both small and medium 
nature due to the change in the number of employees and turnover. 
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All companies are registered in the U.K. Companies House. DE7 was registered in the U.S. 
before moving and getting registered in the U.K. as highlighted by the company founder. In 
terms of the establishment date, the establishment date for all companies ranges between 
2009 and 2018. The oldest is YMX, and the newest is DE7 (table 9.1). 
 
Company name Establishment date Type 
3AB 2015 Limited liability 
DE7 2018 Limited liability 
LW7 2017 Pre-revenue charity 
YMX 2009 Limited liability 
ESA 2015 Limited liability 
Table 9.1 Companies establishment date and type 
 
Companies' ages do not necessarily relate to the maturity of their products because the 
developing rate of the product varies from one company to another. Product maturity 
varies based on different factors, including availability and funding. 
 
9.2 Employees’ Experience 
The above overview shows that companies share similar characteristics. Some of these 
characteristics may have an impact on the design process and adherence such as 
experience. Therefore, companies who already have background experience in patients’ 
needs and behaviour are more likely to target adherence factors during the design process. 
This was observed in the interviews with case studies such as LW7 and ESA, which will be 
covered in this chapter. Observing the interviewees’ background and the general 
information about the company highlights a possible corelation between the founder 
background and target product. For example, LW7’s founder had a background in software 
and game development, which inspired the company solution that uses gamification to 
improve children adherence for daily therapy. This influence was observed during the 
conversation, especially related to the inspiration behind the device. In another interview, 
ESA's co-founder had no design background. However, his experience journey through the 
 Chapter 9: Case Studies Interviews  
 
 164 
AHSN innovation pathway (Figure 9.1) required to get funding and access the NHS trusts 
helped him to build a good understanding of patients’ needs and product characteristics 
(catheter support wearable device) to tailor the wearable product based on the patient's 
case, for example, the location of the catheter. In YMX, the consideration of adherence was 
driven by testing and clinical trials about patients' feedback about product usage. The AHSN 
pathway aims to guide companies through the steps needed to get their products adopted 
by the NHS trusts, and it has a human-centric aspect which focuses on patients’ needs 
during the pathway steps. For example, evaluation steps allow SMEs to test their products 
with patients through clinical trials or the patient advisory group, as discussed later in the 
ESA case study interview. 
 
Figure 9.1 AHSN Innovation Pathway guide for SMEs (Source: Eastern AHSN 




There is no fixed answer to the question of why some companies consider adherence better 
than others. Varied factors are involved in considering adherence before and during the 
development process. Based on the adherence factors discussed in the theoretical 
frameworks, one thing in common between companies, there is either a lack of 
consideration or partial consideration of adherence factors. 
 
In terms of the products offered by companies, SMEs can have one or more products. In 
order to maintain the scope of this research and ensure clarity of the collected data. The 
scope of the study is self-administered patient-centric treatment and treatment support 
technology. The characteristics of each product are shown in Table 3.1 highlighted earlier in 
Chapter 3: Case Studies Methodology.  
 
9.3 Integration with the Healthcare System 
The integration with the healthcare system provides an opportunity for companies to build 
a partnership with hospitals and navigate the regulations and legislation that can help 
companies to sell their products nationally. Additionally, it can help companies to receive 
funding, experience, and access to patients’ evaluation and testing (e.g. patient advisory 
groups and clinical trials). The level of involvement is also associated with the type of 
product and the level of communication between the company and different healthcare 
organisations.  
 
From the perspective of adherence, the integration with healthcare system helps companies 
to clearly understand their patients’ needs, test the treatment device on patients, and get 
feedback to improve the product. Hence, the experience gained from this integration with 
healthcare system can help companies to consider factors that improve patients’ 
adherence, especially for chronic diseases. In the same time, funding, experience, and type 
of the product may stand as barriers for companies to test and evaluate the impact of their 
products. YMX highlighted two factors related to the integration with the healthcare 
system: 
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• Expanding the collaboration between companies and the healthcare system to 
involve consultation and mentorship can help companies to consider the different 
factors in the treatment device design process including patient adherence to the 
regimen 
• Lack of access to patient data impedes companies' ability to build a strategy to 
improve patients’ adherence 
• SMEs working in medical products face a complex range of legislation, as they 
register their products in different countries. Complex legislation can vary from one 
country to another, which may be a barrier for companies to expand their offering to 
other countries.  
 
The above challenges that face companies in order to design health device by considering 
the adherence can be categorised as clinical-side factors. These factors are not related to 
patient-device communication. It is the communication between the company and the 
healthcare system. Other adherence factors can be related or affected by the relation 
between the treatment and healthcare system include:  
• Patient information 
• Patient-centred shared knowledge 
• Effective communication 
• Understanding of patient behaviour 
 
In terms of the integration with the healthcare system, three main stakeholders can be 
identified: the healthcare system, SMEs, and patients as shown in figure 9.1. The 
interviewees described their relations with the healthcare system, which should include the 
relation between patients and the healthcare system and how this impact adherence to the 
treatment.  




Figure 9.1 The relation between the Healthcare system, SMEs, and patients. 
 
Figure 9.2 shows SMEs’ activities and maturity from the perspective of integration with the 
healthcare system and direct market sales. Each circle represents a company. Each circle is 
divided into top and bottom halves. The top half reflects NHS integration, and the bottom 
one refers to direct market sales. The maturity levels are divided into four levels: 
• No integration: the company does not have any integration with the healthcare 
system or has any activities to sell the device in the market 
• Early stage (research): The company is on the early stage of the collaboration with 
the healthcare system or the market access 
• Partial integration: The company is integrating with the healthcare system. In the 
market, companies can sell their products with a specific arrangement such as 
limited sales units. 
• Full integration (market sale): The company's product is fully sold and implemented 
in national hospitals. In terms of the market, the product is sold on shelves without 
limitations. 





Figure 9.2 Visualisation for the companies’ maturity based on its integration with the 
healthcare system 
 
The above figure presents an interesting status for 3AB company. The company started 
earlier than other start-ups such as ESA. As the founder highlighted, the development of the 
treatment device moved slower than other companies because of financial, experience, and 
team commitment barriers. Because of the lack of funding, previous company founders and 
stakeholders could not maintain their duty toward the company, which affects its progress 
in the device development. Financial barriers are shared between the company and other 
SMEs, regardless of their industry. In response to these barriers, founders may be able to 
sustain for a limits time because hinders increase and lead to other problems. As the 
financial limitation stands on the top of the SMEs barriers, this affects their ability to do any 
evaluation or testing their product (e.g. clinical trials, evaluation studies, or patient advisory 
group). 
 
While YMX is the oldest case study company, there is not significant development of the 
relationship between them and the NHS. Interviewee one indicated that there is no formal 
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integration with the healthcare system in the UK (NHS). While the NHS was enthusiastic 
about the company's solution, the collaboration was limited in the form of financial funding 
and a grant. These funds were granted to the company through NHS research and funding 
bodies such as the ‘National Institute of Health Research’ (NIHR). This answer may highlight 
one of the barriers that face SMEs, which is the lack of support in terms of skills and 
experience. While financial support presents one of the barriers that faces SMEs, other 
barriers need to be considered, such as marketing experience and management experience 
(Larsen and Lewis, 2007). Based on this, providing only funding for SMEs may not be a 
sufficient support scheme. 
 
“So in the past we work with patients through less or less the NHS because there's an 
issue there that they see themselves very much of holding patient medical records.” 
YMX interviewee 
 
Interviewee one indicated that there was work done with patients. However, it faced 
difficulties due to the obstacles related to accessing medical records for patients. The 
arrangements related to clinical trials held inside NHS hospitals involved the Clinical 
Research Network (CRN), which was responsible for the usage of NHS facilities for clinical 
trials and the company paid for this utilisation. Another group involved in collaboration with 
the company is the Academy of AHSN.  
 
The description of the relation between the company and the NHS is limited to funding and 
usage of facilities. The limited ability to access patients’ data presents a barrier for 
companies to understand patient adherence and consider it. A broad collaboration between 
SMEs and the NHS may contribute to building effective health and medical technologies. 
 
ESA is having good collaboration and integration with the healthcare system. The company 
follows the AHSN innovation process, which demonstrated success. The company has 
another partnership with the NIHR. These connections help the company to access the NHS 
trust hospitals and Young Patients Advisory Groups (YPAG), which allows the company to 
get feedback, address individual patient cases, and understand the patients’ needs related 
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to their attached catheter line. Another company who is having an integration with the NHS 
is LW7. 
 
Because the founder has a family condition that inspired him with the solution device, he 
built a good connection with the NHS trust for this particular disease (cystic fibrosis). So, 
although the company is small and relatively new, it could build a good relationship with the 
NHS trust and other healthcare bodies. Probably this is the reason behind their ability to go 
through clinical trials early. The interviewee highlighted that a second clinical trial is 
underway. The first clinical trial was over 24 weeks period, then it was extended to another 
24 weeks. The initial feedback from the sample was positive in terms usage of the solution.  
9.4 Design Thinking Process 
Most of the companies are on at early stage of development. The development of the 
product presents an early prototype (e.g. 3AB and DE7), while others have a more 
developed product status (e.g. ESA, and LW7, and YMX).  
 
9.4.1 Idea Inspiration 
One of the characteristics that mark out a creative design process is the developing of ideas 
and how the early process of problem framing is conducted to diverge different ideas that 
may evolve to become the product idea.  
 
“the starting point is what the health care industry called the unmet needs. 
The unmet need really identifies that there is a problem. And it is noticing or 
seeing identifying that patients that are fitted with lines wherever they are in 
their body, there are no robust, clinically approved, regulatory approved 
products to meet that unmet need. “ ESA interviewee 
 
Table 9.2 highlights the source of the product idea or how the product idea developed from 
each company. Some interviewees were able to describe the inspiration process better than 
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others similar to how Cross (2005) described that some designers are more able to describe 
the final idea rather than the cognitive process of how they reached it. 
 
Company Source of idea (inspirational source) 
3AB Student project on quit cessation 
DE7 Professional experience + education + previous product 
LW7 Personal family case + professional experience + education 
YMX 
Previous published research + apply Multi-Perspective Problem Framing 
(MPPF) 
ESA The unmet needs in healthcare 
Table 9.2 The inspirational source behind the treatment (or treatment support) of each 
company 
 
9.4.2 Design Thinking Characteristics 
While some companies did not follow a design thinking process such as the Double Diamond 
(Design Council, 2015), the core value of the process lays in the characteristics that add 
value for the design of the product. Table 9.3 shows the design characteristics that emerged 
during the content analysis by each case study. Also, the last column shows the reference to 
the literature studies. 
Design characteristic SMEs applying it Reference to literature 
 3AB DE7 LW7 YMX ESA 
 
Focus on patients’ needs      (Cross, 1994; Brown, 2011) 
Inclusive1       
Iterative and prototyping2      (Brown, 2011) 
Problem solving      (Cross, 1994; Brown, 2011; Dorst, 2012) 
Creative and inspiration3      (Buchanan, 2001; De Mozota, 2003;  
      Mozota, 2003 Dorst, 2012) 
Table 9.3 Design thinking characteristics, the companies applying it, and the literature 
highlighted each factor 
 
1 The inclusive factor involves a co-creation and working with different parties (e.g. 
patients, clinicians, and carers) to reach a testable product. While all the companies got the 
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chance to conduct an evaluation practice (e.g. clinical trials, evaluation study), this practice 
involves evaluating the medical product effectiveness rather than its commercialisation. 
2 Iteration and prototyping refer to building various prototypes for the product test and 
share it to get feedback and subsequently improve the future version. While all the 
companies created different prototypes of its products, few were able to make an 
advantage of the co-create practice. For example, ESA meet with patients, carers, and 
clinicians to share ideas about the medical device, then the professional stakeholder meets 
to review and provide feedback on each prototype especially when the patient requires a 
tailored solution. 
3 The creative and inspiration characteristics, in the table above, refers to the how the idea 
of the treatment device is inspired or originated. It doesn’t consider the product design 
characteristics, which will be overview later in this chapter. 
 
9.4.3 Product Development 
During the conversation with companies' representatives such as 3AB and DE7, new 
companies are more able to address feedback than established firms, including shifting the 
product scope to a different type of patients (e.g. focusing on Alzheimer patients in DE7, 
and expanding beyond weight loss in 3AB). For example, 3AB expanded the scope of the 
product to any conditions that require behaviour change. Larger companies such as YMX 
may not be able to consider radical feedback especially when the cost is high with limited 
resources. Accordingly, radical changes are postponed even it may be important changes. 
 
“Yes, well, the steps of how the process works in reality is we start with a an initial 
meeting with interested parties, with the clinicians, that will be the clinical champion will 
invariably be a consultant specialist on the field wants the specialist in the field, the 
champion, if you like endorses the go ahead to collaborate, and then the infrastructure 
will be built around them. So the specialist nurses is a national institute of health 
research, clinical researchers,” ESA interviewee 
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Although companies didn’t show a clear application of any design process stages, creative 
design practices have been followed during the product development. For example, ESA 
distinguished between problem definition and the solution. For example, ESA highlighted 
that co-working with patients, clinicians and consultants to understand the problem and 
then transform the basic ideas into prototype. Since the product is tailored based on each 
patient case such as the position of the catheter line, the company representative considers 
information related to the catheter position and patient’s measurements.  Then, the all the 
stakeholders meet again to provide feedback on the prototype. The iteration process 
continues until reaching a prototype that can be tested on patients. 
  
“the patients will tell you exactly what they 
want.” ESA interviewee 
 
9.4.4 Design Factors  
3AB interviewee highlighted human factors as a group of factors that the designer of the 
product considered. These factors include how it fits the human body, so its parts do not 
detach from the main device.  The latter factor can be considered part of the user 
experience and product usability. 
 
When trying out the wearable device some people adhered to the regimen and others 
stopped using the product because they did not adhere to the regimen from the first place. 
This reveals another impact of weak adherence to the treatment regimen. Patients who do 
not follow the recommended regimen of treatment end up by stopping using the treatment, 
which will have a negative impact on patient health and waste of the treatment cost. 
Another point highlighted by the interviewee is the importance of patents’ feedback. While 
the designer builds the device with specifications in mind, patients' feedback can provide 
information about improving the product that addresses patients' needs. 
 
The above answer from ESA reveals a factor related to the development of the treatment 
device. While there is an appreciation of patient adherence, there is not any evidence to 
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consider the importance of adherence at the early stage of the device development, which 
may be because there is no instrument to measure companies’ transfer of theoretical 
adherence frameworks into an action plan or a tool to identify consideration of adherence 
during the development. Accordingly, companies do not or "partly" consider adherence.  
This unclear picture of adherence drives companies to push their products to the market 
seeking consumer opinions. While firms can apply some of the consumer feedback, some 
feedback requires significant changes which increase the device production cost. Therefore, 
this feedback may be ignored due to its inapplicability. 
 
Based on the findings from the content analysis, table 9.2 below tries to map design factors 
identified from the content analysis to the SMEs who mentioned it during the five 
interviews. For example, two companies (3AB and DE7) have considered the “patient 
friendly” factor in designing the product. Both “patient experience” and “considering 
patient feedback” factors were considered by all the five companies. 
 
Design factor                                                             Companies 3AB DE7 LW7 YMX ESA 
Patient friendly      
Patient needs1      
Patient experience (positive & negative)      
Considering Patient feedback      
Patient expectations      
Considering risk factors2      
Sociability      
Table 9.4 Design factors highlighted during the content analysis for the interviews 
1 Patient needs in this table refers to considering the needs in the designing the form and 
function of the product. 
2 Considering risk factors in designing the product itself to avoid patient harm and improper 
use of the treatment. 
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9.4.5 Design Value 
3AB interviewee highlighted the importance of design to add value to the business, identify 
consumer needs, and other requirements (usability and materials). The interviewee focused 
on the role of designers rather than the design practice itself, which may be related to the 
interviewee’s background as a designer. This observation aligns with Cross (2005) as 
designers tend to describe design from their practical perspective. Then, the interviewee 
moved to talk about the branding and packaging role in enhancing the communication 
between the device and patients. However, the financial barriers can hinder design from 
achieving its target aims. 
 
The role of design as a driver for behaviour change was discussed. The interviewee 
mentioned that the first intention of the product was not a behaviour change, yet the initial 
focus was smoking cessation. The journey through the device design process and user group 
feedback can lead to changing the product target toward another disease or type of 
patients. In DE7, the interviewee described the current state of the product as a prototype. 
He appreciates the role of design in the look of the product. The treatment device is used at 
bedrooms; therefore, their design needs to be acceptable in this context.  
 
"Okay, so what I have worked today, it is repeatable, but I 
would still say it is a prototype," DE7 interviewee 
 
For examples, how it will be added as part of the mattress and how specific parts of the 
device will appear for patients while using the device. 
 
“priceless?” ESA interviewee commenting on the value of design 
 




The interviewee described the role of design based on its value as priceless. Its value can’ be 
just added a budget, it extended this limit to add wide range of benefits for the product 
development. The above overview of the design value and how companies perceive it 
indicate two points: 
• There is an agreement that design can add a value for the PDP. 
• There is no or insufficient knowledge of the exact design value toward the business. 
Some views limit the value of design to only the ethical aspects ignoring the impact 
of design in business innovation and competitiveness in the market. 
9.5 Barriers of Product Design and 
Innovation 
 
SMEs face varied types of internal and external barriers (Nauwelaerts, Antwerp and 
Hollaender, 2012; Larsen and Lewis, 2007). In 3AB, the interviewee highlighted two barriers 
that faced the company, which are time dedication and financial funding. The company 
partners kept getting in and out from the company for different reasons, such as getting a 
full-time job. The barriers reflect the team-related challenge. At this early stage, companies 
depend on funding and may face limited financial support, which means that the company's 
founders usually dedicate a long time for none or very little financial support. If this stage 
went longer than expected, some team members find it hard to continue with their 
dedication, so they try to find other financial support and leave the team. Financial barriers 
are pervasive in micro and small firms, and they run on limited funding and financial 
support.  
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While barriers may have a direct and indirect impact on considering adherence, the financial 
barriers come at the top of barriers to considering adherence. Companies find it hard to 
apply any evaluation studies or clinical trials due to the cost of these procedures, and 
subsequently, they do not have a clear idea about patient's adherence to the treatment. 
Table 9.5 shows the innovation barriers highlighted in the content analysis and its 
occurrence in the case studies. 
Innovation barrier                                                   Companies 3AB DE7 LW7 YMX ESA 
Access to information      
Experience      
Access to expertise      
Financial      
HR       
Operational      
Production      
Regulatory      
Teamwork      
Technological       
Time limitations      
Understanding the business      
Process      
Table 9.5 The innovation barriers highlighted by companies in the content analysis 
 
Financial barriers are the most important obstacles facing SMEs, as agreed by all five 
companies. The inability of SMEs to secure funding is why they fail to achieve their strategic 
goals (Larsen and Lewis, 2007; Madrid-Guijarro et al., 2009; Nauwelaerts et al., 2012). Lack 
of experience and skills was considered the second highest barrier to success in the market 
by four out of the five companies. The literature indicated that this lack of skills can be 
marketing skills (Foley and Green, 1995; Freel, 2000) and management skills (Larsen & 
Lewis, 2007). Other barriers, which were reported by a single company, include access to 
information (YMX), teamwork barriers (LW7) and process barriers (ESA). More details about 
key barriers are discussed later in this chapter.   
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YMX interviewee one saw barriers from the perspective of offering a number tailored 
product. The diversity of conflicting needs presents an obstacle to the design of the 
treatment device. For example, designing treatment devices that are wearable or attached 
to the patient's body needs to consider the different measurements of the patient's body.  
 
YMX Interviewee two highlighted that being a small company; it makes it hard to have 
multiple products. The company size and resources only able to focus on one product. This 
reason indirectly linked to one of the barriers that face SMEs, such as limited resources, 
which affects the decision to develop new products. 
 
“I think the biggest barrier to development is a conflicting need for us to have a 
single one size fits all product." YMX Interviewee one  
 
The above issue extends its impact to affect the clinical trials and choice of the trial 
population. When the device is tested, the aim is to address 80-90% of the population. If the 
study did not clearly define the population sample to meet with the product's target 
patients, problems might raise from patients' who do not have the product fit them.  
 
"Do not take to everyone you know if you have got someone who is you know got 
gigantism or someone who has got dwarfism or something they are not going to, you 
know, you are not going to be able to say this patient is 45 years old they need, you 
know, three milligrammes of this drug because it is just that that is just based on an 
average based on averages doors are based on averages, so you know any anything 
that has any kind of physical interaction with a human being is always going to face 
that kind of problem." YMX Interviewee two  
 
While the population selection mechanism is based on the average person, this mechanism 
may not suitable for medical technology as the nature of the usage of the device is different 
from the traditional drugs.  
Interviewee one described the barriers that faced when developing the product. For this 
treatment device, one of the barriers to overcome was people’s different physical 
measurements. The description of the different modifications to the design indicates the 
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importance of the iteration in the design process. While there are some elements of the 
device that cannot be modified such as the technology itself, the ability to modify the 
wearable parts to fit with the patient’s needs can be modified based on patient’s needs. The 
iteration and modifications of the device are continuous because of different reasons such 
as 1) improving the product, 2) address Patient's comments, and 3) changes in the 
technology. 
 
"We have also got so much learning." YMX 
Interviewee two 
 
The process that interviewee two described is a learning curve. The team uses one material 
and then need to change it for a specific reason. Some design issues cannot be anticipated, 
and they require practical, real-life patient usage in order to figure out these issues. The 
nature of a design process here is not only iterative but also learning curve that is guided by 
patient's feedback about the device usage. Another element that affects product 
development over the timeline is the evolution of technology. Products that are developed 
at a specific point of time used the available technology at this time. After developing the 
product, new technologies are introduced that can provide opportunities and 
improvements. The longitudinal observation for the product over its lifetime raised another 
design challenge, which is what is the company's decision to face this challenge? Usually, 
SMEs run in a tight budget and limited resources, which may present one of the company's 
barriers to innovate. 
 
DE7 interviewee discussed the experience barriers that faced the company, and one of the 
barriers is his own experience himself. So, he discussed how his engineering background 
helped to create a complicated solution to how the target design needed to be simple.  
 
“But in terms of look and feel. But for me, as an engineer, I make it a lot more 
complicated than needs to be. So, I would say that the barrier focus groups 
were not being open enough myself in mind to consider a simplistic design. I 
made it too complicated, but it is not. It is not that way. Now it has all been 
changed." DE7 interviewee  




Other barriers are related to intellectual property (IP). The interviewee highlighted that he 
did not want to provide details about the product. Therefore, he could not file an IP patent 
for the product as he did not want to provide details about it. The interviewee filed a trade 
secret instead. 
 
In LW7 case study, medical regulations and funding presented two of the main factors that 
were considered and presented barriers during the development process.  
 
“Finding the right people is challenging.” LW7 interviewee 
 
Another issue that was considered during the development is the expertise of the working 
team. As the device presents a new idea of the treatment technology, the team is required 
to be able to understand the problem and the possible solution in order to visualise the 
solution and understand the founder’s description of the solution. 
 
9.6 Treatment Adherence 
Part of the aim of this stage is to understand how companies consider adherence in the 
treatment design and how adherence is considered in clinical trials or other evaluation 
procedures. 
 
9.6.1 Self-Administration of the Treatment 
The administration of the treatment plays a critical role in determining the level of 
adherence to the treatment regimen. A treatment device can be either fully patient-
administered, partially patient-administered, and fully clinical-administration. The more the 
treatment is patient-administered, the more likely that adherence level decreases (figure 
9.3) 




Figure 9.3 The level of adherence in both patient- and clinical- administered devices 
 
This study aims to explore self-administered treatment technology, which involves both fully 
and partly self-administered solutions. For example, YMX’s and LW7’s devices require 
support at the beginning of the treatment to educate patients on how to use the device 
before they fully administer it at home. In one of the clinical trials for YMX, communication 
with the sample was held every month. In contrast, in another trial, the communication 
with the patient was every six months, and was limited to collecting the usage data from the 
device. In the later trial, patient adherence was 70%, which is higher than the earlier trials 
that showed less than 20% adherence to the regimen. As a result, we may identify the 
communication factors as motivators of patients to adhere to the treatment regimen. 
 
"Yeah, it is very, very simple. It is designed for 
simplicity." DE7 interviewee 
 
Three companies (YMX, LW7, and ESA) out of the five have highlighted the importance of 
communication with patients to improve adherence.  
 
9.6.2 Patient-centric Treatment 
LW7 interviewee highlighted the way feedback is taken from patients. The interviewee 
indicated the importance of prototypes in getting patients’ feedback. Without the prototype 
their feedback is not effective.  
 
“And that feedback would be so undirected and so loose, to be really have no value at all. 
But when you give somebody a prototype, for example, you know, then they frame their 
feedback based upon that prototype,” LW7 interviewee 




For ESA, as highlighted earlier, the process of designing the treatment medical solution 
involves patients’ needs and tailor the solution toward them. As highlighted by the 
interviewee, the design aims to meet requirements from patients, families, carers, and 
clinicians. 
 
While the founder does not have a design background, the design process practice 
presented a good example of patient-centred design. Although, the initial pathway is guided 
by the AHSN, the meetings with patients (or their representatives such as carers, nurses, 
and clinicians) and working with patient advisory groups presented a good application for 
the patient-centred design.  
 
The above model of patient and stakeholders’ involvement in the design and development 
of the product reflects an interesting observation that the patient-centric principle is very 
crucial in building a successful project. However, it needs to be practiced properly in order 
to achieve the intended goal. Part of the company practice is to follow the AHSN innovation 
pathway to integrate with the healthcare system. 
 
In DE7, the design of the product was influenced by varied expertise, including that of a 
clinical advisor, a business advisor, and a statistician. The results of clinical testing used to 
develop the product as well in one of the studies that included 50% men and 50% women. 
The study used several variables to determine the level of sleep quality; these variables 
included patient rating and examining the physiological and physiological status of the 
patient. The results showed that the product helped 50% of the women, and 40% of men to 
sleep deeper. Evaluation studies can provide useful tools to improve device design. 
However, the study aims, design, and expected outcome should be considered to ensure a 
valid outcome that can be used to improve the treatment device. 
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9.6.3 Patient Adherence and Product Design 
While DE7 interviewee did not provide proof related to patient adherence to the device 
therapy, he provided two main points that make him believe that adherence to the therapy 
will be high: 
• The device has a direct impact on improving sleeping. Therefore, the patient will 
most likely adhere to it in order to maintain a positive experience 
• The results of using device therapy are quick and do not need to depend on drugs. 
This advantage can be a factor to influence adherence, especially with diseases like 
insomnia and depression. 
 
"People have tried to come off the sleep system, after they have been familiar with it 
and improve their sleep and realise, they do not sleep as well when they turn off. So, 
in terms of adherence is an easy one, they want to go, they want the extra bed 
asleep. So, they go back on it, right? They, they, they get bruised when they turn it 
off, they realise that they need it." DE7 interviewee 
 
YMX’s Interviewee one and two talked about the pattern of use as a source of information 
about patients’ behaviour when wearing the treatment device and when not wearing it. In 
terms of the factors that affect adherence, Interviewee one highlighted the fear of 
deterioration of the patient’s health condition as one of the motivators to adherents to the 
regimen. Another factor is the follow-up communication between the company and the 
patient. If patients know there is someone who is going to call to follow-up their treatment 
progress, they would adhere to the treatment regimen.  
 
“So I do not want that to be the only message. The biggest message 
for compliance is about finding ways of motivating a patient and 
finding multiple ways. Trying to press on all of those buttons, but it 
cannot be denied that there is one motivation." YMX Interviewee one  
 
Patient motivation is the top factor to improve adherence as interviewee one highlighted. 
However, this factor includes different factors. The company should explore the best 
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motivation factor or group of factors that can affect patient adherence. Another factor that 
can influence patient adherence is reasoning. For example, some patients do not adhere to 
the treatment; then later, they change after facing a specific experience like a shock. Some 
patients rationalise their actions related to adhering or not to adhering to the treatment. 
This factor aligns with the theory of reasoned actions (Bosworth, Weinberger, & Oddone, 
2005). 
 
In 3AB, while the product is in an early stage, it was evaluated through patient user groups 
where some information regarding the usage adherence can be explored. The interviewee 
highlighted that user group member had feedback regarding the physicality of the product 
in terms of efficacy (this may actually be effectiveness, see Section 9.5.3). 
 
"Yes, 78%-82% of respondents reported that using the device had 
helped them achieve their goal, that is, I mean that is a big number for 
such a specific question.” 3AB Interviewee 
 
Thus with respect to confidence in the device to achieve its target within the user group 
sample, the results showed that 78% to 82% of the respondents reported that the device 
helped them to achieve their goal. The interviewee mentioned this percentage in the 
context of discussing adherence, which is high comparing with the literature (Bosworth, 
Weinberger, &Oddone, 2005; Martin, Haskard-Zolnierek & DiMatteo, 2010; Williams, 2014). 
However, this percentage may indicate patients’ opinion about the product rather than 
adherence percentage. A long-term study with clear population sample is required to 
determine the accurate level of adherence to 3AB product. 
 
Table 9.6 below lists the adherence factors and the companies who considered it during the 
design of the treatment device. While all the interviewees acknowledged the important role 
of adherence, the below table shows that only few factors were considered, and few 
companies considered these factors in designing the product. 
  




Adherence factor                                                   Companies 3AB DE7 LW7 YMX ESA 
Communication with patients      
Health belief (patients believes about their own health)      
Knowledge and education      
Patient empowerment      
Protective motivation      
Self-motivation      
Reasoned action      
Behaviour change      
Table 9.6 List of adherence factors considered by the companies 
 
9.6.4 Adherence Considerations and Involvement in 
Clinical trials  
 
3AB sees adherence from the perspective of two parts:  
• The first part is based on how patients use the product in the way intended and 
clearly defined to patients 
• The second part is how the product is used in terms of the target challenge.  
 
While the interviewee may not come to a cross literature definitions of adherence, the 
practice and the experience acquired while developing the device may help to build a clear, 
realistic idea about adherence.   
 
"There are two levels on there; the first level is using actually 
using the product. Yes. So, using the product in the way you 
intend to use the product. And the other level is how the 
product is used in relation to the challenge." 3AB interviewee 
 
Although there is a clear idea about adherence and how to measure patients’ adherence to 
the treatment, there is a lack of a tool to evaluate how adherence is considered for a 
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product (adherence-friendly) during the development stages before moving toward any 
clinical trials or any other patient evaluation procedure.  
 
"Okay, so, in the old clinical trials. No, I do not think it was 
taken into account as we go forward. We have refined how we 
look at compliance." YMX interviewee one 
 
YMX Interviewee one talked about compliance and how it is considered in the clinical trials. 
At the early clinical trials, patient compliance was not considered and then added into 
account in later clinical trials. Clinical trials were expanded to consider patient compliance 
with the treatment. While the treatment has a minimum and maximum usage hour to 
achieve the target goal of usage, the compliance target in the clinical trials had been set to 
the maximum number of hours, which may contribute to unrealistic outcomes. For example, 
the patient may use the product for five hours which is sufficient for the treatment; his 
would still be considered as non-compliance.   
 
Another factor is the surrounding environment. So, if the surrounding environment during 
usage device is supportive for the patient, this can improve adherence. However, clinical 
trials did not consider this factor. In terms of consideration of environmental factors, there 
are two types of clinical trials: efficacy and effectiveness in clinical trials. While the first 
applies the trials in a controlled environment, the second applies the trials in the real-life 
environment (Flay, 1986). The clinical trial setup for the treatment device did not take into 
consideration the environmental factor surrounding patients while they use the treatment. 
As a result of the above consideration for compliance measurements, the results of the 
clinical trials can lead to misleading compliance data.   
 
Another challenge that faces the company in terms of compliance is the accuracy and 
realistic data about compliance reported by patients themselves. For example, patients can 
say they used the treatment for six hours while they only used it for four hours. This does 
not necessarily relate to patient honesty; it is sometimes related to wrong perception, 
especially when the patient is not keeping record of the usage hours.   
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The accuracy of patient feedback can be affected by when and how the question is asked. If 
the question is at an early stage of the trial, the probability of getting an accurate answer is 
higher comparing with late stages. Another factor is how the question is asked. For example, 
if the question about the usage hours was asked by a threatening style, there is a high 
chance of a less honest answer. Sometimes, patients tend to give the clinical trial 
administrators the answers they want to hear, which can also lead to misleading 
information. 
 
“But the way we ask the questions is really important to get to the truth, not the 
answer they think you want to hear.” 
 
Interviewee one highlighted an interesting observation regarding asking patients about their 
actual compliance for the treatment regimen. The format of the questions is used, and the 
way clinicians ask their patient plays an essential role in getting an accurate (true) answer 
about the patient level of adherence. Turner III (2010) and Jacob and Furgerson (2012) 
highlighted the influence of the question format on the outcome answer. While in clinically 
administered trials, the truth (or honesty) factor does not exist, and it plays an essential role 
in patient-administered treatment as it may be the only way to track patient adherence in 
some treatments. 
 
In YMX, Interviewees one and two talked about the pattern of use as a source of 
information about patients’ behaviour when wearing the treatment device and when not 
wearing it. In terms of the factors that affect adherence, Interviewee one highlighted the 
fear of deterioration of the patient’s owns case as one of the motivators to adherents to the 
regimen. Another factor is the follow-up communication between the company and the 
patient. If patients know there is someone who is going to call to follow-up the treatment 
progress.  
 
“So I do not want that to be the only message biggest message for compliance is 
about finding ways of motivating a patient and finding multiple ways. Trying to press 
on all of those buttons, but it cannot be denied that there is one motivation." 
Interviewee one  
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9.7 Patient Communication and Adherence 
Patients who take home a self-administered treatment start can using it without 
administration from the clinicians. However, interviewee one highlighted that they do not 
want this to happen and prefer providing partial clinical consultation or control over the 
treatment due to the following: 
• There is no control over who is taking the treatment and their underlying conditions 
which may add responsibility to the company 
• Approved providers can sell the device and provide consultation services to their 
patients to test and prescribe the treatment accordingly. 
 
As communication is one of the crucial factors that impact patients' adherence to the 
treatment, I found this is an excellent opportunity to get an insight about the company 
communication with patient before and during the intervention. 
 
YMX company and clinicians communicated with patients during clinical visits to set up the 
clinical trials, check patients’ health status, provide the patients with a device replacement, 
get feedback about the treatment, and collect usage data from the device. The other form 
of communication was through phone calls, which aimed to follow-up with patients their 
usage to the treatment device and any feedback they had. The later involvement of 
communication between patients and clinicians show the importance of communication-
related factors to drive adherence. 
The way these communication channels were conducted reveals the following about 
adherence as below: 
• The clinical sessions that included a discussion between patients and clinicians 
regarding their experience with the device and their usage regimen may help 
improving patient adherence. Clinical trials which involve Follow-up phone calls 
showed higher adherence percentage.  
• The interval time between the communication session presented an important 
especially. Shorter communication interval (monthly) has shown higher adherence 
level. 
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As the communication is one of the crucial factors that impact patients' adherence to the 
treatment, further discussion aimed to elaborate this opportunity to get an insight about 
the company communication with patient before and during the intervention, and during 
the clinical trials. The aim of this part of the conversation was also to explore how the 
clinical trials were set up and the impact of this set up on patient adherence. 
 
YMX’s product was a subject of two clinical trials. In order to maintain the anonymity of the 
company, the names of the trials were removed from the context here. The first one used 
an early version of the product; which patients need a new mask every 3 months (due to 
memory and battery capacity). So, patients needed to see clinicians every 3 months. During 
these visits, they were given a new device, got clinician checks, and the data was collected 
from the device. While using the mask, patients were followed-up by a monthly phone call 
the record their experience. The patient adherence to this clinical trial was high and reached 
around 70%. The result of this clinical trial was very supportive as the mask was able to 
prevent (or cure) the degradation of the retina’s thickness, which has a direct impact on the 
RT and DR (Kuchynyka, Grierson, & Veith, 2017). 
 
“So, the classic example, everyone gives is the eyedrops for glaucoma, of 
which the adherence rate is 4%. Generally, and because it is eyedrops, you 
cannot check whether a patient is using it or not." YMX interviewees. 
 
The second clinician trial was not set up by the company itself, which had limited 
involvement in writing the protocol of the study. In this trial, patients were given the device 
without much interference nor support. The patients were using the intervention for two 
months. Every month, patients visit the clinician for a regular check and not to get 
information regarding the device usage information or to collect patients' feedback 
regarding the treatment device. The outcome of the trials showed an adherence level less 
than 20%. One of the interviewees highlighted that in self-administered treatment, the 
adherence might drop to 15% even in severe heart conditions. He highlighted that if 
patients are sent home to use the treatment, they will unlikely adhere to it even in chronic 
conditions.  
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"even for relatively short things, so you know things like antibiotics, for 
example, you know, the doctor will give them a 20-day course of antibiotics, 
they will feel better after a week now stop taking them." YMX interviewees. 
 
YMX Interviewee indicated that there are issues related to considering adherence during 
the clinical trials. These issues can be summarised in the following points: 
• The company knew ahead that low adherence would have a negative impact on the 
outcome related to the abilities of the device. When sharing this information with 
the clinician trial administration, they indicated that clinical trials do not check the 
adherence level without providing a clear rationale for testing it.  
• The time allocated to each patient during the clinician session was insufficient to ask 
questions related to patients’ adherence and usage of the device. 
• The clinical trial was a single-blind randomised controlled trial. Part of the sample 
was using a placedo device (sham). However, the sample who received the sham 
device was able to identify it which affect their adherence to the intervention. 
 
"They knew full well that you could check the patient compliance and 
feedback. Furthermore, you know, we even had informed them that they had 
relatively low patient compliance, and they just said we are not checking. 
They refused to do it exactly why they never really gave us a reason so 
ultimately; it is just going to be speculation. One is you know that if they were 
checking it, they would end up treating patients differently based on whether 
they were behaving or not and." YMX interviewees. 
 
The above statement from interviewee two highlighted another dimension of the barriers 
that face considering adherence factors in clinical trials. Although it could be, the adherence 
factors were not considered during the clinical trials. As a result, the outcome and 
recommendations from the clinical trials can dramatically be affected by eliminating the 
opportunity to consider measuring patient adherence. For example, if a company did not 
consider adherence's factors during the development process, the evaluation of the 
effectiveness of the intervention would be blinded by the low adherence to the prescribed 
regimen. 




While the benefits of self-administration were highlighted, the communication between 
patients is required to empower patients which has positive impact on adherence (Feste, & 
Anderson, 1995; Funnell, & Anderson, 2003; Aujoulat, d’Hoore, & Deccache, 2007; 
McAllister et al., 2012). Adding clinical communication with patients as part of the factors 
that encourage adherence suggests that self-administered health tech does not require full 
disconnection between the patient and the clinicians. So, the dependability on the clinicians 
is reduced to only regular follow-ups (e.g. phone calls or virtual appointments) can help to 
reduce the hospital admission, clinical appointments, surgical intervention cost, and both 
the physical and psychological impact on patients. 
 
9.7.1 Treatment Usage Regimen 
There is a mutual correlation between adherence to regimen and treatment continuation. 
3AB highlighted that patients’ proper adherence to the regimen leads to positive outcomes 
(improvement in the patient's condition), which encourages patients to continue with the 
treatment. In YMX company, patients need to wear the treatment device for a specific 
number of hours daily for 24 months. DE7 treatment device needs to be used daily at the 
beginning in order to see an outcome. In contrast, lack of adherence leads to insufficient or 
no improvement, which subsequently leads to discontinuation of the treatment regimen.  
Another aspect affects patient adherence highlighted by DE7, which is the cost of the 
treatment. When patients pay for the treatment, they are more likely to adhere to it 
compared with the free offered treatment. 
 
9.7.2 Patient feedback 
YMX highlighted the importance of patient feedback in improving the product and 
subsequently, the adherence for the treatment regimen. For example, patients did not feel 
comfortable wearing the device as it causes skin issues. It was interesting that some of the 
patients’ feedback faded away after a short time of usage, and patients get used to the 
device. Therefore, clear analysis for patients’ feedback can help companies to plan a 
strategy to improve the product for both short and long term. 
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In ESA, feedback is collected from patients, parents, and clinicians during the meeting with 
the YPAG to modify the product prototypes to meet both patient’s comfortability and 
treatment goals. DE7’s device aims to provide a comfortable sleeping experience for 
patients, especially by using the device for the long term. The patient's feedback was used 
to improve the device, so it does not interrupt patients’ sleep experience. 
 
9.8 Findings and Summary 
Five SMEs have been interviewed as part of Phase One: Investigate of this study. The aim of 
the interviews is to investigate the state of medical technology innovation, explore the role 
of design in developing innovative treatment technology, and how adherence is considered 
during this development. To this goal, a number of objectives have been set:  
• Explore the current state of SMEs working in the medical technology innovation 
including building understanding of the barriers and opportunities they face 
• Explore how design thinking characteristics are adopted during the design and 
developing of the treatment technology (including the hinders and opportunities of 
its application) 
• Explore how adherence is considered during the design and development of the 
treatment solution 
• Explore how the treatment products are considered in the clinical trials including 
how adherence is considered during the evaluation procedures 
 
This chapter provided a summary analysis of the five semi-structured interviews. The 
transcripts of the interviews are available as a confidential Appendix 9.1. Four of the 
interviews were held based on face-to-face meetings, and one via the Internet. Details 
about the interview methodology were discussed in Chapter 3: Case Study Methodology. 
 
The profile of each company was reviewed and its integration with the healthcare system 
was discussed with the company interviewee. Also, details about each product was covered. 
Some information was eliminated from the discussion here due to anonymity agreement 
with the company. 
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Four companies did not follow any design thinking process. One company (YMX) applied the 
double diamond process in designing the treatment device (Design Council, 2015). While 
there is an acknowledgement of creative design practices and their benefits, companies vary 
in providing evidence related to making use of these practices. There is no strategic-led 
process that can help companies to improve their implementation for design characteristics. 
Most companies run based on the expertise or the professional background of the founder. 
While there is an agreement on the value of design to business, companies did not provide 
sufficient details about this value and how it is considered by the company. In addition to 
the literature studies related to the medical technology innovation. These findings 
contribute to understanding the design process used in the medical technology industry, 
which is one of the study questions (what are the current development processes applied in 
medical technology?). 
 
In terms of the obstacles faced by companies when trying to innovate, all the companies 
have shared barriers that including experience, financial, regulatory, and technological 
barriers. This finding is supported by the literature studies covering the barriers of 
innovation in SMEs, and answers the study question (what are the barriers to and 
opportunities for adopting design thinking?) 
 
The fourth group of questions addressed adherence, its consideration in the design process, 
and its consideration in the clinical trials. A close look at the adherence literature shows a 
lack of studies related to medical technology in general and particularly self-administered 
treatments. The current theoretical models that help understanding adherence (Bosworth 
et al., 2006; Nunes et al., 2009; Sabaté, 2003) do not provide practical guide for companies 
to follow to overview and measure the consideration of adherence factors in the design 
process. Practical considerations when considering adherence extends to the clinical trials, 
where adherence is poorly considered. The journey of YMX case study provides an insight to 
how inadequate consideration of adherence in clinical trials setup can dramatically affect 
the outcome of the trials. 
 
The companies are working in a challenging industry. While self-administered treatment 
technology can provide solutions to many of the challenges that face the healthcare system, 
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there is a gap between the theoretical knowledge, industry application, and evaluation 
(clinical trials). There is a lack of literature studies related to self-administered treatment 
technology. The current theoretical models of adherence do not provide a practical 
mechanism for companies to consider adherence factors in the design of the medical 
intervention. Additionally, these frameworks do not have a sufficient focus on self-
administered medical technology. Regardless of the companies’ appreciation of the 
importance of adherence, the lack of an effective practical approach to understanding 



























































Chapter 10: WearCare II Project 
 
This chapter reports on the second stage of 
this study (Explore). In this stage, the 
WearCare II project was observed in order 
to explore how adherence factors are 
considered in an early stage of the design 
process. The WearCare II project was a 
collaboration between post-graduate 
design students at Northumbria University, 
CPI and AHSN. 
  
Key Topics: 
10.1 WearCare II Role in the Study 
10.2 Observation Time and Location 
10.3 The WearCare II Project 
10.4 Workshop Progress and Reflection 
10.5 Reflection and Discussion 
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The second phase of the research involved observing the post-graduate project of the 
taught Master of Design’s (MA Design) students, WearCare II. It aimed to explore how to 
use design thinking to develop a patient-centred self-administered wearable to monitor vital 
health information. The project was a collaboration between Northumbria University, CPI 
and AHSN. The research aimed to explore how adherence is considered at an early stage of 
the design process.  
 
Two main limitations in the SME interviews indicated a need, and directed the study design, 
for this phase: 
1. Early consideration of adherence in design work could not be observed as the 
companies had already developed the product or a high-fidelity prototype of the 
product, and 
2. The interviews’ limited timeframe prevented observation of new product 
development, especially considering the long-term medical technology development 
process. 
 
Accordingly, the WearCare II project provided an opportunity to observe how adherence is 
considered early in the design thinking process in a similar (or nearly similar) setup to that of 
SMEs. The project environment was similar to that of SMEs: it required teamwork, involved 
team members with a variety of backgrounds and skills and focused on the design process. 
However, there were also differences, such as the financial setup, legislation and company 
setup. This research stage aims to provide a complementary perspective on how adherence 
consideration progresses when exploring the problem and formulating the idea for the 
solution.  
 
10.1 WearCare II Role in the Study 
The WearCare II project presented an opportunity to observe the design practice at an early 
stage of the Double Diamond (Design Council, 2015) process and observe how the 
consideration of adherence progresses from one step to another. A number of limitations lie 
within the WearCare II project itself, such as its practice which varies from real SMEs setup. 
Also, the target of the academic project is different from a commercial company which 
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reflect on the students' practice. Having said that, both opportunities and limitations in this 
stage were acknowledged. WearCare II project presented one perspective to observe the 
design practice as highlighted regarding the SMEs observation limitations highlighted earlier 
in this chapter. In addition to the WearCare II project, other perspectives were used to 
strengthen the understanding of the design practice. These perspectives include: 
1. The interviews with the five case studies' descriptions for the design process of the 
healthcare product 
2. The literature related to the design process and the nature of each stage 
3. The researcher's perspective as a designer with 15 years of experience in various 
design projects  
 
In the WearCare project, the teams were observed doing design practice, while the Delphi 
stage aimed to observe the panel assessing the practice. Accordingly, the WearCare project 
has importance from a design practice perspective. 
Additionally, WearCare project presented a core role in developing the 2nd claim of the 
study highlighted in Chapter 14 (14.2 Research Claims and Contribution to Knowledge). 
 
10.2 Observation Time and Location 
The project ran as part of the Design Thinking DE7001 module, which was part of the MA 
Design post-graduate degree and was conducted between September and December 2019. 
It took place on the university campus in Newcastle upon Tyne. This module investigated 
the design process based on three main components: 1) reflective practice; 2) enterprise; 
and 3) intercultural communication. The first component involved using the reflective 
practice process (explore, act, observe and reflect) to explore the problem space and 
solution space related to the project. 
 
10.1.1 Participants 
The project included eight groups with three to four students in each group. All the groups 
worked on the same project, and the students had different educational backgrounds and 
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experience. This group setup is similar to the structure of real-life micro-size companies and 
start-ups, which are usually a group of partners trying to create a new product to introduce 
to the market. The environment simulated a very early stage in common SMEs’ lives, when 
they consider an innovative product. This setup provided an opportunity to observe how 
this early stage works, and especially the consideration of adherence factors. Below is a list 
of the student groups, the number of students in each group and the solution project’s 
name presented at the end of the semester.  
 
Team No. Number of students  Solution name 
1 4 Don’t Sweat the Small Stuff 
2 4 Insulin Pump 
3 3 Chronic Stress: Discover Recover 
4 4 Push Pal Stress Relief (Osteoarthritis Pain Tracking) 
5 4 Anxiety Disorder 
6 5 Loneliness and Isolation 
7 4 Rehabilitation of Elderly People 
8 2 Food Allergy Detection 
Table 10.1 List of the teams working on the WearCare II project, the number of students in 
each team and the solution name. 
 
10.1.2 Data Collection and Management 
The groups’ work was observed, and the progress of each group was documented as 
follows: 
1. Notes were taken of observations and interpretations of each teams’ practice. 
2. Students were asked about their progress, which was documented through written 
notes. During the two weeks when direct observations could not be performed 
because I could not attend the class, updates were collected through an online 
survey page (the survey was created using Surveymonkey.com). 
3. The final presentation of the groups’ work was recorded, and a transcript was 
created using Otter. The final presentation was documented in photos.  
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I attended the classes on a weekly basis with prior coordination with the course lecturers to 
avoid disrupting the teaching process. In each class, teams were observed for around 5-10 
minutes, and notes were taken to document their practice. I then summarised these notes 
to document the weekly progression of all the teams.  
 
10.3 The WearCare II Project 
CPI and AHSN introduced the WearCare II project. The project’s main theme was ‘How can 
design thinking reposition healthcare towards patient-centred and self-administered 
services?’. The students followed the MPPF method (English, 2007) to explore the current 
situation from different perspectives. According to the MPPF (refer to Chapter 1: 
Introduction, 1.5 Definition of Terms), six centres of inquiry are used to drive push 
questions, which are used to explore the problem. Whitehead (2007) highlighted that in 
order to build a space for innovation ‘fuzzy situation’, six to seven key areas (cornerstones) 
need to be defined to establish a starting point for designers to explore the problem space 
(English, 2007). In the WearCare II project, students were asked to investigate the following 
key areas: 
⁃ Patient needs: Both physiological and psychological factors related to patient needs 
within the context of using the treatment.  
⁃ Patient adherence: The drivers of patient adherence and the factors which affect a 
patient’s compliance with the treatment regimen. 
⁃ The NHS: The healthcare system’s strategic elements, such as function, structure, 
assets and funding mechanisms . 
⁃ Technologies: The products, systems, services and future opportunities for diagnosis 
and treatment. 
⁃ Value networks around about the patient: The stakeholders involved in the 
environment around the treatment. 
⁃ Change factors: The threats and opportunities related to patient behaviour change. 
 
The students created push questions to explore each of the six inquiries and represented 
each answer with a keyword written on a sticky note. They then arranged their findings and 
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investigated the connection between the results related to each centre of inquiry. At the 
end of this process, they defined cornerstones which represented the solution. The 
representatives from both CPI and AHSN introduced the students’ projects at the beginning 
of the semester. They attended a follow-up presentation to review the students’ practice 
and a final presentation at the end of the semester. The representatives provided feedback 
to all the teams and awarded a prize to the winning team. 
10.3.1 Progress and Documenting Observation 
As discussed above, I attended and observed most of the classes. The progress of teams was 
documented weekly through the following methods: 
1. Taking written notes about and interpreting student practice. 
2. Asking students about their progress and documenting their practice. 
3. Using an online questionnaire to document their practice during the classes that I 
could not attend. 
 
Various media were used to take notes, including paper, mobile phone and iPad. The notes 
were then collected, firmed up, and summarised, as highlighted in Table 10.2 before 
highlighting the team practice. During this practice, I shared thoughts and insights with the 
students from the literature studies about their topics in order to highlight useful resources 
without interfering with the course. 
 
Below are general notes regarding the teams’ progress, attending the classes and other 
observations: 
• Some observational data was not available due to two the team was absent or came 
late to the class. 
• The team members had different experience and study backgrounds. While a 
majority of them were from design education, the teams had a multi-disciplinary 
structure. 
• The teams were very similar to early stage start-ups. At this point, the start-up team 
may not know much about the product and therefore will build on their expertise. 
• At the beginning of the project, adherence was presented to the students in one 
lecture at the first week in the semester, so that they would consider adherence 
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factors in the project. This introduction presentation was brief so as not to shift the 
team’s focus entirely to adherence and also so I could gain an overview of their 
practice and how they dug deeper to understand adherence. 
• Team 8 faced some communication and teamwork issues. Therefore, they were split 
into two teams. For this reason, some data for team 8 and team 9 are incomplete.  
10.3.2 Documenting Each Team’s Progress 
In each class, around 5-10 minutes were spent with each team so that I could take notes on 
their progress. I then summarised these notes in order to document the weekly progression 
of all the teams. Generally, groups moved through three stages (Figure 10.1):  
 
Figure 10.1: The progress timeline for the WearCare II project. 
 
• The problem space, where they explored the design challenge  
• The problem/solution space, where they explored the possible solutions, and  
• The solution space, where they defined their proposed solution and drafted ideas  
These three stages defined each group’s state in terms of the findings or identifying the 
possible solution and did not reflect the application of the MPPF itself. 
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Based on the progress highlighted in Figure 10.1 above, written field notes about teams’ 
progress were documented weekly. I then reflected on the field notes (Baarts et al., 2000; 
Mills et al., 2010) and summarised those observations (Table 10.2). A detailed table, 
including field notes and associated reflections about each team, is available in Appendix 
10.1. 
 
Weeks  Observation 
Week 1 • The AHSN speakers and the CPI speaker presented the project brief and 
specifications. 
• Students started to organise themselves into groups. Each group works 
together throughout the semester. 
• I presented the problem of poor adherence to the students and why it is 
important to address.  
Week 2 • Groups were uncertain about choosing a problem to solve. So, they shared 
their own experiences to reach an agreement about the problem. 
• Teams overviewed the project requirements and critical aspects that may 
help them define the health challenge they would like to focus on. 
• Groups explored the different problem perspectives using the MPPF, which 
helped them find key areas of interest (cornerstone). So, they explored their 
own experience, knowledge and their observed relatives and friends. 
• Some of the group discussed adherence together to consider it in their 
project. 
Week 3 • Some teams were still uncertain about the problem they want to address. 
So, they continued to explore the problem space.  
• Some teams defined the problem and started to think about solutions.  
• Some groups started desk and field research to learn more about the 
problem as well as exploring possible solutions. 
• Teams used mind maps related to cornerstones they identified through the 
MPPF. 
• Few groups advanced in considering adherence. I reminded the groups with 
adherence as they dropped it from their discussion 
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Week 4 • The students continued to learn about the areas of knowledge related to 
their defined problem. 
• Their ideas become a bit clearer than before. Many of the groups started to 
either do primary research or develop the solution idea. 
• There is evidence in the solution space of low consideration of adherence as 
an influencer of patient behaviour the during teams’ investigation.  
Week 5 • Students presented their progress to the AHSN and CPI representatives, 
who provided feedback and comments about their work. 
• Groups have a clear definition of the problem they intend to solve. 
• Group presentations included their progress in the solution space and the 
research done toward this goal. 
Week 6 • Groups continued to work on their solutions based on their investigations, 
brainstorming and feedback received from the presentation. 
• Students used tools to help them build the solution and understand the 
business associated with it such as PESTLE analysis and personas. 
• Groups worked on the product design with a focus on the aesthetics and 
function of the product. 
• Some of the groups continued to do primary research through interviews 
and questionnaires. 
Week 7 • Students continued to develop their wearable devices and prepared for the 
final presentation to AHSN and CPI. 
Week 8 • Tuesday is the final presentation for the students in front of AHSN and CPI. 
• Students presented their wearable device solutions during the presentation. 
• Their products showed a focus on the psychological needs and behaviour 
change of patients. This provides an interesting insight: while the teams 
indicated they considered adherence, observing the team practice showed 
insufficient consideration for the adherence factors. 
• They built the early-stage product prototype through sketching and 3D 
modelling. 
Table 10.2 Brief reflections on the teams’ activities during their work on WearCare II. 
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The above table shows a summary of the students’ progress throughout the semester. 
During these weeks, the groups’ practice was recorded into written and audio notes in order 
to explore how the findings can contribute to answering the main research questions 
highlighted in Chapter 1: Introduction. An interesting observation from the teams’ progress 
is the adherence consideration which faded as the team progressed in their projects. This 
insufficient consideration of adherence factors was clearly observed in the teams’ final 
presentations.  
10.4 Workshop Progress and Reflection 
Each of the teams took one of two routes: they either started with a health problem in mind 
(team 2, team 3, team 4, team 5, team 6, team 7, and team 8) or started with no idea about 
the problem they wanted to address (team 1). Choosing which route to take was linked to 
discussions between team members and if they had previous experience with a specific 
health condition. The majority of the teams decided to address problems they had 
personally experienced, representing the reflective practice nature of design (Schön, 1983). 
While there were eight teams in this class; the three teams shown in Table 10.3 below were 
selected based on the following four criteria: 
• The team started with a problem in mind or explored the problem as they moved in 
the process. 
• How adherence was considered during the design process. 
• The design process which was used by the team. 
• The clarity in describing the process. 
 
Of the eight teams, three teams were selected to be overviewed in this chapter (Table 10.3). 
The rest of the teams followed the same process flow of the three selected teams. A table 
with the remaining five teams’ progress is available in Appendix 10.1.  
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Team Selected problem Reason for selection 
One Don’t Sweat the Small Stuff (measurement 
and monitoring health vitals via sweat 
sweat) – Health monitoring 
The team started with no clear 
idea about the problem to 
address. 
Two Insulin Pump (reinventing the Insulin pump) 
– Treatment and monitoring of chronic 
condition 
The team demonstrated partial 
consideration of adherence from 
the diabetic patients’ perspective. 
Four Push Pal (pain-tracking device and app for 
patients with Osteoarthritis) – Monitoring of 
chronic condition 
The team demonstrated partial 
consideration of adherence from 
the chronic osteoarthritis patients’ 
perspective. 
Table 10.3 The overviewed three teams, their solutions and why they were selected.  
 
Below is an overview of the teams’ progress through the design process stages and some 
key findings based on observing the teams. A complete list of the teams’ progress is 
available in Appendix 10.1. 
 
10.4.1 Problem Exploration 
The teams started to explore the problem using the MPPF method to explore the problem 
frame by identifying the cornerstone keywords representing the problem’s definition. 
Teams varied in their search for the knowledge related to the problem. As highlighted 
above, team 1 started without a prior idea about the problem they want to solve, which is a 
key difference between them and the rest of the teams (Figure 10.2). This being the case,  
they started by exploring the centres of inquiry: measurable factors, medical and wearable 
tech trends, ailments, existing wearable med-tech, research opportunity, wearables and 
why a wearable? 
 




Figure 10.2 Team 1’s activities mapped onto the Double Diamond (Source: team 1 final 
presentation). 
 
Along with the above, team 1 presented a clear map for all of their activities to provide a 
design solution for the medical problem they selected (Figure 10.1).  
 
10.4.1.1 Team 1 
Team 1’s cornerstones were different from what was described in the project brief. The 
cornerstones were based on the team discussion and the team’s decision concerning the 
key areas that they were using to explore the problem. Each team used the centre of inquiry 
related to the targeted disease and this may be a reason behind the neglect or poor 
consideration of the adherence factor. This observation shows that a gap can occur 
between the initial requirements and the team’s selected centre of inquiry. Team 1’s 
defined inquiry neglected adherence and its related factors. 
 
 




Figure 10.2 Team 1’s exploration of the centre of inquiry in the value arena (Source: team 1 
final presentation). 
 
Figure 10.2 shows team 1 exploration of the centre of inquiry. Without a clear idea of the 
target disease, the team explored a broader scope of medical technology applications.  
 
10.4.1.2 Team 2 
Team 2 started with a clear idea of the health condition to address (Diabetes). They 
considered adherence in three areas of investigation: Adherence, Patient Education and 
Prediction Model (Figure 10.3). These areas presented a limited consideration of adherence 
factors with no clear idea of why and how the above adherence factors were selected. 
However, the team’s consideration of adherence is interesting. While the team did not 
consider the broader scope of adherence factors, their centre of inquiry keywords show 
they considered adherence within their initial investigations. For example, the above areas 
of investigation are closely related to the adherence factors related to diabetes (Wu et al., 
2020).  




Figure 10. 3 Team 2 created radial maps around the centre of inquiry (Source: team 2 final 
presentation). 
 
The exploration of the prediction models and using machine learning to predict adherence 
behaviour and undiagnosed diabetes cases (Baan et al., 1999; Farran et al., 2013; Cichosz et 
al., 2016) presented an interesting factor: the involvement of machine learning in improving 
patient adherence to the treatment.  
 
10.4.1.3 Team 4 
Team 4 began with a clear idea of the problem area they wanted to investigate, which was 
Osteoarthritis. The team used their research and previous knowledge to identify the centres 
of inquiry related to patients who suffer Osteoarthritis. They then created a radial map for 
each centre, which are: National Health Service (NHS), holistic, arthritis, physical, therapy 
and available knowledge. The team also explored patient needs, behaviour change and 
patient adherence. Although the team did not explicitly consider patient needs and 
behaviour change as part of adherence, both are factors that affect adherence (Figure 10.4). 





Figure 10.4 The radial mind map for the centres of inquiry investigated by team 4 (Source: 
team 4 final presentation). 
 
10.4.2 Problem Definition 
In the second stage of the Double Diamond (Design Council, 2015), the teams converged 
their findings to define the problem in hand. As the teams applied the MPPF method to 
identify the cornerstone keywords related to the problem, they used a centrifuge process to 
progress toward this goal. 
 
10.4.2.1 Team 1 
Team 1 used an integrated mind map to identify the cornerstone keywords that could set 
the problem frame that could then be used to define the target problem in the subsequent 
stages (Figure 10.5). The team defined seven cornerstones: Research opportunities, 
ailments, wearable, why wearable, measurable factors, med and wearable tech trends and 
existing wearable med-tech.  




Figure 10.5 The centrifuge process used to identify the key cornerstones (Source: team 1 final 
presentation). 
 
The team identified the context of the problem and move to the solution space. The 
questions they asked are: 
• Why is it needed? 
• How will it work? 
• When will it be used? 
• How will it be used? 
• Who will use it? 
• How long will it be used? 
• Where will it be used? 
 
 To answer these questions, the team conducted primary and secondary research based on 
many personas. According to the findings, the number of personas was reduced to two 
(Figure 10.6). 





Figure 10.6 The application of ‘5Ws’ method to identify the characteristics of team 1’s 
solution (Source: team 1 final presentation). 
 
Patient adherence was absent from team 1’s initial mind maps. This neglect or insufficient 
consideration of adherence subsequently continued until the stage where the target 
solution’s characteristics began to form. Therefore, adherence was outside of the scope of 
the team progress.  
 
10.4.2.2 Team 2 
Team 2 continued to build an integrated mind map (Figure 10.7) to define the key 
cornerstone. They used the universals (English, 2007) to break the idea down to its 
fundamentals in order to address the solution space. The solution universals are: 
• Removal of medical design language to counteract insecurities and stigmas whilst 
wearing the devices. 
• Accessible to all ages through the NHS. 
• A system to educate users about how to better manage all the factors which affect 
their diabetes. 
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• Utilise multiple pre-existing wearable media technologies for broader data 
collection. 
• Improve GP-patient relationships for better understanding and tailored medication. 
 
 
Figure 10.7 Team 2’s integrated mind map using the centre of inquiries (Source: team 2 final 
presentation). 
 
Team 2 showed early consideration of some adherence factors. The consideration was 
reflected in the following stage (problem definition). For example, the universals reflected 
the consideration of adherence, as highlighted in Table 10.4. 
 
While team 2 considered some adherence factors, others were not considered. The reason 
why some factors were considered and other factors were not is unclear; however, a review 
of other companies who target diabetes reveals that they focus on adherence factors such 




 Chapter 10: WearCare II Project  
 
 214 
Universals Adherence factors References 
Removal of medical design language 
to counteract insecurities and 




Bosworth et al., 2005; 
Martin et al., 2010; 
Williams, 2014)  
Accessible to all ages through the 
NHS. A system to educate users 
about how to better manage all the 




(Nunes et al., 2009; 
Sabaté, 2003) 
Improve GP-patient relationships for 








DiMatte et al., 2012; 
Henson, 1997; Horne et 
al., 2005; Williams, 2014)  
Table 10.4 Mapping team 2’s universals and adherence factors. 
 
10.4.2.3 Team 4 
Team 4 continued to work on the radial maps (refer to Chapter 1: Introduction, Section 1.5 
Definition of Terms) and then used them to build the integrated maps used to define their 
cornerstone keywords which contributed to the solution frame. Figure 10.8 shows the main 
cornerstone keywords: Wearable technology, physical, holistic, inclusivity, available 
information, psychological and physical. As the team moved to the integrated map, the 
keywords related to adherence factors influenced the consideration of adherence (i.e. 
available information, self efficacy and impact). The rest of the teams followed the same 
process as above, focusing on the medical condition that they wanted to address.  
 




Figure 10.8 The integrated mind map for team 4 (Source: team 4 final presentation). 
 
10.4.3 Solution Development 
The third stage of the Double Diamond (Design Council, 2015) is developing the prototypes 
based on a clear definition for the problem and the problem frame. Using the MPPF method 
to define the problem space, teams moved to the prototype stage, where they visualised 
ideas about the intended solution. The observation of this stage provided an opportunity to 
map the consideration of adherence and how this consideration was transformed in the 
move from the problem space to the solution space. Only two teams (team 2 and team 4) 
provided evidence of consideration of adherence factors in their problem framing practice 
before this stage.  
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10.4.3.1 Team 1 
Team 1 began by defining personas for possible patients, which were reduced and filtered 
after their research. Part of their research was to identify the aesthetics of the solution. At 
this point, the team had an idea of their solution frame. To understand the solution’s 
possible aesthetics, they built a mood board to reflect the expected visuals and styles 
(Figure 10.9). 
 
Figure 10.9 Mood boards created by team 1 (Source: team 1 final presentation). 
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During the 'Develop' stage, team one explored different tech wearables and how they are 
used as fashion accessories, especially where and how they are worn on the patient’s body 
(Figure 10.10). 
 
Figure 10.10 Team 1 explores the different wearable options for the medical device. 
 
The product’s final design was based on primary research to discover where patients in the 
sample preferred to wear the device. Accordingly, they decided to design the product to be 
wearable on the wrist. This provided the benefits of easy control and customisation and also 
had to do with many of the existing med-tech and smartwatches in the market (Figure 
10.11). 
 
Figure 10.11 The final design for the product designed by team one (Source: team 1 final 
presentation). 
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Although the team mentioned the consideration of adherence in this stage, there is not 
sufficient evidence of how patient adherence was considered and the strategy used to 
achieve this goal.  
 
Application of Card Sorting 
Card sorting is a tool which can be used to organise concepts and identify their importance 
(Conrad et al., 2019). It is usually used in user experience (UX) to develop user interfaces 
(UIs) for mobile applications. The team used the card sorting method to identify the mobile 
app’s essential features associated with the target application. The starting point was to 
write down the features that could be added to the mobile application on separate cards. 
This practice helped the team members see the application’s content (Figure 10. 12).  
 
Figure 10.12 The application features are on the left. Organised categories is on the right 
(Source: team 1 final presentation). 
 
The features were then arranged and organised into related categories. The team noticed 
that some parts could be removed from the application. Figure 10.13 shows the application 
of the organised data and how they are reflected in the mobile app navigation. 




Figure 10.13 The features organised on the left. The features appear in the mobile app 
navigation (Source: team 1 final presentation). 
 
10.4.3.2 Team 2 
Team 2’s solution was a device (Insulin pump) and software application. The application 
collects data from the patient’s several wearables to build an accurate prediction of the 
patient’s habits and provides alerts on bad habits. Also, the usage of data from multiple 
devices helps the app determine the amount of Insulin required to be injected using the 
Insulin pump (Figure 10.14). The team proposed designing the pump to look less like a 
medical device by using colours. As a result, patients would use the exact amount of Insulin 
required for their case, which would be cost-effective for the NHS due to the high cost of 
Insulin. This would result in more people benefit from the NHS service, especially when the 
treatment is self-administered.  




Figure 10.14 Team 2’s design of the Insulin pump (left) and the associated application (right) 
(Source: team 2 final presentation). 
 
The treatment has an educational component, as it can advise patients to follow a healthy 
diet and encourages habits that can drive a healthy lifestyle. 
 
The final solution shows a level of consideration of adherence factors, including patient 
prediction models, patient education, alerting patients and encouraging a healthy lifestyle. 
These factors were reported during the case studies interviews (Chapter 9: Case Studies 
Interviews) and literature adherence theories (Chapter 6: Theoretical Frameworks of 
adherence). While there may be other factors to consider, the treatment solution’s features 
show that the team was able to consider adherence factors during the design process, 
which contributed to reaching an adequate level of consideration in the final treatment 
solution. 
 
10.4.3.3 Team 4 
Team 4 went through possible solutions which could be used to record and track pain. 
These potential solutions had common criteria, such as being easy to understand, use, hold 
and difficult to forget (Figure 10.15). The device aimed to record the pain level through the 
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number of clicks of a button that the patient pushes. These clicks are saved and collected by 
an app that can provide detailed information about the pain and related data level. 
 
Figure 10.15 Team 4’s draft prototypes of the PUSHPAL solution for osteoporosis pain 
tracking (Source: team 4 final presentation). 
 
The final solution prototype (Figure 10.16) shows the device (PUSHPAL) in on and off mode, 
as well as its charging cable. The device can also be used with voice activation for patients 
who cannot use their hands due to osteoporosis pain. The device is connected to a mobile 
app that monitors and shows the pain patterns and records specific activities that may 
increase the pain level. 




Figure 10.16 PUSHPAL device and mobile application (Source: team 4 final presentation). 
 
Team 4 showed poor consideration of adherence factors, and the prototype reviewed above 
does not provide sufficient evidence of consideration of adherence in either the device or 
the mobile application. The only feature that can be linked to adherence is voice activation, 
which is related to usability (the application is user-friendly) and accessibility (the 
application considers patients with disabilities). 
 
10.4.4 Product Delivering 
At this stage, the teams should have a clear idea about the solution frame and have 
transformed the theory into a prototype which can be tested and evaluated. While the class 
was not designed to facilitate creating and testing a product in reality, students nevertheless 
used PESTLE to analyse the market compared to external competing factors (Jonathan, 
2016). They also utilised the Value Proposition Canvas to define the product potential value 
(Figure 10.17). After identifying the value that a product can add to the market, teams could 
use these data to build their business strategy. 




Figure 10.17 The Value Proposition Canvas of team 1 (Source: team 1 final presentation). 
 
For example, team 1 defined their value proposition as follows: 
‘Our product aim is to measure hormone levels as a form of preventative healthcare for 
young adults (18-28) by integrating an electronic sweat monitor into a wearable accessory. 
By doing this, we target to blur the line between medical tech and lifestyle.’ 
 
Each team asked the rest of the class to evaluate the final idea based on the PESTLE factors. 
The teams could then use these data to improve the product idea. Figure 10.18 shows 
examples of the teams’ feedback to each other. Each team then visualised the PESTLE 
analysis findings using a radial map in order to identify the areas that needed to be 
improved (Figure 10.19).  








Figure 10.19 Team 5’s reflection on the PESTLE feedback from team 1 (Source: team 5 final 
presentation). 
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At the end of the project, students presented their ideas for new products to 
representatives from AHSN and CPI. The presentation was an opportunity to explore how 
adherence was considered in the final concept. In Table 10.19, final ideas from the rest of 
the teams that were presented in the final presentation.  
Team 3: Discover Recover (chronic stress) Team 5: COCUMON (anxiety disorder 
patch) 
  
Team 6: Loneliness Lab (a website and 
installation of areas for lonely people to 
meet) 









Table 10.5. Each group presented the final ideas at the end of the semester. (Source: final 
team presentations). 
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10.5 Reflection and Discussion 
The above examples provide an overview of the practice of the eight teams in this project. 
Three examples were selected based on the ideas they had at the beginning of the project, 
the consideration of adherence, the design process used and the clarity of describing this 
process. The rest of the teams worked via a route similar to the examples discussed in this 
chapter. Two teams (team 1 and team 3) did not start with an accurate definition of the 
health condition. One team (team 3) did not show any consideration of adherence-related 
factors. The following can be observed by the early-stage mind maps above: 
• The observation of the above process shows the complexity of the design practice, 
which may present a challenge when considering a complex factor such as 
adherence and maintaining this consideration throughout the process. 
• All the teams acknowledged the importance and impact of adherence on health or 
medical intervention. However, adherence factors were poorly considered during 
the design process of almost all teams. 
• The teams who considered adherence factors did not fully consider the primary 
factors that affect patient adherence. For example, Team 5’s consideration of 
adherence ignored other factors such as communication between patient and 
clinician, motivation, locus of control and social learning. 
• Teams explored areas which are related to their target health condition. These areas 
are related to adherence as they can be mapped onto the theoretical frameworks of 
adherence. For example, team 2 targeted a disease (diabetes) where patients are 
more likely to adhere to the treatment than others.  
 
10.6 Summary and Findings 
The observation of the WearCare II project aimed to see how adherence is considered at an 
early stage of the design process. This perspective was not available in the case study 
interviews as the companies were established and had the product already developed in 
stages which varied from one company to the next. Observing the eight teams working on 
the WearCare II project revealed a number of insights that may help identify the research 
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contribution to knowledge. These observations include: 1) the complex nature of the design 
process, especially considering its iterative nature; 2) the poor consideration of adherence 
factors; and 3) the lack of a mechanism that maintains consideration of adherence factors 
during the iteration stages of the process. The findings from this stage contributed to the 
next stage by triangulating findings about the consideration of adherence at an early stage 
of the design process in the Assess stage). 
 
The above final project ideas show that some teams could provide an adherence-friendly 
health solution, while others could not achieve this target. This observation mirrors real-life 
cases, as some companies can deliver a product based on their initial plan target, and others 
cannot. There may be many reasons for this, but the one which stands out is that there is no 
mechanism or a tool with which companies can measure their compliance with the 
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Chapter 11: Delphi Method Application 
 
This chapter describes the assessment 
stage, which is the last stage in this PhD 
research. The Assess stage involved both 
triangulation of the previously collected 
data and developed consensus on the 
adherence factors. The assessment was 
conducted using the Delphi method, which 
will be covered in this chapter. 
  
Key Topics: 
11.1 Delphi Round One Questionnaire 
11.2 Delphi Round Two 
11.3 Delphi Round Three 
11.4 Findings and Summary 
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Assess is the final stage of this research. Before this point, literature studies related to 
patient adherence, medical technology, and design thinking was reviewed and analysed in 
the Investigate stage. Then, interviews with five case studies were conducted to explore and 
understand the design process and the consideration of adherence during the design and 
development of treatment (and treatment-support) technology. The second stage, Explore, 
involved observation for the Wearcare II post-graduate students’ projects. This stage 
assessed the findings from previous stages and collected a consensus from the panellists on 
a design-focused adherence canvas, a resource that could be used to guide and measure 
adherence consideration during the design thinking process. The primary aim of the stage is 
to find an agreement on an Adherence Canvas influenced by the design thinking process 
and improve adherence during the development of self-administered treatment technology. 
 
Based on the research aim, three words were considered to describe this stage: ‘assess’, 
‘evaluate’ and ‘test’. Based on the Cambridge Dictionary entry for ‘assess’, the word means 
to judge or decide the value or importance of something (Cambridge Dictionary 2020, 
‘assess’). The term ‘evaluate’, in contrast, means to judge or calculate the quality, value or 
importance of something (Cambridge Dictionary 2020, ‘evaluate’). This definition indicates 
the measurable nature of the evaluation process. The word ‘test’ varies from the above two 
as it suggests the questioning of or carrying out practical activities in order to understand a 
specific phenomenon (Cambridge Dictionary 2020, ‘test’). 
 
The term ‘assess’ refers to documenting a specific knowledge or skill measurement in order 
to improve it in the future. The word ‘evaluate’ refers to making a judgement based on 
evidence. The last word, ‘test’, examines someone or something based on a measurable 
guide to identify the level of the skills or improvement reached (Penn University, 2020). 
According to these definitions, the aim of the research and the time limitations of the PhD 
study, the word ‘assess’ is used in this stage to describe the method used to obtain a 
consensus about the adherence framework, which is based on the findings from the 
previous stages. These findings were used to develop a framework that was assessed and 
refined through the Delphi process. This framework can support SMEs during their 
production of treatment devices (5.6 Implementation of Delphi methodology).  
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Two main factors dictated utilising the chosen research method at this stage: 1) the 
confidentiality of information shared by companies (Keeney et al., 2011); and 2) the target, 
namely assessing the proposed framework. Based on these two factors, the Delphi method 
was chosen to obtain a consensus about an Adherence Canvas (Linstone & Turoff, 1975). 
 
Additionally, this study takes a phenomenological approach to understanding the 
phenomenon of adherence and the factors affecting it in relation to the social actor (the 
patient). To achieve this goal, the Delphi approach will be used to assess the factors which 
can be used to improve adherence during the design and development of self-administered 
treatment technology through collecting data from the panellist about what they consider 
are the adherence factors and how adherence can be considered. This approach will guide 
the process and selection of the panel if you mean Delphi, say so as well as its design. 
 
During the Delphi method stage, the U.K. and the world were hit by the COVID-19  outbreak. 
It affected both the business and also the social lives of many people in the U.K., including 
the Delphi panellists and me. The government’s strategy of asking people to stay home and 
work from home had a significant impact on this study. The outbreak’s effect on the study is 
reflected in the panellists’ time in responding to the questionnaire. 
 
11.1 Round One Questionnaire 
The aim of round one was to collect feedback from the Delphi panellists about adherence 
factors. The questions and their categorisation were influenced by the analysis of the data 
collected from the literature studies, case study interviews, and WearCare II study. This 
round’s main aim was to benefit from the experts’ points of view, focusing particularly on 
what they agreed and disagreed on. Therefore, the questions take an open-ended 
qualitative form (Keeney et al., 2011). 
 
The first round ran from 10 February to 27 March 2020. This period included sharing the 
pilot round questionnaire with the sample panellists, analysing the pilot panellists’ 
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comments and circulating the first-round questionnaire. The invitations to answer the first-
round questionnaire were shared with the panellists through an email which contained a 
URL to the questionnaire on SurveyMonkey. Panellists were able to visit the URL and answer 
the questions. The answers were recorded and analysed through SurveyMonkey web tools. 
The above period included follow-up emails and messages to remind the panellists to 
answer the questionnaire.  
 
The first round consisted of five questions. Each question presented a possible category of 
the adherence factors which was influenced by the literature studies. The panellists were 
asked to fill out the questionnaire and confirm answering it through email. Furthermore, 
SurveyMonkey.com sent me alerts of new answers. Below is a list the questions shared with 





PhD Study: Explore the Role of Design Thinking in Improving Patient Adherence in Self-
Administered Treatment Technology 
• Information factors: 
Information is a crucial part of patient treatments (e.g. patient education, usage 
information, and patient perception about the treatment). These factors become 
essential when the intervention is self-administered by the patient. 
What are the information-related factors you would identify as impacting patient 
adherence in self-administered treatment? Please list these factors and add explanations 
where possible. 
• Motivation factors 
Different psychology-based theories highlight motivation as a driver of behaviour change 
and adherence improvement in self-administered treatment technology. 
What motivation-related factors do you think can affect patient adherence in self-
administered treatment technology? Please list these factors and add explanations where 
possible. 
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• Communication factors: 
Communication between patients and clinicians can improve adherence (e.g. monitoring, 
phone follow-ups and regular checks). However, communication can present a challenge 
in self-administered treatment. 
Which communication-related factors would you identify as impacting patient adherence 
in self-administered treatment? Please list these factors and add explanations where 
possible. 
• Product design factors 
In treatment devices, design factors (e.g. device look, usability and affordability) play an 
essential role in the patient’s adherence to the treatment regimen. 
What are the design-related factors you think can affect patient adherence in self-
administered treatment technology? Please list these factors and add explanations where 
possible. 
• Adherence consideration 
During the development process of the treatment device, adherence can be considered in 
different ways (e.g. prototyping, testing and patient advisory groups).  
How can adherence be considered during the development of treatment devices? Please 
list how adherence can be considered during the design and production of self-
administered treatment devices and add explanations where possible. 
Table 11.1 Round one open-ended questions. 
 
The main questions’ headings represent the categories for the adherence factors. The 
questions (highlighted in bold text) were then presented with a description which 
attempted to clarify each section for the panellists. 
 
11.1.1 Round One Analysis 
The time it took to answer this round was longer than expected due to the COVID-19 
outbreak and government’s instruction to work from home, which may have affected some 
of the panel members’ plans to answer the questions. After 27 March, the results of round 
one’s answers were analysed. The response rate was 100%, as all 15 panellists answered all 
the questions. The average time spent answering the questionnaire was 21 minutes.  
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As highlighted in Chapter 5: Delphi Method Methdology, the classic Delphi and eDelphi 
usually involve open-ended questions in the round one questionnaire, which may produce a 
large number of data to be analysed (Keeney et al., 2010). Therefore, content analysis for 
the collected data can provide an opportunity to categorise the data into themes which can 
be easily tracked and processed in the following rounds (Powell, 2003).   
 
Content analysis is a widely accepted method of analysing qualitative data, especially in 
applied research which has been extended so as to be accessible to those who are not part 
of the academic community (Braun & Clarke, 2014). This makes it a suitable tool for the 
nature of this research. In particular, deductive content analysis was used, so the evolved 
codes documented from the panellists’ answers informed the theme development. Another 
feature of the deduced content analysis is the ability to look behind the words for the 
meaning (Smith, 2003). However, a minimal level of interpretation to the content was used 
in order to avoid biased and inaccurate content. 
 
11.1.2 Content Management 
After collecting the answers to round one, the content was copied to NVivo in order to 
apply the thematic analysis. Each of the 15 panellists’ answers were copied to NVivo in files. 
Each File included the responses of one panellist. The Files were named after each of the 
panellists, as no anonymity was needed at this stage. 
 
Each file was reviewed, organised, and highlighted the questions so as to identify the 
questions and their answers. A minimal level of cleaning the content was conducted as the 
text collected was written by the panellists themselves. The responses were refined, and no 
further communication with the panellists was required to clarify any of their answers. 
 
11.1.3 Content Analysis 
An earlier expectation was that there would be many codes generated. This being the case, 
there was a plan to analyse the content to provide codes which represented the panellists’ 
answers, categories and subcategories. This categorisation would make it easier to follow 
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the adherence factors while reviewing the analysed data and when conducting a reliability 
procedure. 
 
The content was reviewed with more focus to analyse each sentence and identify the codes 
they reflected. Each sentence was selected and assigned a code using the Nodes feature in 
NVivo. Along with the code name, a description was assigned for each code to make sure its 
meaning was accurate and improve clarity and accuracy.  
 
Once the coding stage was completed, The created codes overviewed, determined the 
relationship between them and created categories for similar codes. This process involved 
reviewing the codes and the connections between them. Once the categories had been set, 
I exported the content to Microsoft Excel so that I could easily discuss and share it with the 
inter-raters in the following reliability test stage. 
 
The codes, the relevant text and the categories are reviewed and organised in a MS Excel 
document. The generated codes presented a large amount of data, which turned the theme 
identification into a challenging process. Therefore, other subcategories were created to 
define the several sub-sections of the adherence factors. Table 11.2 below shows the 
categories, subcategories and the codes associated with them. The Participants column 
indicates the number of panellists who mentioned each specific code or category. The Item 
Count column shows the number of text phrases coded under the below codes to identify 
the content themes. For a complete list of the codes, their descriptions and the answers 
associated with them, please refer to appendix 11.1. 
 
11.1.4 Inter-rater Reliability  
After finalising the code analysis of the Delphi round one, the inter-rater reliability 
procedure was applied to ensure that the codes were reflective by assigning two raters to 
code the content. The coding results from the researcher and two raters were then 
compared to evaluate the agreement on code names. The term ‘reliability’ itself has various 
definitions, yet these definitions have similarities with each other. Some definitions include 
an agreement between two people on how to interpret the same data using the same 
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methods (Campbell & Fish, 1959). Other definitions reflected the ability to have a 
consistency measurement (Black & Champion, 1976) and the ability to reproduce the same 
answer (Bernard, 2000) based on stable (Lehner, 1979) equivalent (Johnston & 
Pennypacker, 1980) measurements (Guest et al., 2012).  




Categories Subcategories Codes Participants Item Count 
1.0 Communication Patient-clinician relationship Acknowledge change in physician role 1 1 
 Replace communication with monitoring tech 1 1 
 Consistence communication 1 1 
Communication effectiveness Effective communication and feedback 9 16 
 Follow-up and reminders 3 4 
 Language used suitability 1 3 
 Right style of communication 1 1 
 Promotional communications 1 1 
Clinician side implementation Clinical implementation 1 1 
  Clinical trials feedback 1 1 
Intervention usage Intervention support 3 3 
Confidentiality and privacy Reliability and trust 7 10 
Table 11.2 Content analysis and categorisation for Delphi round one questionnaire. 
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Knowledge Adequate shared information about intervention Clear treatment information 7 12 
 Simplicity of information 3 4 
Shared adherence consequences Connecting personalised choices and consequences 1 1 
 Measuring targets of health outcome 1 1 
 Effective treatment testing 3 3 
Understand patient behaviour Mismatch in perception of urgency 1 1 
 Perceived susceptibility – Belief selection 5 6 
 Actual patient behaviour 1 1 
 Identify adherence moments 1 1 
Patient information Patient demographic information 1 1 
 Technology literacy 4 4 
 Treatment literacy 3 7 
Patient-centred shared knowledge Considering patient knowledge 9 16 
 Tailored information 2 4 
 Media used in sharing information 3 3 
Motivation Goals motivators Achievable goal setting 3 4 
Risk motivations Drawback – Punishment 4 4 
 Perceived severity – Punishment 3 5 
Benefits motivators Perceived benefits (reinforcement) – Reward 9 15 
Internal motivators Self-efficacy 4 5 
 Health condition 1 1 
Environmental motivators Subjective norm – Environmental cue 5 5 
Table 11.2 Continued. 
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Patient Experience Product design characteristics Aesthetic 5 5 
 Packaging and usage process 1 1 
Patient-centred design (tailoring) Considers patient characteristics 10 16 
 Psychological factors 3 3 
 Inclusive 1 1 
 Usability 8 14 
Adherence consideration Compliance measurement 2 2 
 Concordance – Participation 5 8 
 Considering adherence during development 3 7 
 Guidance of factors influencing adherence 1 2 
Design research Field research and testing 5 7 
 Design prototyping iteration 3 5 
Device usage Practicality 1 1 
 Affordability 1 1 
 Comfortability 3 3 
 Self-administration to treatment 4 4 
 Social support – Facilitation 8 13 
Table 11.2 Continued. 
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The intercoder (inter-rater) reliability is one of the methods used to measure the agreement 
between multiple coders about the code applied to content analysis—the level of 
agreement of coded data. As the researcher interprets the sample qualitative answers into 
useful codes, the role of the inter-rater reliability is to ensure that the codes are 
representative and agreed upon between multiple coders (Campbell et al., 2013; Kurasaki, 
2000). Additionally, the intercoder reliability provides measurement of the preciseness of 
the codes and their definitions (MacPhail et al., 2016).  
 
The nature of this reliability procedure was affected by its position as part of the Delphi 
study and the Assess stage in the research. Round one collected feedback from panellists 
about adherence factors, and the panellists’ answers were interpreted and coded. 
Accordingly, the reliability procedure aimed to ensure that code names were representative 
by allowing two raters to independently analyse and code the content. Furthermore, at this 
point of the research, data from the literature, interviews and WearCare II observations 
were triangulated to formulate the knowledge which was then assessed during the Delphi 
method (round one and round two). Therefore, the reliability procedure was conducted at 
this point of the research. 
 
11.1.4.1 Selecting and Preparing the Inter-rater  
Two inter-raters were assigned to conduct the inter-rating reliability process. This decision 
was based on 1) the timeline limitations of the study; and 2) limited access to potential 
coders who could make voluntary contributions to the study. A job list was created to ask 
for inter-coders. Then, all the applicants were overviewed. Two were chosen based on the 
following factors:  
⁃ Professional experience: their experience needed to be in related fields, which could 
give them an understanding of the study but not necessarily of adherence. 
Therefore, the selected individuals had expertise in medical research and biomedical 
engineering. 
⁃ Experience in qualitative content analysis: they needed to have a good amount of 
experience in qualitative data analysis. 
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According to the above, rater 1 (R1) and rater 2 (R1) were selected to facilitate the reliability 
process. They were contacted and given, individually, a general overview of the study, what 
they needed to do and the timeframe for conducting the procedure. By the end of the 
induction discussion, they both understood what the research was about, their task and 
that they could not know the other’s identity nor the other’s work. 
 
11.1.4.2 Inter-rater Content Analysis 
Each of the coders received a copy of the open-answer questions and the answers given by 
the 15 panellists. They coded the entire content instead of a sample because—since the 
answers were not very long and varied in length from one panellist to the next—this would 
likely reduce the margin of error in the measurements (Jones, 2004). I asked them to code 
the content and organise the codes into categories and subcategories. There were 101 
codes generated through analysis of the five interviews, which made the inter-rating 
process complex and time consuming. Accordingly, the raters were asked to generate 
representative categories and sub-categories for the related (or similar) adherence factors. 
This aimed to measure the agreement on the categories and subcategories of the content 
created by me (the researcher), R1 and R2. Both raters were given the same content to 
code. Table 11.3 below shows a comparison between code categories of the researcher, R1 
and R1. The codes categories were mapped onto each other and the research codes. 
Complete versions of the two raters’ content analysis, including codes, categories, 
subcategories and description of their inputs, are available in Appendix 11.3.2 and 11.3.3.  
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Researcher R1 R2 R1 R1 
Communication Communication Communication: 1 1 
Patient-clinician 
relationship 












    0 0 





    0 0 














    0 0 
Understand patient 
behaviour 
    0 0 
Patient information Patient information   1 0 
Motivation Motivation Motivation factors for 
adherence 
1 1 
Goals motivators Behaviour motivation Motivating features of 
treatment 
1 1 
Risk motivations     0 0 





    0 0 
Internal motivators Physiological Factors Patient acceptance of 
condition and treatment 
1 1 
Patient Experience Patient Experience Product design 
considerations: 
1 1 







Product characteristics 1 1 
Patient-centred design 
(tailoring) 
  Patient-centricity 0 1 
Adherence 
consideration 
Adherence consideration   1 0 
Design research Design research Iterative design process 1 1 
Device usage Device usage   1 0 
Table 11.3 Summary of the code categories and subcategories for the researcher and both 
raters. 
 
The colouring of the table was used to clearly overview the agreement between the raters. 
This step was made to make the process of calculating each case individually easier. The 
colour code is as follows: 
 Both raters disagreed with the initial code 
 Both raters agreed with the initial code 
 Only R1 agreed on the initial code 
 Only R2 agreed on the initial code 
 
 
11.1.4.3 Inter-rater Agreement Measurement 
A number of instruments can be used to analyse the level of agreement between the raters 
on the suggested categories and subcategories. The goal of this measurement is to calculate 
the agreement between raters while eliminating the disagreement that may occur due to 
chance. Therefore, the percentage method of calculating the agreement was not considered 
(MacPhail et al., 2016). Other methods, such as Cohn’s Kappa (Cohen, 1960) and 
Krippendroff’s Alpha (Krippendorff, 2004), were considered. While Cohin’s Kappa method 
measures the agreement by eliminating the agreement due to chance, Krippendroff’s Alpha 
measures the observed and expected disagreement. Additionally, Krippendroff’s method is 
computationally and conceptually complicated (MacPhail et al., 2016). According to the 
above, Cohen’s Kappa was used to calculate the agreement between R1 and R2.   
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11.1.4.4 Calculation of Cohen’s Kappa Agreement 
The measurements were based on a binary system, with the number ‘1’ referring to an 
agreement with the initial code, and ‘0’ meaning disagreement with the initial code. Table 
11.3 above shows the agreement of both the first and second raters with the initial code. 
The below table 11.4 shows the analysis of the agreement data: 
 
  
Rater 2 (R2)  
 









0 6 3 9 0.4 R10 
1 3 12 15 0.6 R11 
Sum 9 15 24 
 
 
% 0.4 0.6 
  
 
  R20 R21    
Table 11.4 Calculation of Cohen’s Kappa Agreement. 
 
First, Pa  was calculated which represents the observed agreement amongst the raters. This 
value may include the probability of agreement by chance. 
Pa  = (N00+ N11) / 24  
     = (6+12) / 24 = 0.8 
 
Pa: Relative observed agreement amongst raters 
N: Total number of codes (categories and subcategories)  
N00: The raters agreed with each other but disagreed with the initial (researcher) codes 
N11: Both raters agreed with the initial (researcher) codes 
 
As seen in the table above, there are two chances that the raters both agree. The first 
chance is that they agree on the initial code created by the researcher. In this instance, they 
would record the same code (or a code with a similar meaning) in their codebook 
document. The second chance is that they do not record the same code as the code created 
by the researcher in their codebook document. In this case, they agree with each other but 
disagree with the researcher. The second step is to calculate the probability of agreeing with 
each other by chance (Pe). The equation used to calculate this probability is as follows: 
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Pe = (R10 /N) * (R20 /N) + (R11 /N) * (R21 /N) 
    = 0.4 * 0.4 + 0.6 * 0.6 = 0.6 
Pe: Hypothetical probability of chance agreement 
R10: Total disagreed codes by the first rater   |   R11: Total agreed codes by the first rater 
R20: Total disagreed codes by the second rater.  |   R21: Total agreed codes by the second 
rater 
 
Based on the above equation, there is a 0.6 probability that two raters will agree with each 
other by chance alone. Therefore, the final Cohen's Kappa value is: 
K = (Pa-Pe) / (1-Pe) 
   = (0.8 – 0.6) / (1-0.6) = 0.5 
Cohen’s Kappa value ranges from 0 to 1, where 0 means no agreement occurs without 
chance and 1 means that there is a full agreement between the raters without any 
probability of chance. According to this rate, the results show the value of 0.5 (Table 11.5). 
This value means there is 50% of agreement between the raters due a chance. To evaluate 
the value of data reliability in Cohen’s Kappa, Landis and Kock (1977) introduced a new 
method with which to measure the outcome of Kappa’s equation. According to the right 
side of the below table, the value of 0.5 refers to a moderate level of reliability (Cohen, 
1960; Holle & Rein, 2013; Hruschka et al., 2004).  
 






0.61-0.80 Almost perfect 
Table 11.5 Value of reliability and strength of agreement in Cohen’s Kappa reliability test 
(Landis & Kock, 1977). Based on this scale, the strength of this study’s agreement is 
Moderate. 
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Another measurement used to identify the level of reliability is proposed by Shrout (1998). 
There is a controversy in the literature studies between the Landis and Kock (1977) 
measurements and the Shrout (1998) measurements in terms of the level of reliability. 
According to the latter, the outcome value of reliability shows Fair agreement (Holle & Rein, 
2013) as shown in the table below (Table 11.6): 
Value of reliability Strength of agreement 





Table 11.6 Value of reliability and strength of agreement in Cohen’s Kappa reliability based 
on Shrout (1998). Based on this scale, the strength of this study’s agreement is Fair. 
 
In this study, only the Landis and Kock weighting system will be used to evaluate the 
outcome of the inter-rater reliability. Accordingly, the level of reliability is moderate. 
 
11.1.5 Conclusion of Round One 
As a result of the desk research, interviews with case studies and observation of the 
WearCare II project, some factors were identified which impact patient adherence to the 
treatment regimen (i.e. communication with patients, health belief, knowledge and 
education, patient empowerment, protective motivation, self-motivation, reasoned action, 
and behaviour change). However, many of the factors and literature studies were 
influenced by the nature of the clinician-administrated treatment, where patients had no 
control over the intervention regimen. The challenge was to identify the factors which may 
affect patient adherence to self-administered treatments, especially those which use 
technology, where there is minimal to no clinical administration of the therapeutic 
experience.    
 
Several factors have been shown to affect patient adherence to the regimen. Some of these 
factors are generic and may apply to any disease or health condition, and some elements 
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have an influence only on specific diseases (Martin et al., 2010; Williams, 2014). During the 
interviews, each case study elicited  opinions regarding the factors which affect adherence 
related to their products and how these factors are considered during the design process. 
In this study, the Delphi method provided a tool to assess and collect consensus on 
adherence factors that affect self-administered treatment technology. Furthermore, the 
data triangulated from the previous stages help to build an adherence framework and 
canvas. The level of triangulation reflected the open-ended questions in the first round of 
the Delphi study.    
 
The aim of round one was to allow a panel of members, who had different areas of 
expertise related to the scope of the study, to identify and rate the various factors which 
can affect patient adherence to self-administered treatment technology. The open-ended 
questions in the first round allowed the panellists to share their experience and knowledge 
regarding the factors which affect adherence. 
 
11.2 Delphi Round Two 
In round one, adherence factors were categorised into categories and subcategories. These 
data were then triangulated to round two’s quantitative questionnaire in order to assess 
panellists’ agreement on the importance of these factors. The challenge was that a large set 
of factors was collected from round one.  
 
11.2.1 Questionnaire Design 
The aim of the Delphi round two was to identify the agreement of the panellists on the level 
of importance of the factors which affect adherence. These factors had been collected from 
the content analysis of the open-ended questions in round one. However, the factors 
highlighted by the panellists aligned with some factors collected during the interviews and 
secondary research on adherence factors. Accordingly, this round presented a triangulation 
of the adherence factors from the literature and interviews. The adherence factors included 
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in the Likert questions and the adherence factors collected from round one. The 
questionnaire was designed as follows: 
• The questionnaire was based on the Likert Scale question type to afford the chance 
to measure the importance of every subcategory collected from round one. 
• Each category identified in round one required one matching Likert scale question. 
Therefore, there are four questions. 
• Each question presented a category from round one’s content analysis for 
adherence factors. Each Likert scale item presents an adherence subcategory.  
• Next to each subcategory, the adherence factors were listed between brackets to 
give the panellists an idea of the meaning of each subcategory. For example, the first 
question covers Collaboration and partnership-related factors. The first subcategory 
in this question is Patient-clinician relationship, which represents adherence factors: 
(e.g., monitoring tech, consistency, follow ups, feedback, confidentiality, 
adaptability). 
• The rating scale included five levels, in ordinal scale, for the importance of the 
factors. The levels were: Very High (5), High (4), Moderate (3), Low (2), and Very Low 
(1). This scale was selected for two primary reasons:  
• The panellists suggested the factors highlighted in each subcategory, so the aim was 
to assess their importance rather than eliminating them, and  
• There was agreement between many of the factors highlighted in the round one 
analysis and the factors highlighted in the literature studies and the interviews with 
the companies. Therefore, the scale in the round two Likert focused on the 
adherence factors’ level of importance rather than accepting or rejecting the factors 
as a driver of adherence during the development of treatment technology. Round 
two presented an opportunity to understand the panellists’ consensus on the 
adherence factors and their importance. 
• The N/A option was available for panellists who thought that the factor was not 
applicable. 
• A comments section let panellists provide further thoughts about the rating system. 
While these comments may have contributed to guiding the third round, their main 
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purpose was to get the opportunity to collect further opinions from the panellists 
which could be used to build the final Adherence Canvas. 
 
According to the above, the questionnaire was created and populated through 
SurveyMonkey.com and sent to the panellists through email. A copy of the invitation to the 
round two questionnaire is available in Appendix 11.4. At the top of the questionnaire, the 
panellists needed to fill in their first and last name for monitoring and follow-up purposes. A 
copy of the questionnaire is available in Appendix 11.4. 
 
11.2.2 Questionnaire Management and Data 
Collection 
During the period when the questionnaire was being populated, the U.K. government 
announced the lockdown in response to the COVID-19 outbreak. An extension for the 
replies was considered while circulating the questionnaire’s invitations, especially for the 
experts who worked for or closely with the NHS and NHS facilities. Below are the guidelines 
presented to the panellists about this round: 
• The number of questions: Five Delphi questions 
• Type: Likert questions 
• Estimated time to complete: 10-20 minutes 
• The anonymity of data: Anonymised between the panellists 
• Answers deadline: Answers are required within one week from receiving the email. If 
you need more time (especially from NHS panellists, please let me know through 
email). 
 
An invitation to complete the questionnaire was circulated on 15 April 2020. One week was 
the allotted time to fill the questionnaire. However, it took until 4 May 2020 for all the 
panellists to complete the questions. During this period, the panellists were contacted with 
reminders and follow-up messages through email and other communication channels, such 
as Skype and Twitter.  
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11.2.3 Addressing Missing Data 
At this stage, the word ‘addressing’ was used to describe the missing data rather than 
dealing with it. The reason for this usage is that panellists still had the chance to complete 
the missing data or change their minds in the third round of the Delphi study. At this point, 
dealing with missing data was limited to identifying them and contacting the panellists to 
learn more about them. 
 
One of the panellists answered with N/A to the majority to the questions (16 out of 20). Two 
panellists one missed one question each. Although the percentage of missing data was less 
than 5%, these panellists were contacted regarding the missing data to find out if the 
answers to these parts of the questionnaire were dropped intentionally or due to technical 
or unintentional reasons. The two panellists responsible for two of the missing questions 
replied that they missed those questions and that they would complete them in round 
three. One of panellists did not rate one factor because he was not clear about its impact on 
adherence.   
 
The panellist with 16 N/A answers was contacted; the panellist explained that some of the 
questions were not clear to him, so the questions were clarified to the panellist, the aim of 
the questions and the plan for the use of the answers. He also explained that he could not 
modify the answers when he tried to have a second look over them. Therefore, the 
technical issue was fixed and gave him access to reply to the questions so that he would 
have the same opportunity to answer the questions as the rest of the panellists. 
 
After the above procedure was undertaken to validate the missing data, three missing 
values remained from round two (those values were associated with three factors: 
intervention usage, patient information and goals motivators). To handle the two missing 
values, the type of data needs to be clearly defined. Generally, there are three types of 
missing data (Outhwaite & Turner, 2007): 
• Missing completely at random (MCAR): The missing data is independent from any 
value, or any potential values (Rubin, 1976). Pickles (2004) defined the MCAR as a 
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value which has equal chance as any other value. The probability of the missing data 
is equal for any value. 
• Missing at random (MAR): From the probability perspective, there is an equal 
opportunity for data to be missed similar to any other value. The difference between 
this type and MCAR is that the value may not be dependant and affected by other 
values. 
• Not missing at random (NMAR): The data can be considered NMAR if any of the two 
classifications above are not met. 
 
In this study, the missing data can be categorised as MCAR as the participants responsible 
for the missing data cannot be distinguished from the participants responsible for the 
complete data (Outhwaite & Turner, 2007; Pickles, 2004; Rubin, 1976). To address the 
missing values, the imputation methods were overviewed. Imputation is a common strategy 
to deal with missing quantitative data to element uncertainty because of missing values in 
statistics (Tang et al., 2005). Bennett (2001) categorised the imputation methods into three 
main categories based on the amount of missing data: 
• Methods which ignore missing observations 
These methods ignore the missing data and drop it from the analysis. The two main 
methods used under this category are: 1) complete case analysis, in which the missing 
data is dropped from the analysis; and 2) available case analysis, which uses the largest 
set of available data to estimate the desired output. 
• Single imputation methods 
These methods aim to analyse the current data, estimate the missing data and impute 
new values. These tools include: 1) Last value carried forward: this tool is used in 
longitudinal studies—if there is missing data from a particular time or date, the previous 
available data is carried forward and used to impute the missing data;  2) Mean 
substitution: the mean value from other participants is used to impute the missing data; 
3) Regression method: in this method, the current data is used to create a regression 
equation which can be used to create variables that can be used to predict the missing 
value; 4) Hot-deck imputation: this method replaces the missing value with value taken 
from participants with matching variables; and 5) Cold-deck imputation: This method is 
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similar to hot-deck imputation. The difference is that, in cold-deck imputation, the 
imputation value is estimated based on the external knowledge rather than depending 
on the existing data. 
• Other imputation methods 
These tools tend to solve the problem of the single imputation, wherein the latter one 
understates the variability in the database. These tools include: 1) Multiple imputation: 
this method replaces the missing data with 5–10 imputations to complete the dataset; 
and 2) Markov-chain imputation: this tool is used in longitudinal studies (repeated 
patterns of data). It imputes the missing value with transient states such as known 
disease stages to replace the value mechanism. 
 
The percentage of the data missing in round two was less than 5%, which makes imputation 
methods inapplicable (Harrel Jr., 2015; Marshall et al., 2009).  
 
Two main factors contributed to determining the method of dealing with missing data 
(Bennett, 2001): 
1. The participants had a second chance (in round three) to complete and modify their 
answers to the questions. This being the case, the missing values were dropped only 
from this round. 
2. The proportion of missing data was small (less than 5%), and the dataset was not 
large as it included answers from 12 panellists. Therefore, the method which was 
used was ‘ignore missing data. 
According to the above, the method which was used to deal with missing data at this stage 
was ‘ignore missing data’ and the associated analysis method in the SPSS software was the 
‘available case analysis’. In this method, SPSS uses the largest set of available data to 
estimate the missing data. (Bennett, 2001). 
 
11.2.4 Results Overview and Analysis 
In round one, adherence factors merged from the open-ended questions. After collecting 
the results from the panellists, the answers were reviewed before moving to the next step 
of the study. The following points were observed:  
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• There was a 100% response rate, which may reflect an understanding between 
panellists of the value of the research and their contribution to it. 
• There was missing data. This amount was around 5% of all the answers. The method 
of dealing with the missing data is described above. 
• Few comments were added. This had no impact on round two or the following 
round. However, it provided individual feedback about adherence. 
 
At this point, a statistical analysis of the results was carried out to establish initial 
understanding about the panellist’s agreement on the importance of the adherence factors. 
SurveyMonkey.com and SPSS were used to create a general picture of all the collected 
statistics from all the panellists. The data analysed using SurveyMonkey.com showed a 
rough agreement on the level of importance between the panellists. The figures (Figure 
11.1, Figure 11.2, Figure 11.3 and Figure 11.4) provide a visual overview of the answers and 
how the majority of the answers fell on the right side of the scale (High and Very High). 





Figure 11.1 Visual chart of round two answers for question 1 (SurveyMonkey.com) 
 
Figure 11.2 Visual chart of round two answers for question 2 (SurveyMonkey.com)  




Figure 11.3 Visual of chart round two answers for question 3 (SurveyMonkey.com) 
 
Figure 11.4 Visual chart of round two answers for question 4 (SurveyMonkey.co
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SPSS software was used to identify the level of agreement between panellists by observing 
the standard deviation (SD) around the mean. The Descriptive Statistics commands 
(Descriptive and Frequencies) were used to calculate the mean and SD for the 20 adherence 
factors as shown in Table 11.7.   
 
 Factors N Min. Max. Mean Std. Deviation 
Collaboration & Partnership      
Patient Clinician Relationship 15 3.00 5.00 4.4667 0.74322 
Communication Effectiveness 15 3.00 5.00 4.3333 0.72375 
Clinician Side Implementation 15 2.00 5.00 3.8000 0.86189 
Intervention Usage 14 3.00 5.00 4.0000 0.78446 
Confidentiality and Privacy 15 2.00 5.00 4.2000 1.01419 
Knowledge & Information      
Adequate Shared Information about 
Intervention 
15 1.00 5.00 4.2667 1.09978 
Shared Adherence Consequences 15 1.00 5.00 4.1333 1.12546 
Understanding of Patient Behaviour 15 3.00 5.00 4.4667 0.63994 
Patient-Centred Shared Knowledge 15 1.00 5.00 4.0667 1.16292 
Patient Information 14 2.00 5.00 3.8571 1.09945 
Motivation      
Goals Motivators 15 0.00 5.00 3.6667 1.29099 
Risks Motivators 15 1.00 5.00 3.3333 1.11270 
Benefits Motivators 15 3.00 5.00 4.0000 0.65465 
Individual Motivators 15 1.00 5.00 3.8000 1.08233 
Social Motivators 15 1.00 4.00 2.8667 0.91548 
Patient Experience      
Product Design Characteristics 15 3.00 5.00 3.8000 0.67612 
Patient-Centred Design 15 3.00 5.00 4.6667 0.61721 
Design for Adherence 15 2.00 5.00 4.4000 0.91026 
Design Research 15 3.00 5.00 4.3333 0.61721 
Device Usage 15 2.00 5.00 4.4000 0.82808 
Valid N (listwise) 13         
Table 11.7 The standard deviation of round two’s answers. 
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Below are comments on the second round SD table:  
• Table 11.7 indicates that the average of the mean value between the adherence 
factors is around the ordinal value of 4.0. However, the mean column shows an 
agreement around the mean as the values bias toward the right side of the ranking 
system, which shows a varied level of agreement on the importance of each 
adherence factor. An overview for the SD values reveals there is high agreement on 
some of the factors such as: understanding of patient behaviour, benefits 
motivators, patient-centred design and design research. For these values, the 
minimum level of importance is 2 and the maximum level is 5. 
• In contrast, some adherence factors show a high SD level of more than 1.0. These 
include: adequate shared information about intervention, shared adherence 
consequences, goals motivators and risk motivators. The high SD indicates a wide 
range of rating values, so the minimum 1.0 and the maximum rating level is 5.0.  
• The above values show the level of agreement on the importance of adherence 
factors in Delphi round two.  
• The two main benefits of observing the panellists’ data at this stage were: 1) 
understanding the initial answers of the panellists on the importance of adherence 
factors; and 2) understanding how the panellists changed their opinion after giving 
them the chance to review the overall answers from the whole panel. 
• These values are primary data and are expected to change in round three as the 
panellists will have the chance to modify their answers.  
 
11.2.5 Conclusion of Round Two Results 
Round two provided a method for triangulation of the code analysis from round one, 
literature, and interviews. The adherence factors organised in categories and subcategories 
and then, they were provided for the panellists to rate their importance. It represented a 
pivotal stage for understanding the factors of adherence—and their importance—which 
should be considered during the design and development of treatment technology. The 
analysis overview from both Surveymonky.com and SPSS software showed evidence of a 
level of agreement between the panellists; this observation is supported by the value of the 
standard deviation around the mean of each factor. Therefore, the third round of the Delphi 
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process aimed to identify the consensus between the panellists on the results from round 
two.  
11.3 Delphi Round Three 
The initial plan of the Delphi study in this part of the research was to have three rounds. 
These rounds aimed to explore the panellists’ agreement on the factors which affect 
adherence during the development of treatment technology. Accordingly, the results from 
this round were expected to achieve the goal of the study. 
 
In this round, the same questionnaire from round two was circulated amongst the 
panellists. This time, they were able to see the combined answers from round two showing 
the overall rating from the panellists. The revealed data was anonymised, and they were 
able to see specific answers. While they could see the combined answers from the whole 
panel, they were be able to see their previous answers in case they forgot their inputs in 
round two. The procedure aimed to allow the panellists to check the panel answers and 
provide them the chance to change their mind. They had the choice to skip questions or the 
whole questionnaire if they did not want to change their minds. 
 
11.3.1 Administration and Questionnaire Population  
The nature of round three dictated several changes in how the questionnaire was 
constructed and shared with the panellists. These changes included the following: 
• As each of the panellists would be able to see everyone else answers, a separate 
copy of the questionnaire was created. Each copy had a different circulation link. 
This procedure aimed to ensure the security and anonymity of data at this stage. 
• Above each question, two tables were added to show the individual panellist’s 
answer and the combined answers from all the panel members. 
• Panellists were allowed to skip questions or the whole questionnaire if they wanted 
to keep their answers from round two unchanged. 
• The panel members were given a chance to reply by email to confirm if they did not 
want to change their answers or wanted to change one or two factors only, and 
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• Panellists who missed answering any of the questions from round two agreed to 
complete those questions in round three. 
 
The invitation to complete round three was sent to the panellists separately through email. 
Each invitation included a unique link to each of the panellist’s questionnaire. They were 
asked to answer the questionnaire based on the below regulations: 
• ‘You will check and review your answers from Round Two and compare them with 
the anonymised answers from all members of the panel. 
• To modify your rating, answer the question with your new answer. 
• If you do not want to change an answer, skip to the next question. 
Please see details below about the questions and timeline: 
• Number of questions: four optional Likert questions 
• Estimated time to complete: 5–15 minutes 
• The anonymity of data: answers are anonymised between panellists 
• Deadline for response: answers are required within one week from receiving the 
email. If you need more time (especially NHS panellists), please let me know via 
email. 
Note: The link above shows a unique survey link for each of the panel experts to ensure 
anonymity. So, your answers are private.’ 
 
The above statement was added at the top of each questionnaire, and it reflected the 
regulations of the round three questionnaire. Copy of the Invitation and the questionnaire 
are available in Appendix 11.6 and 11.7. 
 
11.3.2 Results Overview and Analysis 
The collection of the round three data used the same procedure applied in round two with 
consideration of the modifications highlighted above in the questionnaire administration 
section. The following were observed in the round three results: 
• All 15 panellists answered all of the questions. Some of them required several 
follow-up emails to answer the questionnaire. 
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• Five panellists changed their answers, including filling in the missing answers from 
round two. One of the 15 only answered the missing question and kept the rest of 
his answers unchanged. 
As there was a separate questionnaire for each of the panellists, I imported the data to SPSS 
software to analyse them, using the Description command to show the mean and SD for the 
adherence factors. Table 11.8 shows a description of the data including the mean and the 
standard deviation around the mean: 
 Adherence Factors N Min. Max. Mean Std. Deviation 
Collaboration & Partnership      
Patient Clinician Relationship 15 3.00 5.00 4.5333 0.63994 
Communication Effectiveness 15 3.00 5.00 4.4667 0.63994 
Clinician-Side Implementation 15 3.00 5.00 3.9333 0.70373 
Intervention Usage 15 3.00 5.00 4.0667 0.79881 
Confidentiality and Privacy 15 2.00 5.00 4.2667 1.03280 
Knowledge & Information      
Adequate Shared Information about Intervention 15 3.00 5.00 4.4667 0.74322 
Shared Adherence Consequences 15 3.00 5.00 4.4000 0.73679 
Understand Patient Behaviour 15 3.00 5.00 4.4000 0.63246 
Patient-Centred Shared Knowledge 15 3.00 5.00 4.3333 0.81650 
Patient Information 15 3.00 5.00 3.7333 0.96115 
Goals Motivators 15 2.00 5.00 3.8667 0.74322 
Motivation      
Risks Motivators 15 1.00 5.00 3.4000 1.12122 
Benefits Motivators 15 3.00 5.00 4.0000 0.65465 
Individual Motivators 15 3.00 5.00 3.8667 0.74322 
Social Motivators 15 1.00 4.00 2.9333 0.79881 
Product Design Characteristics 15 3.00 5.00 3.7333 0.70373 
Patient Experience      
Patient-Centred Design 15 3.00 5.00 4.5333 0.63994 
Design for Adherence 15 2.00 5.00 4.4000 0.91026 
Design Research 15 3.00 5.00 4.2667 0.70373 
Device Usage 15 4.00 5.00 4.5333 0.51640 
Valid N (listwise) 15         
Table 11.8 The description of round three results including the mean and standard deviation. 
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The comparison between round two and round three showed that the panellists modified 
their answers in a manner which led to a reduction in the SD around the mean, which 
reflects an agreement between the panellists on the level of importance of each factor for 
improving adherence. Most of the values were biased to the centre and left side of the scale 
(Very important, Important and Moderate). The importance ratings for two factors had a SD 
of 1 or more (Confidentiality and Privacy, and Risk Motivators).  
 
The first factor, Confidentiality and Privacy, had the minimum rate of low importance (2) 
and a maximum of very important (5). The second factor, Risks Motivators, had the 
minimum value of very low importance (1) and a minimum value of very important (5). 
Design Usage had the lowest SD with minimum value of Important (4) and maximum value 
of very important (5), which showed the highest level of agreement of all the panellists. 
 
Upon reflecting on the previous literature, and the case study interviews, there are two 
observations: 
• These results are based on general treatment adherence without considering that 
these values and/or their level of importance may change with certain diseases and 
in some cases. 
• While the levels of importance are based on the Delphi panellists’ agreement, this 
level may change in real life situations. The extent of change may also vary based on 
the treatment, its development and the SME.  
 
11.3.3 The Point of Saturation 
The initial Delphi method plan was to have three rounds, and this number of rounds is 
supported by literature studies. This decision was made prior to the study start due to the 
following: 
• The timeframe of the study 
• The availability of the panel members  
• The COVID-19 pandemic and the national lockdown 
Another approach is to stop the rounds once the consensus between the panellists has been 
reached (Keeney et al., 2010). In this study, the decision was made to stop at the third 
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round as an acceptable level of consensus between the panellists had been reached.  
Accordingly, while the study was set to three rounds, the level of agreement between the 
panellists was monitored after each round in order to achieve the goal of the Delphi study.  
 
11.3.4 Application Wilcoxon Signed-Rank Test 
To evaluate the significance of the change in responses between round two and round 
three, I applied the Wilcoxon signed-rank test. The decision to use it was based on 
understanding the nature of the statistics as follows: 
1. Ordinal, with no specific distribution normality  
2. The statistics can have dependant or independent relationships, and  
3. The data can be considered an imprecise quantity rather than exact numbers. 
According to the above three characteristics, the statistics in this study can be considered 
non-parametric statistics (Taheri & Hesamian, 2012). 
 
The Wilcoxon signed-rank test is based on three assumptions (Sheskin, 2003): 
1. The sample has been randomly selected from the population it represents 
2. The original scores obtained for each of the ranked objects are in the format of 
intervals (ratio data), and  
3. The underlying population distribution is symmetrical, so the mean, median and 
mode showed equal values. 
The first two assumptions can be applied to the population (the population was quite small, 
so all 15 panellists were used in the sample). The nature of the statistics was based on the 
ordinal data set. To evaluate the applicability of the first assumption, the frequencies of 
round two and round three statistics were generated using SPSS software.  
 
Table 11.8 below shows the mean, median and mode of round two. The table shows 10 
factors with three values equal to each other (the values were rounded up to the nearest 
value). For example, in the ‘intervention usage’, all the mean, median and mode values 
equal four, which means there is symmetric distribution around the mean.
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  Number Mean Median Mode SD 
Patient-Clinician Relationship 15 4.4667 5 5 0.74322 
Communication Effectiveness 15 4.3333 4 5 0.72375 
Clinician-Side Implementation 15 3.8 4 4 0.86189 
Intervention Usage 14 4 4 4 0.78446 
Confidentiality and Privacy 15 4.2 5 5 1.01419 
Adequate Shared Information about Intervention 15 4.2667 5 5 1.09978 
Shared Adherence Consequences 15 4.1333 4 5 1.12546 
Understand Patient Behaviour 15 4.4667 5 5 0.63994 
Patient-Centred Shared Knowledge 15 4.0667 4 5 1.16292 
Patient Information 14 3.8571 3.5 3 1.09945 
Goals Motivators 15 3.6667 4 4 1.29099 
Risks Motivators 15 3.3333 3 3 1.1127 
Benefits Motivators 15 4 4 4 0.65465 
Individual Motivators 15 3.8 4 4 1.08233 
Social Motivators 15 2.8667 3 3 0.91548 
Product Design Characteristics 15 3.8 4 4 0.67612 
Patient-Centred Design 15 4.6667 5 5 0.61721 
Design for Adherence 15 4.4 5 5 0.91026 
Design Research 15 4.3333 4 4 0.61721 
Device Usage 15 4.4 5 5 0.82808 
Table 11.8 The mean, media and mode of round two results. 
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  Numbers Mean Median Mode SD 
Patient-Clinician Relationship 15 4.5333 5 5 0.63994 
Communication Effectiveness 15 4.4667 5 5 0.63994 
Clinician-Side Implementation 15 3.9333 4 4 0.70373 
Intervention Usage 15 4.0667 4 4 0.79881 
Confidentiality and Privacy 15 4.2667 5 5 1.0328 
Adequate Shared Information about Intervention 15 4.4667 5 5 0.74322 
Shared Adherence Consequences 15 4.4 5 5 0.73679 
Understand Patient Behaviour 15 4.4 4 4 0.63246 
Patient-Centred Shared Knowledge 15 4.3333 5 5 0.8165 
Patient Information 15 3.7333 3 3 0.96115 
Goals Motivators 15 3.8667 4 4 0.74322 
Risks Motivators 15 3.4 4 4 1.12122 
Benefits Motivators 15 4 4 4 0.65465 
Individual Motivators 15 3.8667 4 4 0.74322 
Social Motivators 15 2.9333 3 3 0.79881 
Product Design Characteristics 15 3.7333 4 4 0.70373 
Patient-Centred Design 15 4.5333 5 5 0.63994 
Design for Adherence 15 4.4 5 5 0.91026 
Design Research 15 4.2667 4 4 0.70373 
Device Usage 15 4.5333 5 5 0.5164 
Table 11.9 The mean, median mode and SD of the round three results.
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The frequency values (Table 11.9) of round three show equal value between the mean, 
median and mode of the majority of the adherence factors. Sixteen factors showed equal 
values. Four factors showed close values (the values were rounded up to the nearest value). 
 
11.3.5 Application of Wilcoxon Signed-Rank to SD 
I applied to the Wilcoxon signed-rank test to the SD collected in round two and round three 
in order to identity the changes which occurred when eliminating the changes due to 
chance. The test was run using SPSS software on the data in Table 11.10. The Wilcoxon 
signed-rank test is based on the following assumptions: 
a) The sample has been randomly selected from the population it represents  
b) The original scores obtained for each of the ranked objects are in the format of 
interval/ratio data, and  
c) The underlying population distribution is symmetrical (Sheskin, 2003). 
 
  Round 2 SD Round 3 SD 
Patient-Clinician Relationship 0.74322 0.63994 
Communication Effectiveness 0.72375 0.63994 
Clinician-Side Implementation 0.86189 0.70373 
Intervention Usage 0.78446 0.79881 
Confidentiality and Privacy 1.01419 1.03280 
Adequate Shared Information about Intervention 1.09978 0.74322 
Shared Adherence Consequences 1.12546 0.73679 
Understand Patient Behaviour 0.63994 0.63246 
Patient-Centred Shared Knowledge 1.16292 0.81650 
Patient Information 1.09945 0.96115 
Goals Motivators 1.29099 0.74322 
Risks Motivators 1.11270 1.12122 
Benefits Motivators 0.65465 0.65465 
Individual Motivators 1.08233 0.74322 
Social Motivators 0.91548 0.79881 
Product Design Characteristics 0.67612 0.70373 
Patient-Centred Design 0.61721 0.63994 
Design for Adherence 0.91026 0.91026 
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Design Research 0.61721 0.70373 
Device Usage 0.82808 0.51640 
Valid N (listwise) 15 15 
Table 11.10 The SD of the 20 factors in round one and round two. 






11a 8.73 96.00 
Positive 
Rankings 
3b 3.00 9.00 
Ties 1c     
Total 15     
a. Round_2_SD < Round_1_SD 
b. Round_2_SD > Round_1_SD 
c. Round_2_SD = Round_1_SD 
Table 11.11 Wilcoxon signed-rank test on SD. 
In the rank Table 11.11, 11 values showed negative rankings, which means that the SD 
values in round two were lower than round one. Three of the values have been ranked 
positive, which means that the SD for three factors increased from round one. One of the 
values is ranked as a tie, which means that the value in round one and round two is the 
same. Table 11.11 shows that the level of consensus between the panellists has improved in 
round three compared with round one. 
 
In this study’s Wilcoxon test, the null hypothesis is defined as: ‘there is no change in SD in 
round one and round two, and the difference between round one and two follows a 
symmetric distribution around zero’. Table 11.12 below shows the test statistics: 
 
Round_2_SD - Round_1_SD 
Z -2.731b 
Asymp. Sig. (2-tailed) 0.006 
a. Wilcoxon Signed Ranks Test 
b. Based on positive ranks. 
Table 11.12 The test statistics for the Wilcoxon ranked-signed test. 
 
In Table 11.12 above, the assumption of significance is 0.006, which is lower than the 
significance level standard (ϴ = 0.05) (Wilcoxon, 1947). Accordingly, the null hypothesis is 
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rejected and there is a significant change between the SD in round one and round two. 
Round three showed significant agreement between the panellists on the level of 
importance of the adherence factors for self-administered treatment devices, which is a 
contribution to knowledge as there is a lack of literature studies which discuss the 
adherence factors related to medical technology. Table 11.13 shows the adherence factors, 
categories, sub-categories and their importance levels based on final results of round 3. 
 





Patient–clinician relationship (e.g. monitoring tech, consistency, follow-ups, 
feedback, confidentiality, adaptability) 
5 
Effective communication (e.g. suitable language, style of communication) 5 
Clinician side implementation (e.g. clinical implementation, clinical trials feedback) 4 
Usage intervention (e.g. support, reduced communication) 4 




Adequate information shared about intervention (e.g. clear treatment information, 
simplicity of information) 
5 
Shared adherence consequences (e.g. connecting personalised choices and 
consequences, measuring targets fpr the health outcome) 
5 
Understand patient behaviour (e.g. identifying adherence instances, mismatch in 
perception of urgency, actual patient behaviour) 
4 
Patient-centred shared knowledge (e.g. patient knowledge, tailored information, 
usage) 
5 
Patient information (e.g. demographic information, technology literacy, treatment 
literacy) 
3 
Motivation  Goals (e.g. setting achievable goals) 4 
Risks (e.g. perceived severity (suffering–drawbacks) 4 
Benefits (e.g. perceived benefit (reinforcement–reward) 4 
Individual (e.g. self-efficacy, health condition) 4 





Product design characteristics (e.g. aesthetic, packaging and usage process) 4 
Patient-centred design (tailoring) (e.g. usability, patient characteristics, 
psychological factors) 
5 
Design for adherence (e.g. compliance measurement, concordance, patient 
participation in treatment process, guidance on factors influencing adherence) 
5 
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Design research (e.g. field research and testing, prototyping iteration) 4 
Device usage (e.g. practicality, affordability, comfortability, self-administration of 
treatment, social support, facilitation) 
5 
Table 11.13 General adherence factors and their importance (median) based on the Delphi 
results. 
 
11.4 Findings and Summary 
To understand how the study could contribute to building an Adherence Canvas which can 
provide a guideline for companies to consider the factors that can improve patient 
adherence to self-administered treatment technology, the findings from the literature, 
interviews and observations were synthesised after having overviewed the collected and 
analysed data. 
 
The aim of the Delphi procedure was to assess adherence factors that can underpin a 
framework and identify the elements of a resource which can guide companies to measure 
their consideration of adherence during the development stages. A further aim was that the 
instrument could be easily adapted and modified by companies as they develop their 
knowledge about their patients, the medical condition they are addressing and the 
treatment long-term usage of the intervention. The aim of the Delphi method was to assess 
the following: 
• The categories of adherence factors 
• The general factors that affect patient adherence 
• The adherence factors which relate to treatment technology 
• The importance of these adherence factors 
 
The consensus of the panellists on the adherence factors and the data triangulated from the 
previous stages contributed to introducing a Design-Focused Adherence Canvas which can:  
1. Guide companies to the adherence factors which should be considered, especially 
those new companies or companies who develop new technology which do not have 
a clear idea of the factors which affect patients’ adherence to the treatment, and 
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2. Help companies to evaluate the consideration of adherence factors during the 













































Chapter 12: Discussion of Findings 
This chapter reviews the findings of each 
stage in the study and how these findings 
were triangulated against each other. 
Furthermore, this chapter provides an 
overall discussion of the findings, how 
these findings contribute to answering the 
research questions and how they are used 
to realise the primary aim of this PhD 
research.  
Key Topics: 
12.1 Discussing the Literature Review  
12.2 On the Case Studies Interviews 
(Investigate) 
12.3 On the WearCare II Project 
Observation  
12.4 On Assess: Delphi Method 
12.5 Findings and Summary 
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In this chapter, the findings from each research study will be summarised and discussed 
from the perspective of the primary aim of the research, i.e., to explore the role of design 
thinking in improving adherence in self-administered medical technology treatment. Toward 
this aim, three goals were introduced: 
1) Investigate the current design processes in the development of treatment 
technology.  
2) Explore the contribution of design thinking in the development of the treatment. 
3) Assess how the consideration of adherence factors during the design of treatment 
technology impacts the intervention outcome. 
 
From the practical perspective, the findings in response to the research aim and related 
goals will contribute to paving the road to building framework, which can be adopted during 
the design thinking process to help improve the adherence to a medical regimen, especially 
in chronic disease cases. 
 
To achieve the research’s aim and goals, research questions were chosen to guide the 
research stages. These research questions are: 
• What is the role of design and innovation in medical treatment technologies? 
o What is the current state of innovation in medical technology? 
▪ What are the barriers to and opportunities for innovation in medical 
technology?  
▪ What is the role of medical technology in driving patient 
empowerment? 
o How does design influence the innovation of patient-administrated 
treatment technologies? 
▪ What are the characteristics of design thinking? 
▪ What are the current development processes which are applied in 
medical technology? 
▪ What are the barriers to and opportunities for adopting design 
thinking? 
• What is the impact of adherence in self-administered treatment technology? 
o What are the theoretical frameworks of treatment adherence? 
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o How are treatment technologies considered in clinical trials or alternative 
procedures? 
o How is adherence considered in product development and clinical trials? 
 
The first group of questions aimed to understand the role of design in self-administered 
medical technology innovation. To achieve this goal, the questions were divided into two 
sets. The first set of questions aimed to understand the current contribution of innovation 
in medical technology, and the second set of questions aimed to understand the influence 
of design innovation on self-administered interventions. The second group focused on 
adherence and explored how it is considered in literature reviews, design processes and 
clinical trials. 
 
Guided by these research questions, three main activities were undertaken to design the 
research process: 
• Study the knowledge: Data collected through desk and field research were 
examined and analysed to learn about the design process and understand how 
adherence is considered in the process. 
• Analyse the knowledge: The knowledge that was collected was analysed to 
determine how adherence factors are considered during the design process. 
• Assess the knowledge: The modelled knowledge was assessed by a panel of 
professionals. 
 
The research process progressed through three main stages: Investigate, Explore and 
Assess. The Investigate stage had two steps, which were design research and case studies 
interviews. The first stage aimed to understand the design thinking process, theoretical 
frameworks related to adherence, and the current state of the medical technology 
innovation. The second step (case studies interviews) involved interviewing representatives 
of five SMEs working in developing medical treatment (and treatment-support) 
technologies. The aim of these interviews was to explore the application of design in the 
development process and understand how adherence is considered during the development 
of the medical device. The Explore stage (observation) involved exploring the consideration 
of adherence during the design thinking process. The Assess stage included a triangulation 
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of the data collected from the previous stages in order to gain the consensus of a panel of 
professionals on the adherence factors and importance of each factor. This chapter 
summarises and discusses the findings at each step and stage and identifies how these 
findings contributed to progression of the research. 
 
12.1 Discussing the Literature Review  
This literature review covered in Part 3 of this study aimed to understand key knowledge 
linked to the study, including: patient adherence and its factors (Chapter 6), the 
characteristics of design thinking (Chapter 7) and medical technology innovation (Chapter 
8). The following summarises s the findings of the literature review undertaken in these 
three chapters. 
 
12.1.1 Adherence and its Factors 
Major theoretical factors which affect patient adherence to treatments were reviewed and 
discussed in Chapter 7 to answer the question: ‘What are the theoretical frameworks of 
treatment adherence?’. It also reviewed and discussed the literature related to patient 
empowerment and the role of communication between patient and clinician in patient 
adherence. Most of the theories fell under two main categories: Stimulus Response and 
Social Learning (Bosworth, Weinberger, & Oddone, 2005). In terms of the factors in each 
theory, the adherence factors fell under three categories: Motivation, Knowledge and 
Communication. A fourth categories, Experience, was added to the categorisation because 
of the nature of the treatment as a physical or digital product. The Experience category 
included the design-related factors which may affect the patient experience and therefore 
the adherence to the treatment. Another theory was considered while building the 
adherence framework: The Three Factor Model. In this theory, the adherence factors were 
categorised into Information, Motivation and Strategy. While the first and second categories 
share the same factors with the above adherence theories, the Strategy category included 
the communication opportunity and how the social network (and social support) plays an 
essential role in patient adherence. The factors of the latter category and the other 
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literature studies are related to the ‘patient empowerment’ and its role in improving patient 
adherence. 
 
From the perspective of medical technology (Chapter 8: Medical Technology Innovation), a 
number of findings have been identified from investigating the literature, interviewing case 
studies and observing WearCare II project. The findings, highlighted below, generated 
insights that were reflected in the theoretical frameworks of adherence (Chapter 6: 
Theoretical Frameworks of Adherence): 
• There is a lack of theories which consider adherence in medical technology devices, 
especially when they are self-administered. The majority of theories focus on the 
factors which affect patient adherence (behaviour), yet there is no focus on the 
treatment design nor on other communication factors (i.e.  the relationship between 
patients and clinicians). Treatment devices have further design aspects, such 
creativity, aesthetics, function, affordability and usability, which are related to the 
design of the device and user experience. These design-related factors play an 
essential role in patient adherence to the treatment. 
• The current theoretical models of adherence do not consider the practical 
application of the theory in real life contexts. The nature of adherence is complex, 
and the theoretical frameworks do not provide a solution for this major problem 
while also making it more complex by neglecting the practically of the theories. The 
interviews with case studies and observation of the WearCare II project identified 
that participants did appreciate the importance of adherence yet did not consider its 
complex nature. 
 
The current adherence theories don’t consider the factors related to treatment technology 
such as some communication factors and the design-related factors. Therefore, a 
framework that focus on the adherence in treatment technology is needed. Additionally, 
the complex nature of adherence and lack of practicality in adherence theories present 
challenges related to considering adherence in medical technology. Accordingly, a resource 
is needed in order to help companies to consider adherence while designing treatment 
technology.  
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12.1.2 Adherence and Self-Administrated Treatment 
Technology 
The healthcare system faces several difficult challenges. This burden has increased due to 
the COVID-19 outbreak in early 2020. Lack of adherence to treatment interventions 
accounts for some of the healthcare burden. Failing to adhere to treatment interventions 
has negative health and financial consequences, which may include patient death.  
 
Medical technology (especially self-administered technology) plays a significant role in the 
healthcare system, as it can address a variety of current challenges and builds a patient-
centric approach to medical intervention, which reduces the cost of invasive intervention, 
reduces the number of admissions to hospitals and visits to GPs, involves patients in the 
treatment decision through empowering patients and moves toward a mutual partnership 
between patients and clinicians. 
 
However, poor adherence stands is a barrier to effective sustained use of medical 
technology, especially self-administered treatment technology where the patient controls 
the usage of the non-invasive medical technology. A low level of adherence can cause 
medical evaluation procedures, such as clinical trials and patient advisory groups, to 
produce misleading efficiency results. From the patient’s perspective, the failure to adhere 
to the treatment regimen leads to failing to achieve the goal of the intervention, such as 
improving the status of the disease or stopping the degradation of the medical condition 
(e.g. case study YMX). Two aspects of the treatment intervention can increase lack of 
adherence: 
1) The administration of the treatment. For instance, treatments which are fully 
administered by patients away from clinical control are only affected by the adherence 
factors that drive patients to adhere to the treatment.  
2) The lack of consideration of these factors in the design of the medical technology can 
increase the probability of non-adherence. 
 
 Chapter 12: Discussion of Findings  
 
 277 
In the case of chronic disease, patients are required to adhere to the treatment for a long 
period of time or even for the rest of their lives. Extending the period of the intervention 
increases the chance of changes in behaviour and the possible negative impact of 
adherence factors, which increases the risk the occurrence of non-adherence. The above 
discussion addresses the research question: ‘What is the impact of adherence in self-
administered treatment technology?’. 
 
Based on the above, adherence factors play a key role in the success of self-administered 
treatment. This role becomes even more important with self-administered treatment 
technology. Accordingly, considering adherence factors during the design of the medical 
treatment in the way that drives patients to adhere to the treatment may present an 
opportunity for both patients and the healthcare system to overcome several challenges. 
From the patient’s perspective, adherence to the treatment device can improve the medical 
condition, avoid surgical intervention and reduce the burden of traveling to the hospital or 
GP. From the hospital perspective, it can reduce the costs of the surgical intervention, 
wasted medication and hospital admissions and remove the workload on overworked staff.  
 
The above discussion provides an overview of the detailed discussion that occurred in 
Chapter 8: Medical Technology Innovation, which addressed the research question: ‘What is 
the role of medical technology in driving patient empowerment?’. 
 
In relation to the adherence literature, this study investigated the design literature and 
claims that there is a significant lack of studies focusing on patient adherence and the 
practical consideration of adherence during the development of self-administered health 
technology. This finding is highlighted as a sub-claim in Chapter 14 (14.2 Research Claims 
and Contribution to Knowledge). 
 
12.1.3 Design Thinking and Innovation 
Design thinking plays a key role in the aim of this research, as it supports the human focus 
needed to consider adherence and connect this to the solution space during design 
innovation. The process of design thinking can provide an opportunity for SMEs to have 
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greater success in their innovation of medical technology. One of the most important 
characteristics of a creative design process is the ability to explore the problem from 
different perspectives in the problem space. This can help to develop a comprehensive 
definition of the problem and consider solutions relation to a value arena space - which you 
need to define (Dorst, 2010). The characteristics of design thinking that can add value to 
medical technology innovation include the following: 
• Driver of creativity and innovation: Design thinking creates processes that turn 
creative ideas into innovative products (Cox, 2005). The reason behind this is the 
deep exploration in the problem/solution space. 
• Focus on human needs: A focus on human needs is one of three pillars in design 
thinking processes, the others are business viability and technology feasibility, 
(Brown 2011). As a result, usability factors and treatment effectiveness can support 
patient adherence to the treatment regimen.  
• Prototyping and iteration: The Develop stage of the Double Diamond Model (Design 
Council, 2015) provides an opportunity to visualise solutions and ttest whether the 
product/service solution addresses patients’ needs.  
 
Consideration of design thinking perspectives and practices provides an answer to the 
research question: ‘How does design influence innovation in patient-administrated 
treatment technologies?’. However, current considerations of adherence in technology 
projects often fail to exploit these positive opportunities. This may be especially true in 
relation to how and when it is considered, as was discussed in the latter part of the case 
studies interviews and the observation of the WearCare II project (Chapter: 10 WearCare II 
Project). The above overview of design thinking supports discussion of the role that design 
can play in medical technology innovation, which addresses the research question: ‘What is 
the role of design and innovation in medical treatment technologies?’.  
 
12.1.4 Adherence and Medical Technology 
Medical technology innovation has many applications in the healthcare system and various 
literature has highlighted its benefits. One of the primary benefits is improving on patient 
adherence, especially in self-administered treatments (Bryant, Van, & Christensen, 2013). 
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On the one hand, patients can save the time and effort of visiting hospitals, and on the 
other hand, hospitals can reduce the workload on staff and long waiting lists. Investigating 
the benefits of self-administered medical technology for patients highlighted two terms 
which are linked to the human-centric focus within Brown’s (2011) design thinking, which 
are unmet and unrealised needs. Exploring the problem and observing it from multiple 
perspectives can provide the opportunity to identify these needs and subsequently address 
them.  
 
12.2 On the Case Studies Interviews 
(Investigate) 
Stage one included semi-structured interviews with the five case study SMEs developing 
treatment (or treatment-support) technology in the UK. The aim of these interviews was to 
investigate the design process and the consideration of adherence factors during the design 
of treatment devices as well as during their testing and clinical trials. The design of case 
studies step is discussed in Chapter 3: Case Studies Methodologies, and the details related 
to its application are covered in Chapter 9: Interviews Overviews. 
 
The process of recruiting the five companies revealed a clear understanding of the medical 
technology ecosystem as only 11 companies (out of 353) met the requirements of the scope 
of the research. It is interesting to note that there are very few companies which focus on 
self-administered treatments. Considering the benefits of adopting self-administered 
treatment solutions (12.1.4 Adherence and Medical Technology), there is a lack healthcare 
solutions that can self-management for treatment intervention. Expanding the technological 
interventions in this category can support patient self-administration of the treatment 
intervention, saves costs and reduce the pressure on the NHS. 
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12.2.1 Opportunities and Barriers for SMEs 
The companies’ setups and founders played an essential role in determining the 
opportunities that are available to them. For example, companies such as LW7 and ESA 
were able to involve themselves with healthcare innovation activities that provide support 
to SMEs working in the medical innovation sector. They were able to get financial support, 
which reduces one of the biggest barriers that faces new companies. Another benefit is 
access to evaluation procedures, such as clinical trials and patient focus groups, which 
provides a unique opportunity to test the application with real patients in hospitals 
environment.  
 
In contrast to the above examples, other companies were not integrated within a healthcare 
system. For example, 3AB experienced a lack of continuous dedication to and work on the 
product design and commercialisation. DE7 were established in the United States of 
America and recently moved to the United Kingdom. Therefore, it may be too early to 
evaluate their integration with the healthcare system.  
 
The companies in this study experienced similar barriers to SMEs working in other 
industries. Most of the internal barriers were related to experience, management and 
technology. The external barriers included access to funding and complex regulations for 
access to different markets. These barriers hindered the companies’ ability to adopt a 
design thinking process. The most prominent barriers were experience and management (in 
part answering the research question: ‘What are the barriers to and opportunities for 
innovation in medical technology?’). Therefore, the companies who had access to academic 
support in relation to the design process used this collaboration to build patient-centred 
treatment such as YMX’s product. Other companies, such as ESA, were able to adopt some 
design thinking practices, such as involving patients in the design process and developing 
iterative prototypes for testing. 
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12.2.2 The Application of the Design Thinking Process 
In SMEs that have started recently, the organisational culture is driven by the team who 
start the company. This was observed in all five companies which participated in this study. 
Therefore, the adoption of a design-driven strategy depends on the team and their 
capabilities and experience. Companies such as LW7, 3AB and YMX had a design 
background; therefore, the design process in these companies was adopted in a more 
systematic way than in other companies, such as ESA, which only partially applied design 
thinking characteristics. In contrast, DE7 did not have any design background, and this was 
reflected in the product design and the lack of involvement of patients in the product 
iteration and development. Exploring the above case studies contributed to addressing the 
question: ‘What are the barriers to and opportunities for adopting design thinking?’ 
 
12.2.3 Adherence Consideration and Clinical Trials 
Generally, there was an agreement between all the companies on the importance of 
adherence. However, the complex nature of adherence was not clearly understood. 
Different interviewees considered individual factors of adherence without considering the 
wide scope of adherence and how they might build a mechanism which considers patient 
adherence to self-administered treatment. Companies who got the chance to work with 
patients and receive frequent feedback from clinicians (ESA) were able to consider 
adherence. Frequent meetings and testing of the product helped the company to consider 
patient adherence in relation to their solution. Application of design thinking characteristics 
improved consideration of adherence factors, as the process focussed on patient needs and 
involved patients in the design of the treatment device. Accordingly, applying design 
thinking can help companies (e.g. YMX and LW7) to consider adherence factors alongside 
patient’s needs. 
 
The complex nature of adherence and the lack of practicality in the theoretical frameworks 
of adherence (Martin, Haskard-Zolnierek, & DiMatteo, 2010) is likely to contribute to the 
current level of consideration in companies. Having a practical guide to help companies 
consider adherence during the design of the treatment device may have a positive impact 
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on patients’ level of adherence. The above discussion about adherence provides answers to 
the research question: ‘How does adherence is considered in product development and 
clinical trials?’. 
 
Another observation I made while talking to the companies in relation to improving 
adherence to the product is that considering adherence in an early stage of the 
development is more affordable than modifying the product after delivering it. The reasons 
for this are financial, technical and team related. After building the product and pushing it to 
the market, the company usually has spent most of its budget and cannot afford changes 
(especially major changes) to improve adherence. From the technology perspective, 
technological barriers can inhibit improving adherence in the product, such as the size of the 
batteries or internal components. Team availability and the time dedicated to making the 
changes can be another reason which prevents the company from making modifications 
that increase adherence. 
 
Medical technology treatment faces specific barriers in relation to clinical trials which are 
related to the setup of the clinic trials themselves. The setup of clinical trial protocol 
requires a clear consideration of the nature of the medical treatment technology, as 
highlighted by interviews with representatives from YMX, to produce accurate and 
representative results regarding the effectiveness of the treatment technology. This 
includes considering adherence factors (especially in long-term and chronic diseases). 
Examples of factors which could be considered in YMX’s trials are the communication 
between the clinicians and patients during follow-ups to the treatment and consideration of 
the minimum usage required to achieve effective results.  
 
LW7’s experience with clinical trials showed a positive impact, especially when patients 
provided positive feedback and asked to extend the use of the device. This result may be 
related to the kind of treatment, as LW7’s device was designed to improve patient 
adherence to physiotherapy through gamification. The experiences which YMX and LW7 had 
in clinical trials inform the answer to the research question: ‘How do treatment technologies 
are considered in clinical trials or alternative procedures?’. 
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12.3 On the WearCare II Project Observation  
The observation of the development process of the self-administered treatment technology 
was not applicable due to the limitations highlighted in Chapter 10: WearCare II project. 
Accordingly, WearCare II project presented an opportunity to observe the development of 
healthcare ideas and how adherence is considered through the development process. It is 
essential to understand the role of this stage and do not over-estimate nor underestimate 
its contribution to the study. this observation provided an opportunity to see how different 
ideas evolve and how adherence is considered at an early stage of the design process. The 
observation contributed to understanding how design influences the innovation of patient-
administrated treatment technologies.   
 
While all the teams showed appreciation of the value of adherence, teams varied in how 
well they considered it. Some teams did not consider or only poorly considered adherence 
factors, and other teams showed partial consideration of some factors of adherence. Yet 
this consideration may have changed as the teams progressed in designing the solution. This 
was reflected in the final presentation where the teams presented their suggested solution. 
The above observation highlighted another perspective which is how adherence is 
considered in product development contributed to the second claim of this study (Chapter 
14: Conclusion and Contribution to Knowledge). 
 
 12.4 On Assess: Delphi Method 
The time frame of this PhD research study and commercial risk considerations ruled out an 
action research methodology where an adherence framework was tested within product 
development. Assessment replaced action research, with the Delphi method implemented 
to assess the results of the research through the consensus of a panel of academics and 
practitioners in different fields related to the study. Refer to Chapter 11: Delphi Method 
Application for detailed information related to the Delphi panel and application of the 
Delphi method. 
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The Delphi method played two main roles in the study: a triangulation tool to the findings of 
the previous steps (literature review, case studies interviews and WearCare II observation), 
and assessment of the factors affecting adherence to self-administered treatment 
technology. The main purpose of round one was to understand adherence factors as seen 
from the Delphi panel and compare it with the factors identified from the theoretical 
frameworks of adherence and the interviews of the case studies (refer to 11.1 Round One 
Questionnaire in Chapter 11). The analysed results of the the first round align with the 
literature studies and the case studies’ interviews, such as Follow-up and Reminders in the 
Communication category (Dayer et al, 2013; DiMatte, Haskard-Zolnierek, & Martin, 2012; 
Vervloet et al, 2012), Perceived susceptibility – Belief selection in Knowledge category and 
Self-efficacy in the Motivation section (DiMatte, Haskard-Zolnierek, & Martin, 2012; 
Martin, Haskard-Zolnierek, & DiMatteo, 2010; Williams, 2014). In the conversation with 
YMX company, Follow-up and Reminders factor has been highlighted as one of the factors 
that improves patient adherence to the intervention regimen (refer to Table 11.2 Content 
analysis and categorisation for Delphi round one questionnaire in Chapter 11). 
 
The aim of round two and three was to identify the level of importance of each factor or 
group of factors. Round three has shown significant agreement between the panellists on 
the importance level of importance in each factor. This reflected on the Standard Deviation 
(SD) as majority of the factors lays below the 1.0. Also, the Null hypothesis of agreement 
due to chance was rejected in Wilcoxon test (the assumption of significance is 0.006). For 
more details on the results of the SD of each factor and the calculation of Wilcoxon test, 
refer to 11.3.5 Application of Wilcoxon Signed-Rank to SD in Chapter 11. 
 
12.5 Findings and Summary 
This chapter summarised the findings resulting from the research and highlighted the 
findings which answered the research questions related to the design process, medical 
technology innovation and the consideration of adherence. The literature review provided 
an opportunity to explore the role of design in the medical technology innovation sector, 
the current state of the sector, barriers and opportunities and how medical technology 
contribute to driving patient empowerment.  




The overview of the case study interviews explored the application of design thinking in the 
SMEs working on self-administered medical treatment technology. The discussion covered 
the consideration of adherence and how this consideration can affect the results of the 
clinical trials using the evaluation and testing procedures as an example. The observation of 
the WearCare II project provided an opportunity to observe the design of treatment devices 
from a different perspective, especially in an early stage of treatment design and how 
adherence is considered in the process.

















Chapter 13: Introducing a Design-Focused 
Adherence Canvas 
 
This chapter introduces a Design-Focused 
Adherence Canvas. A resource which 
results from the progress of activates that 
resulted the Adherence Framework. This 
Adherence Canvas is introduced to improve 
consideration of patient adherence in the 
use of self-administered medical 
technology. The framework is the result of 
a Delphi process that was grounded in the 
earlier studies. An example (with dummy 
data) is used to describe the steps of using 
the model in organisation context. 
Key Topics: 
13.1 Introduction to the Design-Focused 
Adherence Canvas 
13.2 Description of the Design-Focused 
Adherence Canvas 
13.3 Tracking Design Changes 
13.4 Adherence Canvas Resources and 
Support Materials 
13.5 Findings and Summary 
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Over the course of this research, the roles that design thinking can play in empowering 
patients and improving medical technology innovation were identified. From the 
perspective of adherence, the literature studies reviewed agreed on its importance, 
especially when the treatment is patient-administered. However, there are various 
challenges when considering adherence factors. This chapter introduces a Design-Focused 
Adherence Canvas which can be used during a design process to assess consideration of 
adherence factors at each stage. The factors used in this model are based on the consensus 
on the adherence factors in the Delphi method. The Adherence Canvas presents a synthesis 
of the findings in this study and has not been tested in practice due to time limitations and 
commercial risk.  
 
The relevance and importance of specific adherence factors and how the framework is used 
are subject to adaptation and customisation based on the testing and evaluation of the 
treatment technology. Accordingly, two models will be discussed in this chapter: an 
Adherence Canvas, and an Adaptable Adherence Canvas. 
 
13.1 Introduction to the Design-Focused 
Adherence Canvas 
The proposed Design-Driven Adherence Canvas arises from the results of the Delphi method 
and is influenced by three areas of knowledge: the literature studies, the findings of the 
current research and the design practice observation, as highlighted below: 
 
13.1.1 Literature Studies 
The literature studies provided a key element in forming the Design-Driven Adherence 
Canvas. These studies focused on both adherence as well as evidence-based design. 
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13.1.1.1 Lack of Full Practical Adherence Framework 
As highlighted earlier in this study (Chapter 6: Theoretical Frameworks of Adherence and 
Chapter 12: Discussion of Findings), three main points were observed in the theoretical 
frameworks of adherence: 
• Although various studies discussed the theoretical models of adherence, few of 
them presented a practical framework which can be adopted by companies in 
professional practice. 
• Existing Adherence Theories mainly targeted clinically administered medical 
intervention without specifically considering patient-administered intervention, 
especially the treatment technology. 
• The design research literature has shown a significant lack of studies that focus 
on patient adherence and the practical consideration of adherence during the 
development of self-administered health technology.  
• It was understood that factors may change from one disease to another, yet no 
practical model was presented which considers how the various factors manifest 
in professional practice. 
 
To address the above three issues in the resource (Design-Focused Adherence Canvas) 
should consider the following: 
• Practical: The resource should be simple, easy to understand, and viable in different 
types of companies and different stages of the product design, development and 
testing. 
• Inclusive: The resource should consider the factors which affect adherence to 
patient-administered treatment technology, including the design factors. 
• Adaptable: The resource be adaptable to the varied adherence factors related to 
specific diseases. While the model includes factors which the Delphi method agreed 
as important, some diseases require a focus on specific factors. Therefore, the model 
has two versions: a generic model and an advanced model. 
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13.1.1.2 Evidence-Based Design 
The evidence-based design has been used in the healthcare system as an approach for 
decision making in implementing designs projects in the healthcare systems such as space 
design in hospitals (Ulrich et al., 2011). Based on the three methods covered earlier (7.6 
Evidence-Based Design), the Health Environments Research & Design Journal (HERD) model 
(Table 13.1) presents a relevant scaling mechanism to treatment technology.  
 
Based on the findings of both the interviews and the observation, the consideration of 
adherence factors in the initial plan of the design process may be affected by various 
factors, which may affect its consideration in the final product or service. Accordingly, an 
evaluation mechanism can assess consideration of different Design-Focused Adherence 
Canvass during the design stages. The implementation of evidence-based design may 
contribute to maintaining the consideration of adherence factors through the design 
process, prototype iteration and product testing. 
 
  Level 1 Systematic reviews of multiple randomized controlled trials (RCTs) or 
nonrandomized studies; metaanalysis of multiple experimental or 
quasi-experimental studies; meta- synthesis of multiple qualitative 




Level 2 Well-designed experimental (randomized) and quasi-experimental 
(nonrandomized) studies with consistent results compared to other, 
similar studies. 
 Level 3 Descriptive correlational studies, qualitative studies, integrative or 
systematic reviews of correlational or qualitative studies, or RCT or 
quasi-experimental studies with inconsistent results compared to 
other, similar studies. 





Level 5 Opinions of recognized experts multiple case studies. 
 Level 6 Recommendations from manufacturers or consultants who may have a 
financial interest or bias. 
Table 13.1The HERD Evidence Based Levels (Stichler, 2010). 
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13.1.1.3 Adherence Factors 
The Delphi method aimed to assess and triangulate the results of the previous research 
stages. In particular, it aimed to assess the general factors which can be considered during 
the design of the self-administered treatment technology to improve adherence. The 
consensus of the panellists on general adherence factors categorised into four categories 
(Table 13.2). 
13.1.1.4 The Influence of Design Practice 
The third area which contributed to designing the Design-Focused Adherence Canvas. An 
overview of design practice and how the design process works was conducted. In general, 
design practice is used to determine (vote) the level of consideration (how it is used) and 
observe the maintenance of this consideration (when it is used) as below: 
• When to use the Adherence Canvas 
As an evaluation tool, it can be used between the stages of the design process and 
before the testing to evaluate the level of consideration of adherence factors in each 
version of the product. For example, the Adherence Canvas can be used in the 
Discover stage of the Double Diamond (Design Council, 2015) as a resource to guide 
companies (especially new SMEs) to adherence factors that they need to consider in 
the design of treatment device or application. It presents a guide to explore the 
problem space related to adherence. In the Define stage, the Adherence Canvas 
defines the adherence factors that need to be considered during the design of the 
treatment solution and their importance. In the Develop stage, the Adherence 
Canvas presents a resource with which to evaluate the consideration of adherence 
factors in the treatment prototypes. In this case, the factors that receive a low rating 
in the consideration scale are iterated and improve in further versions. The Deliver 
stage provides an opportunity to test products and use patients’ feedback to 
understand the adherence factors and their impact on patient adherence.  
• Evaluate the consideration of adherence factors 
Several practices within companies use a yes/no voting system for designs and 
prototype options to determine the viability of a design from different perspectives. 
An example to this practice is the Google design sprint, where the team votes for the 
ideas in order to select the workable one (Larusdottir et al., 2019; Martinez et al., 
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2018; Wichrowski et al., 2015). Another example which applies the voting system is 
the affinity diagram tool, which is used to organise product features into categories. 
Part of this practice is to determine the importance of these features (Alänge, 2009; 
Widjaja & Takahashi, 2016). 
 
13.2 Description of the Design-Focused 
Adherence Canvas 
The Design-Focused Adherence Canvas presented in this chapter presents a visualised 
resource for companies to guide them and measure the consideration of adherence factors 
in the design process. These factors are of based on the Adherence Framework which was 
developed based on the Delphi process (Chapter 11: Delphi Method Application). The 
adherence factors and the level of their importance (Table 13.2) presents the main structure 
of the Design-Focused Adherence Canvas which is described below  
 
13.2.1 Design-Focused Adherence Canvas: What is it? 
The Design-Focused Adherence Canvas is a one-page Likert Scale Radial Graph 
that allows companies to evaluate how adherence is considered in the treatment device 
during and after the design process. It evaluates the consideration of the general factors 
which affect adherence. There are two versions of the Adherence Canvas: 
• Design-Focused Adherence Canvas: This is the general model which is based on 
the consensus of Delphi process (Figure 13.1) on an Adherence Framework for 
treatment technology including the factors affecting patient adherence and the 
importance of each factor. These factors were agreed upon by the panel of 
academic and professionals during the Delphi method. It can be used in to 
address major diseases, evaluate new products and by companies who do not 
know the exact adherence factors affecting their treatment intervention are. In 
this case, companies can use it as a starting point before refining the factors.  
 




Figure 13.1The Design-Focused Adherence Canvas. 
 
• Advanced Design-Focused Adherence Canvas: This model does not include any 
factors nor any levels of importance. It can be used by experienced companies 
who have a clear idea of the factors which affect their patients’ adherence. 
 
Figure 13.2 The Advanced version of the Design-Focused Adherence Canvas. 




The Adherence Canvas consists of the following components: 
• The adherence canvas (Figure 13.2) consists of a Likert Scale Radial Graph. The shape 
is divided into four sections. Each section represents a category of adherence factors 
(Collaboration and Partnership, Knowledge and Information, Motivation and Patient 
Experience). 
• The radial scale consists of five coloured circles which progress from red (centre) to 
green (outer circle). The red circle, or level one, refers to a very low consideration of 
the adherence factor, and the green circle, or level five, refers to the highest 
consideration. 
 
Below is a brief description of the Advanced Design-Focused Adherence Canvas and how it 
can be used to explore how treatment technology considers the related adherence factors. 
The above findings influence the process below: 
1. The model consists of a Likert Scale Radial Graph 
2. . The scale consists of five coloured circles which have a corresponding number. The 
red inner circle corresponds with the number one and indicates a very low 
consideration of the adherence factor. The green outer circle corresponds with the 
number five and refers to the highest consideration. 
3. The circle is divided into four sections. Each section represents a general category of 
factors. These factors are drawn from the investigation of adherence theories 
covered in the literature review. The four sections are: 1) knowledge; 2) motivation; 
3) communication; and 4) patient experience. These sections are defined based on 
different adherence theories and adherence factors defined by the WHO and the 
NICE. As a result, a total of 20 adherence factors are listed. 
4. Each adherence factor has a level of importance scale which rates the importance 
from 1-5, where 1 is the lowest importance and 5 is the highest importance. The 
default importance rating uses the data resulted from the Delphi method (Table 
13.2). The importance rating provides an idea of which factors should be considered 
the most. 
The advanced model is very similar to the generic model (13.3). The only difference 
between the two is that the advanced model does not include any factors or a rating. 
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The company’s team needs to add the factors and rate them based on the company’s 
own experience. 
 
13.2.2 The Physical Description of the Design-Focused 
Adherence Canvas 
The model will be made available online for companies to download and use under the 
Creative Commons Licence Attribution-NoDerivs CC BY-ND, which states: ‘This license lets 
others reuse the work for any purpose, including commercially; however, it cannot be 
shared with others in adapted form, and credit must be provided to you.’ (Creative 
Commons, N/A. p.1). 13.3 Adherence Canvas Resources and Support Materials included 
details on the resources that will be available to provide support for the Adherence Canvas 
usage. 
13.2.3 How Can it be Used? 
The below example provides a step-by-step visual guide to the usage of the Design-Focused 
Adherence Canvas. This example will use placedo (dummy data) answers in the Adherence 
Canvas to visualise how it works in a real organisational setup. The below example assumes 
that the team consists of five employees from different departments, and they are 
evaluating a prototype’s consideration of adherence, which is the Develop stage in the 
Double Diamond process (Design Council, 2015). 
 
13.2.3.1 Before Using the Model 
The following steps occur before the voting process to organise the team and decide which 
type of model to use: 
1) The model uses votes from team members with different expertise who are involved in 
designing the treatment technology. Accordingly, the first step is to assign a team for 
the process. 
• Determine if the company will use the Generic Design-Focused Adherence 
Canvas or the Advanced Design-Focused Adherence Canvas based on the existing 
experience with the treatment and target patient. 
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13.2.3.2 The Voting Process 
Voting is a commonly used method to determine team’s selection on multiple of choices 
such as the affinity diagram where the participants vote for the priority of multiple elements 
or severity level of several problems such as software problems (Alänge, 2009; Elmansy, 
2016). Design sprinting is another method that uses the voting system to select between a 
number of layout design options (Banfield, Lombardo, & Wax, 2015; Elmansy, 2016). 
 
In this process, the team reviews and discusses the treatment device details, features and 
possible prototypes. This revision helps the team members recall the product specifications. 
Next, the company needs to determine the voting method to use. Usually, there are two 
methods: 1) Voting using dots and counting the dots, or 2) If anonymity is required, using a 
simplified version of the eDelphi method consisting of two rounds. 
 
Once the above practice is defined, the team may move forward as below (the steps below 
use a two round Delphi method): 
1) The team facilitator codes the factor by colouring it based on its consideration. 
Irrelevant factors are coded with the colour black (Figure 13.3). 
• The team anonymously votes on how adherence factors are considered in the 
design idea. In Figure 13.3, the votes are marked with an X. 
 
 




Figure 13.3 Round one of anonymised voting on the consideration of each factor. 
 
2) After finishing the first round, the team votes again in a second round, this time with the 
ability to see each-others’ votes anonymously. If more than one consideration level 
shares the same importance, the voters should repeat the voting by considering that 
each level should have a unique level of importance (Figure 13.4). 
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Figure 13.4 Round two of the voting session, with the chance to modify answers. 
 
3) The team repeats the process for all factors. If there is an irrelevant factor, the team 
facilitator can ignore or block it out with the colour black. 
 
13.2.3.3 Post the Voting Process 
The results of the first round of voting are used to iterate the product to improve the 
consideration of the adherence. The process is repeated in different stages to improve the 
product, then the team can visualise the different votes to overview how the adherence 
factors were considered in each prototype (Figure 13.5 and Figure 13.6). 
 
Figure 13.5 The results of first usage of the model. 
 




Figure 13.6 The results after improving the product’s consideration of adherence. 
 
The voting process can be also applied to different stages of the design process (Double 
Diamond). After the voting process, team members discuss the results of Design Driven 
Adherence Canvas voting and implement it to improve of future prototype versions. 
 
13.3 Tracking Design Changes 
The changes in the voting throughout the rounds can provide interesting observations about 
the adherence factors consideration. The comparison between design consideration for the 
adherence factors in Figure 13.5 and Figure 13.6 presented three scenarios: 
1. Some factors can be improved using the development process through applying 
iteration and prototype evaluation or testing. 
2. Some factors cannot reach the highest consideration rate because of internal and 
external development factors (i.e. treatment requirements, regulations or 
technological barriers). 
3. Some factors were ignored (excluded) either because they are irrelevant or can’t be 
changed due to internal or external factors, such as the second case of factors.  





Figure 13.7 The development of adherence factor consideration from round one on the right 
to round 2 on the left. 
 
The frequent usage of the Adherence Canvas improves the team’s understanding of the 
patients’ nature and the adherence factors that should be considered, especially in relation 
to specific diseases. By this time, the Adherence Canvas’ role shifts towards an evaluation 
tool to ensure that the factors are considered in future products. 
 
13.4 Adherence Canvas Resources and 
Support Materials 
The Adherence Canvas will allow companies to download the tool and implement it into 
health technology development. The following resources will be provided along with the 
Adherence Canvas. 
The Adhere Canvas website (available at: https://www.adherencecanvas.com): The website 
will include: 
• The Adherence Canvas in PDF format to download 
• Video tutorials and visualised articles to guide companies on how to use the 
canvas 
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• Contact information to get in touch with the researcher for more information 
and book online sessions if needed 
• YouTube videos: video resources will be available on my YouTube channel and 
the Adherence Canvas channel to provide a usage guide and video presentation 
about the Adherence Canvas usage 
• Industrial articles on my website: https:/www.designorate.com: these articles 
will cover the usage of the Adherence Canvas and case studies related to it 
 
 
From the academic perspective, the following resources will be provided: 
• Conference and journal publication to introduce the Adherence Canvas and 
background research 
• Conference poster and speaking participation to introduce and discuss the 
Adherence Canvas 
• Publish a book that provides a complete guide to the Adherence Canvas 
 
13.5 Findings and Summary 
This chapter presented the Design-Focused Adherence Canvas, which synthesises the 
findings of this study. It provides a tool to map the consideration over different design 
stages. Two models were introduced—the Generic Design-Focused Adherence Canvas and 
the Advanced Design-Focused Adherence Canvas—the latter of which can be used by skilled 
companies who already have knowledge of the adherence factors which relate to the 
designed technology. This chapter provided an example of the application of the model 
using placedo (dummy) data to show the steps which companies need to follow to use the 
Adherence Canvas. 
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This chapter will briefly overview the research and discuss its contribution to knowledge, 
which will be presented as two claims. The contributions to knowledge will be presented 
and mapped to the research process (Chapter 12: Discussion of Findings). Also, the research 
limitations will be discussed. Finally, this chapter will recommend future work based on the 
research findings. 
 
14.1 Research Overview 
This section will briefly summarise the research aims, objectives, methodology, and process 
as a guide for the discussion of claims in the following section. The main research aim was 
to explore the role of design thinking in improving adherence to self-administered 
treatment technology. To this goal, three main initial objectives have been presented: 1) 
investigate current design processes in treatment technology; 2) explore the contribution of 
design thinking to development of the treatment technology; and 3) assess the impact of 
considering adherence factors during treatment technology design. To address these 
objectives, the research questions below were asked: 
• What is the role of design and innovation in medical treatment technologies? 
o What is the current state of innovation in medical technology? 
▪ What are the barriers to and opportunities for innovation in medical 
technology?  
▪ What is the role of medical technology in driving patient 
empowerment? 
o How does design influence the innovation of patient-administrated 
treatment technologies? 
▪ What are the characteristics of design thinking? 
▪ What are the current development processes which are applied in 
medical technology? 
▪ What are the barriers to and opportunities for adopting design 
thinking? 
• What is the impact of adherence in self-administered treatment technology? 
o What are the theoretical frameworks of treatment adherence? 
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o How are treatment technologies considered in clinical trials or alternative 
procedures? 
o How is adherence considered in product development and clinical trials? 
 
The answers to the above questions were discussed in Chapter 12: Discussion of Findings. 
 
14.1.1 Methodology and Process Brief 
The research consists of three main stages: Investigate, Explore, and Assess. Research 
design and methodology were determined according to each objective and questions need 
to be addressed. Research stages and their aims are briefly highlighted below: 
Stage 1: Investigate 
• Step 1: Desk research 
This step aims to investigate the literature from three perspectives: the theoretical 
frameworks of adherence, design thinking, and medical technology innovation.  
• Step 2: Field research 
Five case studies involved in semi-structure interviews (face-to-face and online) to 
investigate design process and how adherence is considered during it.  
• Step 3: Data Analysis 
The interviews’ transcripts have been analysed using content analysis. The 
transcripts have been imported into nVivo and analysed to identify the emerged 
themes. Data from both literature and interviews’ analysis were triangulated on the 
following steps. 
Stage 2: Explore 
• Step 4: WearCare II project observation 
Overviewing the early state of the design process stood as a limitation in the case 
study interviews. Therefore, WearCare II project was observed to explore how 
adherence is considered in early steps of the design thinking process.  
Stage 3: Assess 
• Step 5: Delphi method 
Data used from previous steps were triangulated and used to build an adherence 
framework which is assessed through three-round eDelphi method. 
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14.2 Research Claims and Contribution to 
Knowledge 
The research makes two main contributions to knowledge:  
• 1st Claim: This research has developed an adherence framework that identifies 
factors that affect patient adherence to self-administered treatment technology 
and the level of importance of each of these factors. 
• 2nd Claim: A design-focused Adherence Canvas, based on the adherence 
framework (1st claim), which is a practical resource for companies to consider 
adherence factors and their level of importance when developing self-
administered treatment technologies  
As a sub-claim of the 2nd claim, the design research literature has shown a significant 
lack of studies that focus on patient adherence and the practical consideration of 
adherence during the development of self-administered health technology.  
 
The two claims and findings that lead to those two claims are discussed below: 
 
14.2.1 An adherence framework that identifies factors 
that affect patient-administered technology 
treatment adherence and their level of importance 
 
The adherence framework (Chapter 13: Introducing a Design-Focused Adherence Canvas) 
integrates findings from literature (Chapter 6: Theoretical Frameworks of Adherence), case 
studies interviews (Chapter 9: Case Studies Interviews), and Delphi method (Chapter 11: 
Delphi Method Application). Literature highlighted the below: 
• Existing adherence theories and frameworks don’t consider the specific forms of 
medical technology interventions (i.e. treatment devices and software apps). 
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To address these two findings, the study investigated adherence factors that affect patient-
administered treatment technology through two steps: 
• Interview answers from five case studies highlighted adherence factors that are 
relevant to their product (medical technology) 
• Round one of the eDelphi method collected panellists’ answers on open-ended 
questions about general factors that affect adherence in patient-administered 
technology. Data generated from this step was reviewed by two inter-rater 
(reliability procedure). Cohen Kappa test was applied to understand the significance 
of the answers after eliminating the agreement based on the chance. 
 
Based on the above two steps’ findings, several adherence factors have been highlighted 
and organised into four categories (segments). This organisation was based on the literature 
about the relation between each group of factors (Martin, & DiMatteo, 2013). Each category 
includes a sub-category (sub-segment) of adherence factors. Inside each sub-category, there 
are examples of adherence factors that need to be considered. Table 13.2 in Chapter 13: 
Introducing a Design-Focused Adherence Canvas. Additionally, the adherence factors’ 
importance (impact) was identified as below: 
• The 2nd round of Delphi method asked the panellists to rate adherence factor’s 
importance through Likert-based online survey. In the third round, they were given 
the same survey from 2nd round (with showing anonymised total answers from 
round two). Panellists were asked to check their answers and change it if they want 
to change their minds. The result’s significance was evaluated using Wilcoxon test to 
eliminate agreement by chance.  
 
Over the course of the study, two main research results contributed to building the 
adherence framework: the feedback from the cases studies interviews and the 1st round of 
the Delphi method. The first feedback from interviews reflected each company’s experience 
about the adherence factors that affects their target patient’s adherence. The 1st round of 
the Delphi method involved asking 15 panellists from related background (designing for 
medical devices, medical psychology academics, NHS, AHSN, CPI, and Philips Design). 
Accordingly, a consensus has been reached on the framework from both academic and 
practitioner perspectives. 




14.2.2 A design-focused adherence canvas, based on 
the adherence framework (1st claim), which is a 
practical resource that records how adherence factors 
are being considered and their level of importance. 
 
The second claim is a canvas visualisation of the framework that provides a practical 
resource for companies to track consideration of adherence during the design of the 
treatment technology. The finding in literature (Chapter 6: Theoretical Frameworks of 
Adherence) that guided the research toward this gap in knowledge:  
• Existing adherence theories don’t provide a practical mechanism for companies 
to consider adherence in their product or service. 
 
the observation from both case studies interviews and Wearcare II project observation 
highlighted the following findings: 
• While SMEs appreciated the importance of adherence (Chapter 9: Case Studies 
Interviews), there is no guide to help SMEs to sufficiently consider possible 
adherence factors. Therefore, some companies consider adherence factors 
based on previous experience (YMX), previous experience (LW7), or no 
experience (DE7).  
• Observing adherence consideration in an early stage of WearCare II project 
(Chapter 10: WearCare II project observation) highlighted that while some teams 
considered adherence at the project’s beginning, this consideration faded or was 
obscured by other factors as they progress in the design thinking process. 
 
The adherence canvas presents a visualisation for the adherence framework supported in 
the first claim. The above two observation presented the need for a resource that can help 
companies and guide them consider adherence factors. However, the current literature 
theories don’t present a practical method for companies to consider adherence (Chapter 6: 
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Theoretical Frameworks of Adherence).  Accordingly, this study developed an Adherence 
Canvas, a resource that can guide companies to consider adherence factors and measure 
this consideration as they progress in the design process (Chapter 13: Introducing a Design-
Focused Adherence Canvas). 
 
As a sub-claim of the 2nd claim, the design research literature has shown a significant lack 
of studies that focus on patient adherence and the practical consideration of adherence 
during the development of self-administered health technology.  
14.3 Study Limitations 
During the study, several limitations faced the research practice. These limitations and their 
impact on the research process and results are highlighted below: 
 
14.3.1 Case Study Limitations 
The first group of study limitations was related to recruiting SMEs for step two's interviews. 
There were two limitations highlighted below:    
• Few SMEs are working in patient-administered treatment technology. While 353 
companies were reviewed, only 11 companies met the requirements of the research 
scope and were invited to the study. 
 
The limitation above highlights the question: why is there a lack of companies who address 
patient-administered treatment technology? Also, it highlights a gap in the healthcare 
industry related to self-administered health technology interventions. Although various 
studies highlighted the benefits of self-administered health technology (Eaton, 2019; 
Wamble et al., 2019), there is a lack of patient-administered interventions. Therefore, 1) this 
gap presents an opportunity for further research on the self-administered treatment 
technology and how to fulfil this gap and encourage patient empowerment, and 2) this gap 
can be one of the reasons behind the insufficient studies related to health technology 
interventions such as mental health apps (Grist, Porter, and Stallard, 2017). 
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• It wasn't easy to persuade companies to join the study. Out of 11 companies, only 
five companies agreed to join the study and proceed in the interviews. Companies 
who declined to join the study gave reasons such as the lack of availability and fear 
that participating would distract their team.                                                                            
 
The second limitation highlighted the question: what are the reasons that prevent 
companies from participating in the research? Part of the barriers that face the research in 
health technology may be related to the companies themselves, such as their limited 
resources (see Chapter 3: 3.4 Case Studies Recruitment). The discussion with case studies 
highlighted other barriers such as lack of experience, the fear of affecting their funds and 
revealing private information related to their products. The companies' refusal to join the 
study can be considered another barrier facing studies in healthcare technology. 
 
Another limitation was related to the content analysis is the application of a reliability 
procedure. The interviews provided an understanding of adherence from the perspective of 
established SMEs, which was part of the triangulation towards the final Assess stage (the 
Delphi method). 
 
The limitations above had no significant impact on the step's outcome and the aim of the 
interviews with the case studies (investigate the consideration of adherence in the design 
process). 
 
14.3.2 WearCare II Observation Limitations 
The second stage (Explore) aimed to understand how the adherence factors were 
considered early in the design thinking process. However, two main limitations were 
identified: 
1. The medical technology development process takes a long time compared with the 
timeframe of the study, which stood as a limitation to observe companies in an early 
stage of the design process. 
2. Companies are cautious about exposing their new product information, especially at 
an early stage, as other companies could steal it. 
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Based on the two limitations above, the WearCare II project was observed. The project 
provided an environment setup that allowed design groups to work together in exploring 
the problem space and define the solution space of the health technology. While there are 
differences related to financial and legal priorities, those differences do not significantly 
impact the aim of the observation. There are significant differences, such as the aim of the 
project and the practice. 
 
Hence, WearCare project provided an opportunity to observe how adherence is considered 
at an early stage of the process. From the latter perspective, this limitation did not have a 
significant impact on the study. However, two main limitations were highlighted: 1) 
observing the whole design process inside an organisation setup from beginning to end was 
not possible, and 2) some elements, such as the project budget, documentation and project 
management, were not available to observe.  
 
A clear scope of the target of the WearCare II observation is needed to identify its 
contribution to the study. The observation of the WearCare II project aimed to observe the 
consideration of adherence from the design practice perspective. The findings from the 
observation, interviews, and secondary data were triangulated in the Delphi method, 
particularly how adherence's factors were considered and evaluated in the PDP (refer to the 
second claim, see 14.2 Research Claims and Contribution to Knowledge). 
 
14.3.3 Delphi Study Limitations 
The medical technology development process is longer than the PhD study duration. 
Accordingly, testing the findings with an actual organisational setup was inapplicable. So, 
the final stage involved assessing the outcome of the previous stages. The Delphi method 
resulted in an agreement between the panellists on the final adherence framework and the 
importance of adherence factors. While the final stage presents two contributions to 
knowledge (14.2 Research Claims and Contribution to Knowledge), further work will provide 
the opportunity to test the adherence framework and adherence canvas in an actual SME 
setup. 
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The decision to use the Delphi method to assess the triangulated findings from the 
Investigate and Explore stages highlighted the timeframe of the research as one of the 
barriers that face adherence in self-administered health technology studies. The study of 
adherence, especially in chronic diseases, requires long term studies that can test the 
results over the years of using the intervention, especially when adherence to the treatment 
decreases over the intervention time.  
14.4 The Opportunity of Exploring Designers 
Practice in Considering Adherence 
On reflection, whilst the researcher considers that the study presents a sufficient overview 
of the design practice that led to address  the main research question, the limitations 
associated with literature review (Chapter 7 Design Thinking), interviews (Chapter 9: Case 
Studies Interviews) and WearCare II project (Chapter 10: WearCare II Project) affected the 
ability to strengthen and expand the evidence related to how designers consider adherence 
in self-administered treatment technology development. The below reflections highlight the 
opportunity to expand and strengthen the evidence related to how designers consider 
adherence during the PDP. During the reflection below, both terms of companies and 
designers are used exchangeably as the product design is developed by designers or 
employees with design expertise (Cross, 2011; Michlewski, 2016): 
• The number of case studies recruited in the study was limited by the research 
timeframe and the limited number of companies working in self-administered 
treatment technology. Without timeframe limitation, recruiting case studies could 
provide the opportunity to explore a broader range of designers' practices, 
particularly in considering adherence and its factors. The choice of companies could 
consider: 
o Company size: the recruitment of more medium-sized firms could also allow 
a broader exploration of how adherence is considered within these 
companies. 
o Company maturity and experience: Expanding the recruitment criteria to 
involve companies with various experiences in developing self-administered 
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treatment technologies. Exploring the PDP in these companies could allow 
the study to explore the design practice and how it is affected by its expertise 
in product development. 
• WearCare II project observation aimed to explore the design practice and how 
adherence is considered during the early stage of the PDP. The limited timeframe 
presented the main barrier in this stage. This limitation stood against the 
observation of the PDP within companies' environment, especially with considering 
project length and its current development stage. Without this limitation, this stage's 
observation could be conducted inside SMEs starting new health technology 
products to observe and record design practice and how adherence is considered in 
this early PDP stage. This observation setup would increase the strength of evidence 
related to adherence consideration in the early PDP, which could feed into a more 
comprehensive implementation of the Adherence Canvas. For example, designers 
with no experience in adherence could use the canvas as a guide to the adherence 
factors to consider improving adherence. 
• The above awareness of limitations and opportunities to understand the 
consideration of adherence in design practice presented an essential role in planning 
the future of this research and how designers can use the Adherence Canvas during 
the PDP. The Adherence Canvas will be available to use in their PDP, so the 
researcher will observe companies to explore how the canvas can help them 
consider adherence. For instance, companies can focus only on the factors that are 
relevant to their target patients. 
 
14.5 Future Work 
The proposed Adherence Canvas (including the adherence framework) is a resource that can 
guide companies to consider a comprehensive evidence-based framework of adherence 
factors. However, due to the study’s timeline limitation, testing the canvas with companies 
was not possible. Accordingly, future research should introduce the Adherence Canvas (v 
1.0) to: 
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• SMEs working in designing and developing patient-administered medical 
technology. The canvas will be introduced as an open-access resources for 
companies and collect data about its effectiveness in addition to feedback from 
companies to improve the canvas 
• Healthcare organisations (i.e. AHSN, NHS, NIHR, and CPI) to discuss it 
implementing in health technology pathway as one of the resources provided for 
start-ups 
 
The Adherence Canvas will be made available online to be used under the copyright 
Attribution-ShareAlike 3.0 Unported (CC BY-SA 3.0) (Creative Commons, NA). 
 
Companies will be invited to download and use the Adherence Canvas and provide feedback 
to evaluate its impact on adherence outcome. The feedback from the companies will be 




This study aimed to investigate the role of design thinking process in improving adherence 
in patient-administered medical technology. Over the course of the study, a mixed method 
research strategy has been adopted to investigate the design process and the consideration 
of adherence in SMEs designing patient-administered treatment technology in the UK. 
Several findings have been identified. From the perspective of adherence, literature studies 
have highlighted the negative impact of poor adherence, the benefits of medical technology 
innovation, and the opportunities for applying design thinking in medical technology 
innovation. However, the advantages of medical technology innovation and the application 
of design thinking cannot be achieved without a clear understanding and consideration of 
patient adherence for self-administered treatments. Accordingly, two main gaps were 
identified in the literature related to adherence: there is a lack of theoretical adherence 
frameworks that address treatment technology devices and applications, and current 
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adherence frameworks provide no practical mechanisms for companies to consider 
adherence while designing treatment technologies. 
 
Throughout the research process findings were identified. Based on the interview with five 
case studies working in developing patient-administered medical technology, there is a 
general agreement on the importance of patient adherence. However, there is no effective 
consideration for adherence factors during the developing of the treatment products. 
Companies have varied in applying the design process and considering adherence during it. 
During the observation of WearCare II project, the teams working in the project applied the 
design thinking process. Part of the process was considering patient adherence using the 
MPPF method. However, the consideration of adherence faded as the teams progressed in 
developing the medical technology.  
 
Based on the above findings, the study claims two contributions to knowledge: the first 
claim is the development of an adherence framework that identifies factors that affect 
patient-administered technology treatment adherence and their level of importance. This 
claim is based in integration of findings from the literature, case studies interviews, and the 
Delphi rounds. The second claim is the development of a design-focused adherence 
canvas, based on the adherence framework (1st claim), which is a practical resource that 
records how adherence factors are being considered in relation to their level of importance. 
The later claim is influenced by the findings of by the literature, case studies interviews, and 
WearCare II project observation. The Adherence Canvas presents a visualised resource for 
the Adherence Framework to guide and help companies to consider adherence factors that 
affect patient-administered treatment technology. Limitations of the current findings 
indicate the need for future work, including testing the Adherence Canvas with existing 
SMEs to collect a good sample of anonymised data on its effectiveness. Additionally, it will 
be presented to the healthcare organisations in the UK to provide for companies as a 
resource to improve adherence.  
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